Doctor of Philosophy by Hellem, Tracy Lynn
 
   
	   	  
  OPEN LABEL TRIAL OF CREATINE AS A TREATMENT OPTION FOR 
 















A dissertation submitted to the faculty of  
The University of Utah  














College of Nursing 
 






   



















   
	   	  
The University of Utah Graduate School 	  	  	  




The dissertation of Tracy Lynn Hellem 
has been approved by the following supervisory committee members: 
 
Gwen Latendresse , Chair 10/24/2014 
 
Date Approved 
Lee Ellington , Member 10/24/2014 
 
Date Approved 
Marjorie A. Pett , Member 10/24/2014 
 
Date Approved 
Kelly Lundberg , Member 10/24/2014 
 
Date Approved 




and by Patricia Morton , Chair/Dean of  
the Department/College/School of Nursing 
 





   
	   	  
ABSTRACT 
 
 Methamphetamine (MA) is a powerful drug that results in short- and long-term 
consequences for users. Study findings suggest that female MA users have higher rates of 
comorbid depression and anxiety than male MA users. Further, neuroimaging studies 
have found that female MA users have lower levels of brain phosphocreatine (PCr) 
measured by magnetic resonance spectroscopy (MRS) brain compared to male MA users.  
 Treatment options for the comorbidity of depression and MA dependence are 
limited. The results of an integrative review of treatment options for comorbid MA use 
and depression suggest that psychological, a combination of psychological with 
pharmacological and pharmacological approaches are not effective. Further, gender 
differences with response to treatment are understudied.   
Magnetic resonance spectroscopy has been used in drug abuse research to 
investigate brain chemistry changes with substance use. There have been nearly 50 
publications over the past 10 years that describe MRS changes in substance use disorders. 
While MRS studies of MA dependence have been most frequently studied, information 
from all drug classes have demonstrated quantitative correlates of injury relevant to 
substance use. 
 The nutritional supplement creatine has been used as an adjunctive treatment for 
depression in female adolescents and adults. Further, creatine has been associated with 
increased brain PCr levels in healthy volunteers. Considering, a within subjects study was 
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conducted using 8 weeks of daily creatine to treat depression among female MA users.  
Primary outcomes of the study included Hamilton Depression Rating Scale 
(HAMD) scores and brain PCr levels. Secondary outcomes included Beck Anxiety 
Inventory (BAI) scores and substance use. The results of the study showed a reduction in 
HAMD scores as early as week 2. Brain PCr levels were found to be higher at the second 
scan compared to the first scan (M = 0.233, SD =  0.009, t(9) = -2.905, p < .01). Also, 
BAI scores were reduced as early as week 1, as well as a reduction by over half in MA-
positive urine drug screens by week 6 (baseline: 50% MA positive urine drug screens; 
week 6: 21.4%). Finally, creatine was well tolerated.  
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The focus of this research was comorbid methamphetamine (MA) use and 
depression among females. The study proposed an intervention of 8 weeks of creatine 
treatment for females diagnosed with major depressive disorder and MA dependence. 
The Hamilton Depression Rating Scale (HAMD) was used to measure depression 
throughout the course of the study. In addition, phosphorus magnetic resonance 
spectroscopy (31P MRS) was used to compare pre- and postcreatine treatment brain 
phosphocreatine (PCr) concentrations. This chapter includes a background about MA use 
rates, describes consequences of MA use, outlines rates of depression among MA users 
and discusses comorbid anxiety among MA users. Finally, it describes the statement of 
the problem, study purpose, specific aims and significance of the study. 
 
Methamphetamine Use Rates 
Methamphetamine is a psychostimulant drug with high abuse potential. It can be 
smoked, snorted, injected or ingested orally to produce a release of high levels of 
dopamine into the brain and a reduction of dopamine uptake. Methamphetamine use 
results in feelings of pleasure, increased energy, and greater alertness lasting up to 12 
hours. In 2013, the National Survey on Drug Use and Health reported that 595,000
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Americans aged 12 or older reported using MA in the past month (Substance Abuse and 
Mental Health Services Administration [SAMHSA], 2014). Over the past decade MA use 
rates have fluctuated with current use rates stabilizing. Even though overall use rates are 
steady, use rates among males and females are approaching equal proportions (Durell, 
Kroutil, Crits-Christoph, Barchha & Van Brunt, 2008). This use rate pattern is unlike 
other drugs of abuse, which typically demonstrate males using more than females (Durell 
et al., 2008). In some states, more females than males consider MA as their drug of 
choice. For example, in a 2013 report in the state of Utah, more females (27.6%) were 
diagnosed with MA as a primary substance of abuse than males (15.4%) upon admission 
to substance abuse treatment (Division of Substance Abuse and Mental Health, 2014). In 
comparison to other drugs of abuse, alcohol is most frequently diagnosed as a primary 
substance of abuse for males (40.1%) and females (27.8%), marijuana is the second most 
frequently diagnosed primary substance of abuse for males (18.7%) and heroin and 
prescription opiates combined is the third primary substance of abuse for females 
(20.7%) and males (16.5%; Division of Substance Abuse and Mental Health, 2014).  
 
Consequences of Methamphetamine Use 
 Even though the number of MA users in America has stabilized, it remains a 
public health concern because its use is associated with a substantial amount of crime. In 
addition, its consequences, which are discussed below, lead to short- and long-term 
medical and psychiatric concerns (Rawson, Gonzales & Brethen, 2002). The most recent 
estimated economic costs to society related to MA use were obtained in 2005 and 
published in 2009, and these costs were estimated at $23.4 billion (Nicosia, Pacula & 
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Lundberg, 2009). Given the uncertainty in estimating the costs, a RAND Corporation 
study provides a lower bound estimate of $16.2 billion and an upper range of $48.3 
billion annually (Nicosia, Pacula & Lundberg, 2009). Health threats also present major 
economic challenges to individuals and the overall economy (Figure 1), both in terms of 
increased health care costs and lost productivity (Office of National Drug Control Policy, 
2010). These health threats include the risk of contracting human immunodeficiency 
virus (HIV), cardiovascular complications, heart disease, hypertension and stroke (Yu, 
Larson & Watson, 2003). Additional short- and long-term consequences of MA use 
include depression (McKetin, Lubman, Lee, Ross, & Slade, 2011; Thomas, Angoa Perez, 
Francescutti-Verbeem, Shah, & Kuhn, 2010), anxiety (Glasner-Edwards, Mooney, 
Marinelli-Casey, Hillhouse, Ang, & Rawson, 2010a), insomnia, paranoia (McGregor et  
 
 
aOther costs = $1.3 billion in health care costs and child endangerment and $1.2 billion in lost productivity and drug treatment 
 
Figure 1. Methamphetamine economic burden to society from a RAND Corporation 

















   
	   	  
4 
al., 2005), and structural and chemical changes to the brain (Sekine et al., 2003; Yoon et 
al., 2010). Depression is particularly concerning because depression and MA use are 
highly comorbid (Semple, Zians, Strathdee & Patterson, 2007), and this comorbidity 
confounds treatment outcomes and general prognosis (Glasner-Edwards et al., 2008a). 
 
Rates of Depression Among Methamphetamine Users 
The relationship between MA use and depression is likely bidirectional, with MA 
use contributing to changes in mood and being used as a self medicating behavior to 
reduce symptoms of depression (McKetin, Lubman, Lee, Ross & Slade, 2011; Semple, 
Zians, Strathdee, & Patterson, 2007). The prevalence of premorbid depressive disorders 
among patients with MA use disorders is high, with the majority of MA users reporting a 
significant lifetime history of depression (Darke, Kaye, McKetin & Duflou, 2008; 
Zweben et al., 2004). For example, in a study by Hall, Hando, Darke and Ross (1996), 
301 MA users reported a 62% (n =187) rate of depression and a 23% (n = 69) rate of 
suicidality prior to MA use. After initiating MA, users’ rate of depression increased to 
79% (n = 238; Hall, Hando, Darke & Ross, 1996). Notably, female MA users report 
higher levels of depressive symptoms than males (Glasner-Edwards, Mooney, et al., 
2008a, 2008b; Semple, Zians, Strathdee, & Patterson, 2007). Semple and colleagues 
(2007) noted that 60% (n = 87) of MA using women in their study met criteria for 
moderate to severe depression. In another study, female MA users demonstrated 
significantly higher depression scores, measured by the Beck Depression Inventory, than 
did male MA users (19.2 vs. 13.2; Dluzen, 2008), and 38.8% of females (n = 219) 
compared to 29.8% of males (n = 151) were diagnosed with depression in another study 
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(Hser, Evans & Huang, 2005). In a study of adolescent and young adult MA users, 49% 
(n = 49) were found to meet criteria for a current mood or anxiety disorder and 68% (n = 
68) had a lifetime history of a mood or anxiety disorder, with more females (n = 25) 
reporting a lifetime history of a mood or anxiety disorder than males (n = 21; Lubman, 
Allen, Rogers, Cementon & Bonomo, 2007). It is likely that neurobiological and 
psychosocial mechanisms contribute to increased incidence of depressive symptoms in 
females (Dluzen & Li, 2008). 
 
Comorbid Anxiety and Methamphetamine Use 
In addition to depression, anxiety symptoms are often comorbid in MA users, 
with women reporting more generalized, phobic and obsessive compulsive anxiety 
symptoms than men (Zweben et al., 2004). More than one third of women with MA 
dependence (34.9%, n = 66) have a comorbid anxiety disorder and importantly, these 
anxiety disorders are four times more likely to be primary rather than substance induced 
(24%, n = 45 versus 6%, n = 11; Salo, Flower, Kielstein, Leamon, Nordahl, & Galloway, 
2011). 
Intervention research has shown that 3 years posttreatment, 23.4% (n = 123) of 
participants with MA dependence meet criteria for a current anxiety disorder, which is 
associated with increased frequency of MA use during the follow up period (Glasner-
Edwards, Mooney, Marinelli-Casey, Hillhouse, Ang, & Rawson, 2010b). Longitudinal 
studies have also shown that anxiety disorders predict the following adverse outcomes 
after treatment for MA dependence: poorer adherence, increased drug or alcohol 
dependence, psychiatric hospitalization and more than triple the odds of one or more 
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lifetime suicide attempts (odds ratio = 3.1; Glasner-Edwards, Mooney, Marinelli-Casey, 
Hillhouse, Ang, & Rawson, 2010c). 
Although the casual and temporal relationships between anxiety and MA use 
disorders have yet to be fully elucidated, the above findings coupled with the fact that 
anxiety disorders are associated with longer and more frequent MA usage, progression to 
dependence and injection use (Darke et al., 2008) highlight the importance of identifying 
and targeting anxiety symptoms, particularly among female MA users. However, as 
described in the following paragraphs, depression and neuroimaging findings are the 
primary outcomes of this dissertation, and therefore, anxiety is collected as a secondary 
outcome, and is not described in as much detail as the primary outcomes. 
 
Statement of the Problem 
No clear treatment model exists to suggest how the comorbidity of depression and 
MA use is best managed (Hellem, Lundberg, & Renshaw, 2014). In studies of 
antidepressants for the treatment of MA withdrawal, dependence and comorbid mood 
disorders, findings have suggested that antidepressants are ineffective or have 
unacceptable side effect profiles (Cruickshank et al., 2008; Elkashef et al., 2008; 
Galloway, Newmeyer, Knapp, Stalcup, & Smith, 1996; Heinzerling et al., 2010; Shoptaw 
et al., 2008; Shoptaw et al., 2006). Indeed, one placebo controlled trial of the selective 
serotonin reuptake inhibitor (SSRI) sertraline found that participants (n = 59) randomized 
to SSRI experienced sustained cravings and had an increased rate of relapse (Shoptaw et 
al., 2006). This led investigators to conclude that sertraline is contraindicated in the 
treatment of MA dependence (Shoptaw et al., 2006). In addition, well conducted studies 
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of the non-SSRI antidepressant bupropion (n = 36; Shoptaw et al., 2008) and mirtazapine 
(n = 30; Colfax et al., 2011) found no difference from placebo in ratings of depression. 
Further, research on the effects of psychological approaches such as cognitive behavioral 
therapy or motivational interviewing is limited and requires further exploration in larger 
more heterogeneous samples of MA users (Hellem, Lundberg, & Renshaw, 2014).  
Neuroimaging techniques, such as 31P and proton (1H) MRS, are important for 
improving our understanding of the effects of depression and MA on the brain. In 
neuroimaging studies of drug abuse and mood disorders, PCr is of particular interest 
because it serves an important role as a high energy buffer to maintain constant adenosine 
triphosphate (ATP) levels through the action of creatine kinase. The enzyme creatine 
kinase controls the transfer of a phosphate group from PCr to adenosine diphosphate 
(ADP), thereby replenishing brain ATP. Given that ATP production occurs in 
mitochondria, it is not surprising that converging lines of evidence implicate 
mitochondrial dysfunction in depression (Jou, Chiu, & Liu, 2009; Rezin, Amboni, Zugno, 
Quevedo, & Streck, 2008; Shao et al., 2008) and MA use (Sung et al., 2013).  
Magnetic resonance spectroscopy studies reveal a conflicting pattern of metabolic 
change in adults with depression: either higher concentrations of PCr (n = 17; Kato, 
Takahashi, Shioriri, & Inubushi, 1992; Kondo et al., 2011) or lower concentrations of 
PCr (n = 55) when compared to healthy volunteers (n = 49; Forester et al., 2009; 
Iosifescu et al., 2008; Moore, Christensen, Lafer, Fava, & Renshaw, 1997), with the latter 
pattern indicating that some patients with depression have brain energy stores that are not 
being accessed to support cerebral activity. Along those same lines, in a recent 31P MRS 
MA study, Sung and colleagues (2013) found decreased PCr in female MA users (n = 23) 
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compared to male MA users (n = 28). Collectively, these study findings suggest the 
possibility of an alteration in high energy phosphate metabolism in individuals with 
depression and in individuals who use MA.  
Creatine is an organic acid occurring naturally in vertebrates, where it takes part 
in energy homeostasis in tissues with fluctuating energy demands (Kondo et al., 2011). 
Exogenous creatine has been shown to increase brain concentrations of PCr (Kondo et 
al., 2011; Lyoo et al., 2003). Lyoo and colleagues (2003) administrated oral creatine at a 
dose of 0.3 g/kg/day for 7 days and 0.03 g/kg/day for 7 days in a sample of adult healthy 
volunteers (n = 10), and the results demonstrated that brain PCr concentrations increased 
in the treatment group compared to a placebo group. Similarly, in a study of depressed 
female adolescents (n = 5) who took 4 grams of adjunctive oral creatine for 8 weeks, 
brain PCr levels increased significantly (p = 0.02) when compared to a control group, and 
as PCr levels increased, a reduction in depression rating scores was noted (Kondo et al., 
2011). However, there are no published reports of neuroimaging findings in depressed 
adults who have taken creatine. 
 
Purpose of the Study 
When taking into consideration that PCr levels are lower in female MA users and 
in some patients with depression, and that oral creatine may increase PCr levels and 
decrease depression, it is reasonable to hypothesize that oral creatine treatment will 
increase PCr levels and reduce depression in a sample of depressed female MA users. 
This hypothesis was tested by a within subjects design by giving 14 depressed MA using 
females oral creatine for 8 weeks and measuring PCr pre- and posttreatment with 31P 
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MRS. Depressive symptoms were measured by the HAMD. 
 
Specific Aims 
The first specific aim of this study was to describe changes in HAMD scores over 
the course of the study. The hypothesis of this aim was that there would be a decrease in 
HAMD scores over time with creatine treatment. (Note, HAMD scores were collected 
three times prior to intervention, weekly during the intervention and three times post 
intervention). 
The second specific aim of this study was to compare pre- and postcreatine 
treatment brain PCr levels using 31P MRS. The hypothesis of this aim was, compared to 
baseline, PCr levels would statistically significantly higher at the posttreatment scan. 
 
Significance 
 Creatine is an attractive candidate for the treatment of depression in MA users for 
a number of reasons. First, previous MRS studies have reported decreased brain creatine 
plus PCr levels in MA dependent individuals (Sung et al., 2013). Because of MA’s 
neurotoxic effects, MA users may benefit from an increase in PCr levels. Second, 
depression has been associated with high levels of drug craving (Nakama, Chang, Cloak, 
Jiang, Alicata & Haning, 2008), which can be related to relapse, and therefore, treating 
depression in female MA users may improve treatment outcomes. Third, antidepressant 
effects have been documented in preclinical and clinical trials of creatine (Allen, D’Anci, 
Kanarek, & Renshaw, 2010; Kondo et al., 2011) Finally, creatine is available over the 
counter and offers a relatively inexpensive treatment option.  
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CHAPTER 2 
 
REVIEW OF THE LITERATURE 
 
This inquiry is based on the assumptions that a bidirectional relationship between 
methamphetamine (MA) and depression may exist, MA use and depression result in 
changes in high energy phosphate brain metabolism, and exogenous creatine may correct 
or modify high energy phosphate brain metabolism in depressed female MA users. The 
following review of the literature is composed of four sections focused on these concepts. 
The first section is an overview of the history of MA and comorbid depression and MA 
use, the second section discusses gender differences in depression, the third section 
reviews magnetic resonance spectroscopy (MRS) and MRS studies of depression and 
MA and the fourth section presents the history and use of creatine treatment.  
 
History of Methamphetamine: Medicinal and Illicit Use 
Methamphetamine is a powerful central nervous stimulant with high potential for 
abuse and dependence. It is a derivative of amphetamine that was initially synthesized by 
a German chemist in 1887, and studied extensively for the first time in the early 1930s 
(Anglin, Burke, Perrochet, Stamper, & Dawud-Noursi, 2000). Because of its stimulation 
on the sympathetic branch of the autonomic nervous system, the first medical use of 
amphetamine was in 1932 as a nasal spray for the treatment of asthma (Anglin, et al., 
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2000). MA was first synthesized from ephedrine by a Japanese pharmacologist in 1893 
(Suwaki, Fukui, & Konuma, 1997), but it did not became widely used until World War II 
when Japan, Germany, and the United States distributed it to military personnel to 
enhance performance. The first epidemic of illicit MA use occurred in 1945 – 1957, with 
an estimated 5% of Japanese young adult abusers (Anglin et al., 2000). 
 In the United States, over the counter amphetamine tablets were available until 
1951. In the 1960s, amphetamine was used as a medication to treat obesity, narcolepsy 
and depression, with use reaching its peak when 31 million prescriptions were written in 
1967 (Hanson, Venturelli, & Fleckenstein, 2000). During the same decade, a liquid form 
of MA was used as a treatment for heroin addiction, and as a result, a new abuse pattern 
developed involving MA alone or MA and heroin combined (Anglin et al., 2000). The 
first illicit MA laboratories appeared in San Francisco in 1962, and by the mid-1960s, 
motorcycle gangs in the Bay Area seized the manufacturing and distribution of MA along 
the West Coast (Miller, 1997). Methamphetamine started out as a prescribed medication 
but within decades it became a substance of abuse associated with crime, gangs and 
violence. 
 Methamphetamine use decreased in the 1970s largely due to restrictions on legal 
production by the Controlled Substance Act of 1970. Subsequently, increased production 
of illicit MA resulted, and at the same time, typical MA users shifted from white and blue 
collar workers to college students, young professionals, and women (Anglin et al., 2000). 
In 1971, all forms of amphetamine were classified as Drug Enforcement Administration 
(DEA) Schedule II drugs (Miller, 1997). Despite these efforts, in the 1980s, MA use 
began to rise again, largely due to the production of MA in clandestine labs. Greater 
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involvement of Mexican drug traffickers occurred in the late 1980s after increased law 
enforcement efforts targeted the sales of ephedrine, an ingredient found in over the 
counter cold remedies and the main ingredient in MA (Anglin et al., 2000). By the early 
1990s, the use of MA had spread from the West toward Southwestern and Midwestern 
states, and simultaneously, another surge of MA use occurred in Hawaii. In 1996, there 
was an annual 169% increase in MA laboratory seizures, and in response to the 
widespread public health concern regarding MA use and production, the Comprehensive 
Methamphetamine Control Act was passed (Anglin et al., 2000). 
 With the turn of the century, MA use rates continued to rise with an estimated 12 
million Americans over the age of 12 having used MA in their lifetime (Substance Abuse 
and Mental Health Services Administration [SAMHSA], 2004). Over the last several 
years, MA rates have been declining, however, the consequences of MA use are still a 
major public health concern. Both acute and chronic MA abuse have serious medical and 
psychiatric repercussions. Short- and long-term health effects of MA abuse include 
stroke, (Perez, Arsura, & Strategos, 1999), cardiac arrhythmia (Haning & Goebert, 2007), 
depression (McKetin, et al., 2011; Thomas, Angoa Perez, Francescutti-Verbeem, Shah, & 
Kuhn, 2010), anxiety (Glasner-Edwards et al., 2010), insomnia, paranoia (McGregor et 
al., 2005), and structural and chemical changes to the brain (Sekine et al., 2003; Yoon et 
al., 2010).  
 In the sections that follow, research that underscores the comorbidity of MA use 
and depression, including studies that show alterations in brain energy metabolism are 
discussed. There is a specific focus on the increased risk and response to treatment for 
females with comorbid depression and MA use.    
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Comorbid Depression and Methamphetamine Use 
Among the consequences of MA use, depression is of significant concern because 
MA use and depression are highly comorbid, and this comorbidity worsens the overall 
prognosis and treatment outcomes (Glasner-Edwards et al., 2010). The association 
between MA use and depression is likely bidirectional (McKetin, et al., 2011; Semple et 
al., 2007), with short- and long-term MA use resulting in mood changes, and MA use 
being a compensatory behavior to alleviate symptoms of depression (Koob et al., 2013). 
Further, MA is known to reduce concentrations of dopamine and serotonin, which 
predispose MA users to depression (Sekine et al., 2003; Thomas et al., 2010).  
Unlike many other drugs of abuse, MA use rates are greater in females than males 
(Division of Substance Abuse and Mental Health, 2014), and the average age of onset of 
MA use in females is younger (19.2 years) compared with males (20.6 years; Dluzen & 
Liu, 2008). Furthermore, females report that their initial MA use is an attempt to lose 
weight or a result of coping with a negative mood, whereas males report ability to work 
more and improve sex as reasons for their initial use (Bretch, O’Brien, von Mayrhauser, 
& Anglin, 2004). As such, it is not surprising that several studies have shown that 
comorbid depression and MA use rates are higher in females compared to males 
(Glasner-Edwards, Mooney, et al., 2008a, 2008b; Semple et al., 2007). However, it is 
important to note that in the general population rates of depression are higher in females 
than males, and therefore, this comorbid depression and MA use in females may 
represent a type of self-medication or may be the result of existing gender differences. 
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Gender Differences in Depression 
Gender differences in the prevalence of depression are well documented. 
Consistent study findings suggest that approximately twice as many females are 
depressed than males (Andersen, Thielen, Bech, Nygaard, & Diderichsen, 2011; Hankin 
et al., 1998; Piccinelli & Wilkinson, 2000; Weissman & Olfson, 1995). By the middle 
teenage years, females experience more than double the rate of depressive disorders 
found in males (Garrison et al., 1997; Wade, Cairney, & Pevalin, 2002). This 
approximate 2:1 gender difference in depression continues throughout the reproductive 
years (Kessler, McGonagle, Swartz, Blazer, & Nelson, 1993). In addition to increased 
incidence, initial episodes of depression are longer in duration and more severe in 
symptomatology in females compared to males (McCauley et al., 1993). Females are 
more likely than males to have atypical symptoms of depression, such as hypersomnia 
(i.e., excessive sleep) and hyperphagia (i.e., excessive eating), to have comorbid anxiety 
disorders, and to attempt suicide (Gorman, 2006). Globally, depression is among the most 
common disorders affecting females throughout their lives, and is the leading cause of 
disability among women between the ages of 15 and 44 years (Lopez, Mathers, Ezzati, 
Jamison, & Murray, 2006). Moreover, depression is associated with high-risk behavior 
such as illicit drug use (Marmorstein, Iacono, & Malone, 2010).  
 Recently the Utah Department of Health published a report on depression and 
antidepressant use in Utah (Gaskill, 2010). Using health insurance claims from 899,323 
Utah residents, antidepressant use was examined, and over 6 million pharmacy claims 
from 2009 were reviewed. Of interest, they reported that 84,000 individuals were 
prescribed antidepressants, resulting in antidepressants being the most widely prescribed 
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medication in the state. When comparing antidepressant utilization by gender, researchers 
noted that females are prescribed antidepressants at a rate of more than twice that of 
males. A recent study by Mental Health America ranked Utah the most depressed state in 
the nation (Healthcare, 2007). Their results indicated that among adults, 10.1% 
experienced a depressive episode in the past year (Healthcare, 2007).  
 
Neuroimaging as a Translational Tool 
 A barrier to translational psychiatry and substance use disorder research is the 
lack of measurable correlates of illness and recovery. Magnetic resonance spectroscopy is 
a useful probe of tissue chemistry and metabolites of biochemical interest that can be 
measured to improve our understanding of the effects of depression and MA on the brain. 
Proton (1H) and phosphorus (31P) MRS are commonly used nuclei in evaluating the 
central nervous system. Studies utilizing 1H MRS measure cerebral concentrations of 
creatine, N-acetyl aspartate (NAA), glutamate (Glu), glutamine, (Gln), gamma-
aminobutyric acid (GABA), choline (Cho) and myo-inositol (mI). By contrast, 31P MRS 
studies examine concentrations of phosphocreatine (PCr), phosphomonoesters (PME), 
beta nucleotide triphosphate (β-NTP, largely ATP), and intracellular pH.  
 
Magnetic Resonance Spectroscopy Studies of Depression  
Phosphorus MRS findings in adults with depression (n = 56) have consistently 
shown a characteristic pattern of metabolic change: reduced β-NTP concentrations and 
higher PCr concentrations when compared to healthy volunteers (n = 35; Iosifescu et al., 
2008; Moore, Christensen, Lafer, Fava, & Renshaw, 1997; Volz et al., 1998). This 
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pattern, which is more common in females than males (Renshaw et al., 2001), suggests 
that some depressed patients have increased brain energy stores that are not being 
accessed to support cerebral activity. This specific pattern of altered energy metabolism 
is associated with an increased likelihood of treatment response to both selective 
serotonin reuptake inhibitors (SSRI) antidepressants and thyroid hormone (Iosifescu et 
al., 2008). There is one published report of 1H MRS in depression with a sample of 
adolescents (n = 5), and these findings also indicate alterations in brain energy 
metabolism (Steingard et al., 2000). In healthy adults (n = 10), administration of the 
dietary supplement creatine can induce resting brain energy metabolism changes (Lyoo et 
al., 2003), suggesting the possibility of using creatine treatment to modify brain high 
energy phosphate metabolism in patients with depression. 
 
Magnetic Resonance Spectroscopy Studies of Methamphetamine  
Several 1H MRS studies have suggested neuronal loss and glial dysfunction in 
chronic MA users. Specifically, levels of the neuron associated amino acid NAA and 
levels of creatine+PCr have been reported as decreased in the basal ganglia (n = 39; 
Ernst, Chang, Leonido-Yee, & Speck, 2000; Sekine et al., 2003), and in the anterior 
cingulate cortex (n = 69; Nordahl et al., 2005; Nordahl et al., 2002; Salo et al., 2007) in 
MA users compared to healthy controls (n = 38). Alterations in Cho and mI are also 
involved in neural processes that have been associated with long-term MA use. Study 
findings suggest that Cho concentrations increase shortly after abstinence is initiated, 
possibly as a result of the brain attempting to repair MA induced injury (Ernst et al., 
2000; Nordahl et al., 2005). Myo-inositol is considered a glial marker (Brand, Richter-
   
	  
22
Landsberg, & Leibfritz, 1993), and therefore, findings of increased mI levels may reflect 
glial proliferation in MA users (Ernst et al., 2000; Sung et al., 2007).  
There is one published report of 31P MRS findings in MA dependence, and the 
findings suggest lower PCr concentrations in MA users compared to healthy controls. 
Interestingly, female MA users (n = 23) had significantly lower PCr ratios than male MA 
users (n = 28; Sung et al., 2013). These data are consistent with alterations in high energy 
phosphate metabolism in MA dependent participants, since PCr serves as a buffer to 
maintain constant ATP levels. Exogenous creatine treatment, which has been shown to 
increase PCr in 10 healthy volunteers (Lyoo et al., 2003), might provide beneficial effects 




 A French scientist, Michel Eugene Chevreul, first described creatine as a 
nitrogenous organic acid that occurs naturally in vertebrate animals in the 1830s. Acting 
as a substrate for hydrogen ions, creatine facilitates the production of ATP from ADP, 
thus increasing the amount of free energy available within cells (Kamber et al., 1999).  
Creatine has a role in high-energy phosphoryl group transfer during skeletal muscle 
contraction via the creatine kinase reaction. The enzyme creatine kinase catalyzes the 
reversible reaction of creatine and ATP, forming PCr and ADP (McLeish & Kenyon, 
2005). The intracellular creatine/PCr ratio plays an important role in maintaining an 
adequate supply of energy, in the form of cellular ATP (Wallimann, Wyss, Brdiczka, 
Nicolay, & Eppenberger, 1992). Phosphocreatine may be viewed as a reservoir of high 
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energy phosphate, which supplies ATP, the primary energy source in cells, on demand. 
Consequently, creatine plays a significant role in energy homeostasis of cells with 
intermittently high energy requirements (McLeish & Kenyon, 2005).  
Creatine plays a role in transferring energy from the mitochondria to the cytosol 
in tissues with high-energy requirements such as brain and skeletal muscle (Wyss et al., 
1998). Creatine was also recently identified as a potent natural survival and 
neuroprotective factor for developing nigral dopaminergic neurons (Andres et al., 2005). 
Creatine supplementation improves the function of the creatine kinase/PCr system by 
increasing cellular creatine and PCr levels, improving the rate of ATP resynthesis, and 
maintaining cellular-energy homeostasis (Jost et al., 2002). 
Clinical trials in humans provide evidence for creatine's effect on brain function. 
A study published by Rae et al. (2003) showed that increasing oral creatine intake 
resulted in a significant positive effect on both working memory and intelligence in 45 
vegetarian young adults. These results were in agreement with the observations that brain 
creatine levels correlate positively with recognition memory (Ferrier et al., 2000), and 
that creatine supplementation reduces mental fatigue on a serial calculation task 
(Watanabe, Kato, & Kato, 2002). The latter study also showed reduced activation 
stimulated oxyhemoglobin delivery to the activated area following creatine 
supplementation (Watanabe et al., 2002). This suggests that creatine supplementation is 
acting to smooth fluctuations in the blood oxygen level-dependent response curve, which 
results from brain activation (Gjedde, Poulsen, & Ostergaard, 1999; Madsen, Cruz, 
Sokoloff, & Dienel, 1999), possibly by altering rates of ATP synthesis in the 
mitochondria through the mitochondrial creatine kinase adenine nucleotide translocase 
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porin complex (Wallimann et al., 1992; Walter et al., 2000).  
Creatine is currently being investigated as a treatment for neuromuscular and 
neurodegenerative diseases. As a treatment for muscular dystrophy, creatine has been 
shown to significantly improve muscle strength and daily activities in (n = 36; Walter et 
al., 2000). In a study of Huntington’s disease, supplementation with creatine 
demonstrated increased brain and serum creatine concentrations, which returned to 
baseline after a washout period (n = 64; Hersch et al., 2006), suggesting that oral creatine 
may increase brain creatine availability and activity. Because of strong evidence that 
mitochondrial impairment plays a role in the pathogenesis of Parkinson’s disease (Andres 
et al., 2005), creatine has been explored as a treatment option. Study findings suggest that 
creatine supplementation may delay increases in the Unifed Parkinson’s disease Scale by 
as much as 50% in 67 medication naïve adults with Parkinson’s disease (Investigators, 
2006). Collectively, these study findings suggest the potential neuroprotecive effects of 
creatine treatment.  
 
Creatine’s Potential Antidepressant Effects  
Data from preclinical animal studies suggest that creatine has sex dependent 
antidepressant properties. The Prosolt Forced Swim Test (FST) is the most widely 
employed experimental animal model of depression. Fed to rats, diets enriched with 4% 
creatine for 6 weeks confer a longer period until immobility in female rats compared with 
rats fed 0% creatine. In male rats, however, creatine has the opposite effect (Allen, 
D'Anci, Kanarek, & Renshaw, 2010). Moreover, supplementation with 4% creatine in 
female rats was of greater benefit for reducing depression like behavior than 10mg/kg of 
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fluoxetine (Allen, D'Anci, Kanarek, & Renshaw, 2012). The gender specific nature of 
these findings may be due to the fact that estrogen receptors are quite common in 
mitochondria (Gorman, 2006). Estrogen has potent effects on mitochondria, particularly 
at times of mitochondrial stress (Simpkins, Yang, Sarkar, & Pearce, 2008). 
 In an 8 week open label study of 4 grams of creatine augmentation in female 
adolescents (n = 5) who failed to respond to an SSRI, Childhood Depression Rating 
Scores (CDRS) were reduced by 56% (Kondo et al., 2011), and further, the researchers 
noted that brain PCr concentrations increased when compared to a control group (n = 10; 
Kondo et al., 2011). In a placebo controlled trial of creatine augmentation in female 
adults, the creatine augmented group (n = 25) showed statistically significant 
improvements in depression rating scores from baseline compared with the placebo group 
(n = 27; Lyoo et al., 2012). In both published depression studies, creatine was well 
tolerated with few adverse events reported. The exact intracellular mechanism underlying 
how adjunctive creatine bolsters antidepressant efficacy of SSRI therapy remains 
unknown, but its engagement in brain energy metabolism is one possible explanation.  
To date, no studies have examined the effect of creatine supplementation in 
female MA users. Given the gender specific effects of creatine in animal models (Allen et 
al., 2010) clinical trials in males should be deferred until efficacy and safety have been 
shown.  
 
Safety Profile and Toxicity of Creatine  
Retrospective and prospective studies in humans have found no evidence for 
long-term or short-term significant side effects from creatine supplementation taken at 
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recommended doses (Mihic, MacDonald, McKenzie, & Tarnopolsky, 2000; Poortmans et 
al., 1997; Poortmans & Francaux, 1999, 2000). Most controlled studies of creatine report 
an absence of side effects or report no differences in the incidence of side effects between 
creatine and placebo (Shao & Hathcock, 2006). Mihic and colleagues (2000) have 
demonstrated that creatine loading increases fat free mass, but does not affect blood 
pressure or plasma creatinine in adult males and females. 
Reports in the popular media of links between creatine use and muscle strains, 
muscle cramps, heat intolerance, and other side effects are not supported by the medical 
literature (Shao & Hathcock, 2006). Studies conducted in athletes and military personnel 
indicate a substantial safety level of both short- and long-term creatine supplementation 
in healthy adults (Bennett et al., 2001; Greenwood, Kreider, Greenwood, & Byars, 2003; 
Greenwood, Kreider, Melton, et al., 2003; Kreider et al., 2003; Poortmans & Francaux, 
1999; Robinson, Sewell, Casey, Steenge, & Greenhaff, 2000). Concerns about high dose 
creatine’s association with renal toxicity are based exclusively on two published case 
reports, and in one of the cases, the patient had a documented preexisting kidney 
condition (Koshy, Griswold, & Schneeberger, 1999; Pritchard & Kalra, 1998). Literature 
reviews and expert consensus panels have concluded there is no evidence supporting an 
association between creatine and renal disease (Farquhar & Zambraski, 2002; Poortmans 
et al., 1997; Terjung et al., 2000; Yoshizumi & Tsourounis, 2004).  
Concern has been raised regarding creatine’s potential for adverse effects on the 
kidneys and renal system, in part because creatine supplementation can increase urinary 
creatine and creatinine excretion (Harris, Saderlund & Hultman, 1992). In response to 
these concerns, Poortmans and Francaux conducted studies of the effect of creatine 
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supplementation on renal function, showing that short-term supplementation did not alter 
glomerular filtration rate in 5 male athletes (Poortmans et al., 1997), and that chronic 
supplementation of up to 5 years’ duration did not impair renal function in 9 healthy 
athletes (Poortmans & Francaux, 1999). In a letter published in The Lancet, Poortmans 
and Francaux (1998) reported that laboratory results show that oral creatine 
supplementation has no adverse effects on the renal responses of 20 healthy individuals. 
Schilling and colleagues (2001) conducted a retrospective study of participants (n 
= 26) who had been taking oral creatine from 0.8 to 4 years, at an average dose of 9.7 
grams per day. Data were collected on 65 health related variables. These included a 
complete blood count, 27 serum chemistries, and anthropometric data including vital 
signs and % body fat. On all 65 variables, group means fell within the normal clinical 
range. The authors concluded that long-term creatine supplementation does not result in 
adverse health effects (Schilling et al., 2001).  
Evidence to date suggests that even aging, debilitated, medically fragile patients 
are able to tolerate creatine supplementation. Bender and colleagues studied elderly 
patients with Parkinson’s disease who had received either placebo or 4 grams/day of 
creatine for 2 years. They found no differences between the creatine (n = 40) and placebo 
(n = 20) groups in laboratory markers of renal dysfunction (Bender, Samtleben, Elstner & 
Klopstock, 2008). Interestingly, the participants who received creatine performed better 








In summary, the prevalence of depression is more common in females than males, 
and individuals with an underlying mental illness may use substances to alleviate 
negative emotions. Females in particular have higher rates of MA use compared with 
males, which is unlike other drugs of abuse. Research studies suggest that females tend to 
use MA as a mechanism for losing weight or to cope with depression.  
Magnetic resonance spectroscopy abnormalities in MA dependent participants are 
suggestive of neuronal loss, glial dysfunction, and reduced levels of PCr. The nutritional 
supplement creatine is under investigation as a treatment for Parkinson’s disease, 
Huntington’s disease, muscular dystrophy, and major depressive disorder (MDD). 
Magnetic resonance spectroscopy studies of creatine treatment demonstrate an increase in 
brain PCr, suggesting that creatine may improve high energy phosphate metabolism. In 
addition, creatine treatment has been shown to have sex dependent antidepressant 
properties in animals. Finally, in depression studies of females, creatine treatment has 
demonstrated a decrease in depressive symptoms.  
The proposed study will fill a gap by describing the results of creatine treatment 
in female adults with comorbid depression and MA use. Previous research has shown that 
adjunctive creatine treatment may reduce depression in adult and adolescent females with 
MDD, but there are not any published reports of creatine as a treatment option for 
comorbid depression and MA use. Understanding if a novel over the counter treatment 
option with few side effects is efficacious would be an important step in MA research. 
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FRAMEWORK, METHODOLOGY, ANALYSIS AND DATA, AND  
SAFETY MONITORING PLAN 
 
In this section, an overview of the framework for this study, including definitions 
of and relations among key concepts, study design, data collection methods, statistical 
analysis plan and data and safety monitoring plan is provided.  
 
Theoretical Framework 
The hypotheses and aims of this study are based on both theorized and measured 
physiological responses to MA use and the self-medication hypothesis of drug use. 
Methamphetamine is known to reduce concentrations of dopamine and serotonin, which 
may result in depressive symptoms (Sekine et al., 2003; Thomas et al., 2010). Increasing 
evidence from human and animal studies indicate a relationship between dopamine and 
serotonin transmission in the central nervous system and depression. In preclinical animal 
studies of MA administration, a 65% reduction of vesicular dopamine uptake was 
observed 1 hour after MA treatment (Brown, Hanson, & Fleckenstein, 2000). In human 
positron emission tomography MA studies, findings demonstrate significant decreases in 
dopamine transport density in abstinent MA users compared to healthy controls (McCann 
et al., 1998; Volkow et al., 2001). In addition, research has shown that MA use results in 
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a decrease in serotonin transporter density (Sekine et al., 2006) and serotonin transporter 
activity (Fleckenstein, Gibb, & Hanson, 2000). This reduction in uptake and 
transportation is interpreted as resulting in lower concentrations of dopamine and 
serotonin (Fleckenstein et al., 2000). In agreement with the evidence that there is an 
association between decreased dopamine and serotonin levels and depression, these 
findings suggest that a reduction in dopamine uptake and transport density may be linked 
to the depressive symptoms experienced by MA users.  
A key MRS finding has noted a decrease in PCr levels in MA users, an effect that 
was more prominent in females (Sung et al., 2013). Neuronal energy demands are met 
through a shift in the creatine kinase reaction equilibrium (PCr2+  + ADP <===> Cr + 
ATP2+), which is designed to maintain a constant ATP concentration (Andres, Ducray, 
Schlattner, Wallimann & Widmer, 2008). The report of PCr being lower in MA users (n 
= 51) relative to healthy controls (n = 23; Sung et al., 2013) provides some evidence that 
MA use compromises brain energy metabolism.  
 The self-medication hypothesis of drug use posits that individuals use substances 
as compensatory behavior to alleviate symptoms of an underlying mental illness 
(Khantzian, 1985). Further, it explains that the substance an individual comes to rely on 
is not a random choice (Khantzian, 1985). Considering the common symptoms of 
depression: anhedonia, sleep disturbances, weight loss or gain, and fatigue, it is not 
unreasonable to think that a depressed individual would use MA to alleviate symptoms. 
However, there is a paucity of literature discussing the self-medication hypothesis in MA 
users. There are published reports discussing reasons for initiating MA use, and to get 
more energy (n = 44) or stay awake (n = 34), escape (n = 24) and lose weight (n = 19) 
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were frequent responses (Bretch et al., 2004; Semple et al., 2007).  
In summary, the relationship between MA use and depression appears to be 
bidirectional. As explained above, MA use causes disturbances in dopamine, serotonin, 
and brain energy metabolism predisposing an individual to depression. Moreover, 
individuals with depression, specifically those who experience low energy, sleep 
disturbances, weight gain and fatigue, may gravitate towards MA to alleviate depressive 
symptoms. However, there is a gap in the literature addressing the self-medication 
hypothesis in MA users, but it is not unreasonable to surmise that individuals with 




This study involved a within subjects design to describe the relationships between 
creatine treatment and depression and creatine treatment and brain PCr levels. 
Longitudinal prospective depression data were collected from 14 females with depression 
who use MA. Neuroimaging data were collected pre- and postcreatine treatment from 10 
of the females. Statistical analyses included a linear mixed effects repeated measures 
model and a paired t-test and Wilcoxon Signed Ranks test.  
 
Study Design 
A within subjects design of creatine monohydrate treatment of 14 depressed 
female MA users (the power analysis calculation is descried in the Statistical Analysis 
section of this chapter) was proposed. This was a pilot study to collect preliminary data 
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for a grant submission that proposed a randomized control trial (RCT) of creatine and 
placebo in depressed female MA users. All participants in this pilot study were treated 
with 5 grams of daily creatine for 8 weeks. The recommended creatine dose, 5 grams 
daily for 8 weeks, was based on doses that are most commonly used in clinical research 
trials and safety and efficacy consideration (Kondo et al., 2011; Lyoo et al., 2012). A 
dose of 5 grams daily was well tolerated in the only RCT of creatine as a treatment option 
for depression in adult females. Lyoo and colleagues (2012) reported no differences 
between the placebo and creatine groups with respect to adverse events, and there was a 
statistically significant decrease in HAMD scores in the creatine group. A dose of 5 
grams was also well tolerated in the current study and adverse events are reported in 
Chapter 6. The following example doses have been used orally in adults (age > 18): 
• For older adults (age = 71 years): 0.3 grams/kilogram for 5 days, followed by 0.07 
grams/kilogram for 79 days (Chilibeck, Chrusch, Chad, Shawn, Davison & 
Burke, 2005) 
• Cholesterol reduction: 20-25 grams per day for 5 days followed by 5-10 grams 
daily (Earnest, Alamada & Mitchell, 1996) 
• Chronic obstructive pulmonary disorder: 5.7 grams 3 times per day for 2 weeks, 
followed by 5.7 grams per day (Fuld et al., 2005), and 0.3 grams/kilogram per day 
for 7 days followed by 0.07 grams/kilogram daily for 7 weeks (Faager, Skold, 
Rundgren, Tollback & Jakobsson, 2006) 
• Congestive heart failure: 20 grams for 5 days (Andrews, Greenhaff, Curtis, Perry 
& Cowley, 1998) 
• Depression: 3-5 grams daily for 4 to 8 weeks (Kondo et al., 2011; Lyoo et al., 
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2012; Roitman, Green, Osher, Kami & Levine, 2007) 
• Muscular dystrophy: 10 grams daily for 8 weeks (Walter et al., 2000) 
 
Variables 
 For specific aim one, to describe changes in HAMD scores over the course of 8 
weeks of creatine treatment in depressed female MA users, there is not an independent 
variable and depression is the dependent variable. For specific aim two, to compare pre- 
and postcreatine treatment in depressed MA users measured by 31P MRS, there is not an 
independent variable and the dependent variable is PCr levels. 
 
Participant Selection Criteria 
  Using purposive sampling, 14 depressed female MA users were recruited for this 
open label trial of oral creatine. Table 1 and the following text describe study eligibility 
criteria. Females were considered for participation if they were between the ages of 18 – 
64 years, and met the operational definition of depression as a HAMD of 15 or greater 
and DSM-IV criteria of major depressive disorder (MDD) identified by the Structured 
Clinical Interview for DSM-IV Disorders (SCID-I/P) with psychotic screen (First, 
Spitzer, Gibbon, & Williams, 2007). An age range of 18 – 64 was chosen based on data 
published by the Utah Division of Substance Abuse and Mental Health (2014) regarding 
primary substance of choice by age. These data show that second to alcohol, MA was the 
preferred drug of abuse for adults between 35 and 64 years old. Further, MA was the 
third most preferred drug of abuse for adults between the ages of 25 and 34 years and the 
fourth preferred drug of abuse for adults less than 25 years of age (Division of Substance 
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Abuse and Mental Health, 2014). In a study of posttreatment status of MA users who 
entered outpatient treatment, 62.7% (n = 71), compared with 62.9% (n = 72) at baseline, 
of the sample reported continued depression despite MA discontinuation 12 months after 
treatment initiation (Rawson et al., 2002), and therefore, females who met SCID-I/P 
diagnostic criteria for MA dependence or abuse within the last 12 months were 
considered for participation. 
  With respect to exclusion criteria, individuals who met criteria for bipolar 
disorder or psychotic features on the SCID-I/P were not invited to participate. 
Individuals were not considered for study participation if they had renal disease because 
to date it cannot definitively be stated if short- or long-term creatine usage is harmful to 
the kidneys. Females were also excluded if they were diabetic because one report 
suggests that creatine might influence insulin production, although studies of creatine 
administration on insulin production in humans have not yet been conducted (Benzi, 
2004). Since GI discomfort has been reported in some individuals taking creatine (Smith 
& Dahm, 2000), females with GI diseases, such as colitis (e.g., infectious colitis, 
ulcerative colitis, Crohn’s disease, and ischemic colitis) or diverticulitis, were excluded.  
Females with a diagnosed seizure disorder were also be excluded, because in one 
report, the authors suggest that creatine might be implicated in possibly related seizure 
activity, although it is important to mention that the reported seizure activity was 
associated with hypoglycemia, secondary to a cardiovascular accident or cardiac arrest 
(Haller, Meier & Olson, 2005). Moreover, the seizure events were reported through the 
Food and Drug Administration’s MedWatch System, but they did not undergo a formal 
review (Haller, Meier & Olson, 2005). Current suicide risk identified by administration 
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of the C-SSRS excluded a female’s participation. Females treated with an antidepressant, 
antipsychotic or mood stabilizing medication were also excluded. The purpose of this 
study was to evaluate creatine administration as a stand alone treatment rather than an 
augmentation treatment. Finally, a positive HIV test or elevated liver enzymes, which 
were determined by a blood draw at the screening visit, excluded individuals as well as a 
contraindication to magnetic resonance scan, such as ferromagnetic items in the body 
that could not be removed. 
 Study withdrawal criteria included early termination if a participant experienced 
intolerable or clinically significant side effects to creatine, hospitalization for suicide 
ideation, positive pregnancy test, incarceration, and/or initiation of an antidepressant, 
antipsychotic or mood stabilizer. In addition, the principal investigator (PI) retained the 
right to withdraw participants from the study without their permission, in the event they 
were unwilling or unable to maintain adherence to the research protocol. Screening, 
enrollment and early termination data are presented in Chapter 6.  
 
Definitions 
Definitions used in describing the status of participants in the trial were as 
follows: “screened” participants were those who signed an informed consent form and 
provided any demographic or baseline assessments whether or not they met the eligibility 
criteria. “Enrolled” participants were those who meet eligibility criteria, completed the 
baseline 31P MRS scan and were dispensed study medication at visit 1. “Completed” 
participants were those who completed the duration of the study through the follow up 
visits. “Partial completed” participants were those who completed 8 weeks of study drug 




 The study was divided into three phases: screening (or baseline), treatment and 
follow up phases (Table 2).  
 
Recruitment and Informed Consent  
Participants were recruited from Assessment and Referral Services (ARS). The 
following information about ARS and Interim Group Services is summarized from 
information posted on http://medicine.utah.edu/ars. Assessment and Referral Services is a 
freestanding clinic within the Department of Psychiatry at the University of Utah. It 
occupies 6000 square feet in downtown Salt Lake City close to public transportation and 
approximately 3 miles from the University of Utah. It consists of 20 full time staff and 
approximately 30 part-time staff. Salt Lake Behavioral Health Services contracts with 
ARS to provide two different functions. One is to provide assessments and referrals for 
individuals in Salt Lake County who have been arrested for driving under the influence; 
or who are seeking substance abuse services voluntarily or due to other court mandates. 
The second is to provide Interim Group Services (IGS), which are free groups for 
individuals awaiting Salt Lake County funded substance abuse treatment services. 
There are two primary purposes of IGS. The first is to serve as the first step for 
adults who are residents of Salt Lake County and do not have the monetary benefit to pay 
 
Table 2. Study phases 
 Baseline phase Treatment phase Follow up phase 
Week # -1 0 1 2 3 4 5 6 7 8 9 10 11 12 
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for substance abuse treatment. In almost all cases, those individuals are referred to IGS to 
begin the process of admission to treatment. The second purpose of IGS is to offer 
individuals a safe and supportive environment while they wait for treatment availability, 
which may be up to a 3 month wait.  
At their first IGS meeting, individuals are provided with information regarding 
the scheduling of their clinical assessment. Assessments include a clinical interview, the 
American Society of Addiction Medicine Placement Criteria, and information from the 
Bureau of Criminal Identification if the individual has a pending legal issue. Individuals 
are then referred to the appropriate treatment agency based on issues such as their clinical 
needs, need for county funding, level of care indicated, and the compatibility between the 
agency’s location and hours of operation with the individual’s residence and employment 
situation.  
During the assessment, ARS staff screened individuals for study participation. If 
an individual was female, between the ages of 18 – 64, reported depression and MA as a 
primary drug of choice, the screener provided the potential participant with the PI’s 
phone number. Subsequently, females who called were asked preliminary screening 
questions by phone, and if they passed the phone screening, a formal informed consent 
process with the PI was scheduled to occur in a private office at ARS.  
Consent for study participation was obtained prior to the conduct of any study 
procedures, including the initial assessment to determine whether the participant met 
study inclusion criteria. The participants completed an assessment of understanding of the 
consent process after the consent process was completed to document their understanding 
of the nature of the study. The informed consent process was open ended, and females 
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were given the opportunity to ask questions and take the consent form home to review it 
before signing it.  
During the informed consent process, the study purpose, study procedures, risks 
and benefits of participation, contact information and statement about research related 
injuries were discussed. In addition, an explanation of reasons that the PI would withdraw 
participants from the study, the compensation schedule and use of protected health 
information (PHI) were also discussed.  
Study fliers with the PI’s contact information were also hung around ARS, and 
interested females called for additional information. If a female passed the preliminary 
phone screening, she was invited to attend an informed consent process visit.  
 
Facilities   
A private office at ARS was used for conducting screening and subsequent study 
visits. The office is stocked with clinical equipment, such as a blood pressure machine 
and a scale to measure weight, and blood drawing supplies. In addition, urine pregnancy 
and drugs of abuse tests were stored in the private office. Neuroimaging took place in the 
MRI suite at the University of Neuropsychiatric Institute (UNI) on a Siemens 
MAGNETOM Verio 3.0 Tesla 70cm bore MRI scanner.  
 
Data Collection and Management 
Study data were recorded on Case Report Forms (CRFs). Completed CRFs were 
filed in participant binders and stored in a locked office with access limited to research 
personnel. De-identified data from CRFs were entered into SPSS® version 20 for 
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Macintosh computer. Forms that had missing or inconsistent data were recorded in the 
database; however, a “missing data” code (-99) was entered in place of each piece of 
missing or inconsistent data. 
 
Measures 
The following instruments and their purpose with respect to the current study are 
listed as follows: 
• Structured Clinical Interview for DSM-IV Disorders (SCID-I/P) with psychotic 
screen was used to determine study eligibility (e.g., determine if MDD and MA 
dependence/abuse within the last 12 months is present or absent) 
• Hamilton Depression Rating Scale (HAMD) was used to evaluate change in the 
severity of depression over the course of the study 
• Beck Anxiety Inventory (BAI) was used to evaluate change in the severity of 
anxiety over the course of the study because anxiety and MA dependence and 
anxiety and depression are often comorbid 
• Columbia Suicide Severity Rating Scale (C-SSRS) was used to determine 
eligibility criteria and as a safety tool to assess suicidality over the course of the 
study  
• Drug History Questionnaire (DHQ) was used to collect baseline drug use history 
to describe the sample 
• Urine drug testing was used to measure the presence (or absence) of substances of 
abuse (e.g., MA, opiates, THC, cocaine and benzodiazepines) 
In the following paragraphs, psychometric properties of each of these 
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measurements are discussed. Internal consistency, test retest reliability and interrater 
reliability and content, construct, and criterion related validity from published reports are 
outlined. However, it is worth pointing out that traditional psychometric approaches are 
questioned as being appropriate for scales like the HAMD and BAI considering they 
were developed based on clinical classifications rather than an underlying construct 
(Fayers & Hand, 2002). Regardless, since traditional psychometric properties are more 
commonly understood and reported, they are included for the HAMD and BAI in the 
following paragraphs, and a more detailed discussion regarding reliability and validity of 
these scales is included in Chapter 6. Further, reliability estimates from the current study 
are also discussed in Chapter 6.  
In addition to the above mentioned measurements, self-report drug use over the 
past 48 hours data for methamphetamine, cocaine, THC, opiates and benzodiazepines 
will be collected. Self-report drug use data will include use (yes or no), and if yes, 
quantity. Consistent with the self medication hypothesis (Khantzian, 1985), if mood 
symptoms improve, drug use may be reduced, and use will be monitored by self-report 
use as well as urine drug testing (discussed below). Demographic data, including age, 
race, ethnicity, marital status, income level, history of antidepressant treatment, and years 
of education were also collected to describe the sample, as well as an inquiry regarding 
treatment program attendance. Finally, adverse effects were monitored using a checklist 
of medication adverse effects. 
Structured clinical interview for DSM-IV disorders.  The SCID-I/P is a semi-
structured clinician administered interview used to determine Axis I disorders (First, 
Spitzer, Gibbon, & Williams, 1997). Considering that the SCID-I/P is based on DSM-IV 
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diagnostic criteria, reliability for categorical constructs is reported in terms of Kappa, 
which is a statistic that corrects for chance agreement (Viera & Garrett, 2005). Relevant 
to the sample recruited in this study, Kappa values ranging from .64 to .90 (Lobbestael, 
Leurgans, & Arntz, 2011; Segal, Kabacoff, Hersen, Van Hasselt, & Ryan, 1995; Skre, 
Onstad, Torgersen, & Kringlen, 1991; Williams, et al., 1992; Zanarini & Frakenburg, 
2001; Zanarini, et al., 2000) have been reported for the MDD section of the SCID-I/P and 
.76 – 1.0 (Lobbestael, Leurgans, & Arntz, 2011; Skre, Onstad, Torgersen, & Kringlen, 
1991; Williams, et al., 1992; Zanarini, et al., 2000) for the substance dependence/abuse 
section. Also relevant to the sample of interest, interrater reliability for raters was found 
to be Kappa = 0.81 for the depression module and Kappa = 0.78 for the substance use 
disorder module of the SCID-I/P were reported for a sample of 922 females (Bromberger 
et al., 2005).  
Validity of the SCID-I/P can be evaluated in terms of how well it reflects the 
DSM-IV diagnostic criteria, although, this can be complex because the SCID-I/P is 
typically used as the “gold standard” to which other measures are compared to (First et 
al., 1997). Extensive pilot and field testing suggest acceptable content validity of the 
SCID-I/P in mixed age samples (First et al., 1997). A summary of the criterion related 
validity studies indicate there is a high level of correspondence between SCID-I/P 
determined diagnoses and other variables including clinical symptoms of disorders (First 
et al., 1997). Relevant to the sample that was recruited, there is good evidence for 
concurrent validity in a sample of substance abusers (n = 83 inpatient and n = 17 day 
treatment participants) with a current diagnosis of major depression on the SCID and the 
Addiction Severity Index (ASI) psychological severity score (M = 0.62, SD = 0.14, p < 
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.001; Kranzler, Kadden, Babor, Tennen, & Rounsaville, 1996). In addition, in the same 
sample, excellent discriminate validity for current alcohol and drug abuse/dependence 
SCID diagnoses and the ASI alcohol score have been established (M = 0.60, SD = 0.22, p 
< 0.001; Kranzler et al., 1996). 
Hamilton Depression Rating Scale.  The HAMD is a semistructured clinician 
administered depression rating scale and is the most widely used rating scale for 
depression (Bagby, Ryder, Schuller & Marshall, 2004; Hamilton, 1960). The original 
HAMD consisted of 17-items, and later it was revised to a 21-item scale with four 
additional items (diurnal variation, paranoid ideation, obsessive/compulsive symptoms, 
and depersonalization/derealization) that are not summated in the total score (Iannuzzo, 
Jaeger, Goldberg, Kafantaris & Sublette, 2006). The 17-item HAMD consists of 17 items 
that are rated on a 3 or 5 point scale that represent the level of severity for that symptom 
(i.e., item) over the prior 7 days. An item score of 0 indicates absence of symptoms for 
that item, whereas an item score of 1-5 suggests mild to severe symptoms for that item. 
The total range is from 0 to 50, with scores of 0 to 3 suggesting “normal” or “no illness;” 
those between 4 and 7 indicating “borderline ill;” scores between 8 and 15 representing 
“mildly ill;” scores between 16 and 26 signifying  “moderately ill” and capture diagnostic 
criteria for major depressive disorder; scores greater than or equal to 27 are considered to 
be in the range of “markedly” or “severely ill” (Furukawa, Akechi, Azuma, Okuyama, & 
Higuchi, 2007). 
Internal consistency of the HAMD has been reported with Cronbach’s alpha 
ranging from 0.46 – 0.92 (Bagby et al., 2004). Cronbach’s alpha of 0.46 was reported 
from a study evaluating depression severity in a sample of 100 elderly participants with 
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physical illness, and the author concluded that the HAMD is an unreliable tool for 
measuring depression in their population of interest (Hammond, 1998). Test retest 
reliability is satisfactory at the item level with Pearson’s r  > 0.70 in all of the published 
studies (Bagby, et al., 2004). Finally, reports of interrater reliability have shown 
acceptable agreement among raters, with Kappa values of 0.81 – 1.00 (Iannuzzo et al., 
2006). The use of a structured interview guide has been shown to increase interrater 
reliability from a Pearson’s r as low as 0.39 without the structured interview guide to a 
Pearson’s r of 0.78 with the structured interview guide (Bagby, et al., 2004).  
Validity of the HAMD has been extensively evaluated, and findings suggest that 
it is a highly valid instrument for defining and measuring depression in adult patients 
with mental illness (Bagby, et al., 2004). However, there are no reports on the HAMD 
being valid in a sample of MA users. There are questions on the HAMD related to sleep 
and appetite and responses to these questions could be influenced by amount and 
frequency of MA use. For example, an MA using individual may report insomnia 
because she recently used MA for several days in a row. As such, questions on the 
HAMD related to sleep would be scored based on her insomnia related to MA use and 
not necessarily based on her mood (i.e., depression).  
In the area of content validity, concern with regard to the HAMD adequately 
capturing the current operationalized definition of depression has been raised (Bagby et 
al., 2004). The HAMD items are based on the DSM criteria for depression, and the DSM 
has been revised three times since the inception of the HAMD. However, the core items 
of depression on the DSM remain unchanged, and similarly, the core items of the HAMD 
have remained the same for 40 years (Bagby et al., 2004).  
   
	  
53
Fourteen separate instruments have been used to evaluate convergent validity, and 
several of the studies reported intercorrelations > .70. To measure discriminant validity, 
investigators have attempted to detect depression in patients with medical conditions 
rather than psychiatric disorders. Their findings suggest that positive predictive power 
was low and variable even though sensitivity, specificity, and negative predictive power 
were large and consistent (Bagby et al., 2004).  Also, studies have been conducted 
comparing predictive validity of the HAMD with other scales measuring depression, such 
as the Beck Depression Inventory (BDI) and Zung Self-Rating Depression Scale, and the 
HAMD was found to be more sensitive to change than other scales (Bagby et al., 2004). 
Beck Anxiety Inventory.  The Beck Anxiety Inventory (BAI) is a 21-item self-
report instrument for assessing the severity of anxiety (Beck, Brown, Epstein, & Steer, 
1988). Each item offers four response choices scored from 0 to 3, with a higher score 
representing a more severe experience of the symptom. Adequate internal consistency has 
been reported in samples of nonpsychiatric patients, inpatient psychiatric patients and 
outpatient psychiatric patients with Cronbach’s alpha ranging from 0.83 to 0.95 (De 
Ayala, Vonderharr-Carlson & Kim, 2005). Test-retest reliability is satisfactory with a 
mean reliability estimate of 0.66 and time intervals between administrations ranging from 
7 to 112 days with an average of 32 days (De Ayala et al., 2005). Relevant to how the 
BAI was administered for this study, a 1 week test retest estimate of 0.75 has been 
reported (Beck et al., 1988). Since the BAI is a self-report tool, there are no reports of 
interrater reliability. 
Validity of the BAI has been evaluated and results indicate that it is a valid tool 
for measuring the construct of anxiety. With regard to content validity, the BAI addresses 
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the majority of DSM symptoms of generalized anxiety in addition to 11 out of 13 of the 
DSM symptoms of panic disorders (Beck et al., 1988). Findings from studies of construct 
validity indicate acceptable convergent and discriminate validity. For convergent validity, 
correlations in the range of 0.47 to 0.71 between the BAI and the Cognition Checklist 
Anxiety Subscale, the State Trait Inventory, the Anxiety Subscale of the Symptom 
Checklist-90-Revised, and the Hamilton Rating Scale for Anxiety and anxiety diaries 
have been reported (De Ayala et al., 2005). Studies of discriminant validity have shown 
that the BAI is highly correlated with the Beck Depression Inventory (r = .61; Steer, 
Ranieri, Beck, & Clark, 1997) but factor analysis results indicate that the Beck 
Depression Inventory items load on different factors than BAI items (Beck et al., 1988). 
Methamphetamine contributes to a large release of norepinephrine in the central 
nervous system, and these levels have been noted to be elevated for several months after 
discontinuing MA use (Rothman et al., 2001). Heightened anxiety in both active MA 
users and abstinent individuals may be due to changes in the noradrenergic system 
(Rothman et al., 2001). Consequently, anxiety data are being collected as a possible 
confounding variable. 
Columbia Suicide Severity Rating Scale.  The C-SSRS is a semistructured 
clinician administered scale to assess for suicidality (Posner et al., 2011). There are two 
forms of the C-SSRS: a baseline scale and a past week scale. The baseline scale is used to 
establish lifetime and current suicide attempts or ideation, and the past week scale 
evaluates sucidality over a period of 7 days (Posner et al., 2011). Reports of internal 
consistency in studies of adults with depression and/or other psychiatric concerns have 
shown acceptable internal reliability with a Cronbach’s alpha = 0.73 for baseline and past 
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week (Posner et al., 2011). In a study of adolescents with a history of a recent suicide 
attempt, internal consistency of the C-SSRS was noted to be high, Cronbach’s alpha = 
0.937 for the initial visit and 0.946 for the past week visit (Posner et al., 2011).  
Three separate studies of adults or adolescents with psychiatric diagnoses −	 a 
treatment study of adolescent suicide attempters (n = 124), a medication efficacy trial 
with depressed adolescents (n = 312) and a study of adults presenting to an emergency 
department for psychiatric reasons (n = 237) −	 evaluated convergent and divergent 
validity. Pearson’s r was calculated from comparing components on the C-SSRS with 
other instruments measuring similar constructs. These results indicate strong convergent 
validity, with the C-SSRS baseline moderately correlated with the Scale for Suicide 
Ideation (r = 0.52), and the C-SSRS past week scale moderately correlated with the 
suicide item on the Montgomery Asberg Depression Rating Scale (MADRS; r = 0.69; 
Posner, et al., 2011). The past week C-SSRS was compared with depression items on the 
MADRS and BDI, and the C-SSRS demonstrated strong divergent validity when items 
on the MADRS and BDI did not overlap with items on the C-SSRS except with the 
suicide items (Posner et al., 2011). Finally, an assessment of predictive validity, using the 
Columbia Suicide History Form and the suicide evaluation board classifications, 
demonstrated that baseline C-SSRS ratings significantly predicted suicide attempts 
(Posner et al., 2011).  
Drug History Questionnaire.  The DHQ is a single page form that includes nine 
different classes of drugs: alcohol, cannabis, hallucinogens, depressants, inhalants, 
narcotics, stimulants, tranquilizers, and other drugs (Sobell, Kwan & Sobell, 1995). The 
following self-report information is collected for each individual drug class: 1) was the 
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drug ever used, and if so 2) number of years used; 3) was the drug prescribed; 4) last year 
the drug was used; and 5) frequency of past use during a typical month. Self-report data 
collection is often the only viable approach to assessing drug history, and participants’ 
responses may be influenced by their ability to recall information or their willingness, or 
lack thereof, to share information (Napper, Fisher, Johnson & Wood, 2011). There are 
relatively few published studies that have addressed the psychometric properties of self-
report measures of drug use. The only published report of psychometric properties of the 
DHQ evaluated test retest reliability (Sobell et al., 1995). The results of the study indicate 
that drug abusers currently in a treatment setting can reliably (Pearson’s r values ranged 
from 0.53 – 0.89) report drug use information (Sobell et al., 1995). The DHQ is being 
collected to evaluate drug use characteristics.  
Urine drug testing.  Urine drug testing is regarded as the gold standard for drug 
testing because urinary assay allows for the evaluation of presence or absence of certain 
drugs with acceptable specificity, sensitivity, low cost, and noninvasive administration 
(Manchikanti et al., 2010). In this study, FDA cleared, Clinical Laboratory Improvement 
Amendment (CLIA) waived five panel (opiates, benzodiazepines, cocaine, THC and 
methamphetamine) drug screening test manufactured by Drug Test Success will be used. 
The five panel test was compared with other commercially available rapid drug tests 
using approximately 300 specimens, and accuracy results showed > 97% agreement 
(“One Step Drug Test: Marijuana, Cocaine, Opiates, Amphetamine, Methamphetamine 
and Benzodiazepines,” n.d.). Specificity and sensitivity tests indicate that the five panel 
test is highly specific at detecting positive tests at 5 minutes after the card was dipped in 
urine, and very sensitive at + 25 % cutoff range for the respective urine metabolites 
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(“One Step Drug Test: Marijuana, Cocaine, Opiates, Methamphetamine and 
Benzodiazepines,” n.d.). The use of drugs of abuse may influence an individual’s mood, 
and therefore, urine drug testing occurred at each study visit. 
 
Study Procedures 
To determine if an individual was eligible for study participation, a screening visit 
was conducted. At the screening visit, the SCID-I/P was administered to determine a 
diagnosis of MDD or other Axis I disorders and MA dependence or abuse within the past 
12 months. The HAMD, BAI, C-SSRS and DHQ were also administered. Finally, a urine 
sample for a pregnancy and drugs of abuse panel was collected, as well as vital signs and 
recording of concomitant medications and self-report drug use. Following the screening 
visit, participants were scheduled for the baseline 31P-MRS procedure. At the baseline 
31P-MRS visit, the HAMD, BAI and C-SSRS were administered, as well as collection of 
urine for pregnancy and drugs of abuse testing, vital sign monitoring, recording of 
concomitant medication and self-report drug use.  
At the first study visit the HAMD, BAI and C-SSRS were administered, as well as 
collection of urine for pregnancy and drugs of abuse testing, vital sign monitoring and 
recording of concomitant medication, self-report drug use and study medication 
dispensing. Participants were then to be seen twice weekly for a total of 8 weeks (see 
Table 3 for a list of procedures by week). After 56 days (+ 3 days) of creatine treatment, 
participants were scheduled for their end of treatment 31P MRS scan. Finally, participants 
were seen for three follow up visits, 7 days (+ 3 days), 14 days (+ 3 days) and 21 days (+ 
3 days) after their last dose of creatine.  







Table 3. List of study procedures by week 
 
 Baseline phase Treatment phase Follow up phase 
Week # -1 0 1 2* 3* 4* 5* 6* 7* 8* 9 10 11 12 
Informed Consent x              
Demographics x              
Medical History & 
Physical Exam x              
Phlebotomy for 
Serum Labs (CBC 
& CMP) 
x          x    
Phlebotomy for 
HIV Screening x              
Urine Sample for 
Pregnancy & Drug 
of Abuse Testing  
x x x x x x x x x x x x x x 




x x x x x x x x x x x x x x 
**Dispense Study 
Medication   x x x x x x x x     
DHQ & SCID-I/P x              
***HAMD & BAI x x x x x x x x x x x x x x 
C-SSRS x x x x x x x x x x x x x x 
Vital Signs, Con 
Meds, Self-report 
Drug Use 
x x x x x x x x x x x x x x 
Adverse Event 
Monitoring    x x x x x x x x x x x 
31P MRS Scan  x         x    
CBC = complete blood count; CMP = comprehensive metabolic panel; IGS = Interim Group Service; DHQ = Drug 
History Questionnaire; SCID-I/P = Structured Clinical Interview for DSM-IV Disorders with psychotic screen; 
HAMD = Hamilton Depression Rating Scale; BAI = Beck Anxiety Inventory; C-SSRS = Columbia Suicide 
Severity Rating Scale; 31P MRS = phosphorus magnetic resonance spectroscopy 
*During the 8 weeks of treatment, participants will be seen twice weekly (visits separated by at least 48 hours) 
**Study medication will be dispensed at the first study visit of the week 
***HAMD & BAI will be collected at one of the twice weekly study visits 
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Magnetic Resonance Spectroscopy 
All participants were scanned using a 3 Tesla clinical whole-body MRI system 
(Siemens Medical Solutions, Erlangen, Germany) located at the University of Utah 
Neuropsychiatric Institute (UNI). Scanning consisted of a phosphorus spectra (31P-MRS) 
scan with anatomic images. The magnetic resonance (MR) system is equipped with 
multinuclear capability, with 8 kHW wideband RF amplifiers, and the necessary 
hardware and software for conducting multinuclear experiments. Anatomic MRI scans 
screen participants for gross structural abnormalities, and acquire high resolution images 
for the use of gray and white matter segmentation and coregistration with spectra data. 
Participants were placed supine on the scanner table and were given a set of foam 
earplugs to attenuate sound. After localizer imaging, anatomical MRI was obtained using 
a three-dimensional chemical Magnetization Prepared Rapid Acquisition Gradient 
Echo (MPRAGE) pulse sequence. The parameters for the structural MRI were as follows; 
T1 weighted image: TR=2000 ms, TE=3.37 ms, TI=1100 ms, average number=1, flip 
angle=8°, FOV=256 mm, matrix 256x192x144, bandwidth=300 Hz/pixel, slice thickness 
1.0 mm and no gap. To screen for structural abnormalities, a board-certified Radiologist 
at the University of Utah reviewed all images. 
 
Compensation 
Participants were compensated up to a total of $290 in the form of gift cards to a 
variety of local businesses including, but not limited to, restaurants, grocery stores, 
bookstores, and coffee shops, as long as the locations did not sell alcohol or cigarettes. 
Compensation was given using the schedule below.  
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1. $25 - Screening   
2. $25 - Baseline neuroimaging 
3. $25 - Visit 1 (initiation of study drug) 
4. $10 - First weekly visits for weeks 2-8 (total = $70) 
5. $5 - Second weekly visits for weeks 2-8 (total = $35) 
6. $25 - Week 9 (end-of-treatment neuroimaging) 
7. $25 - Week 10 
8. $10 - Week 11 




Five grams of creatine was dispensed on Day 0. Participants were instructed to 
take creatine with food, and to stir creatine into a noncarbonated drink such as water,  
juice, coffee, or tea. Participants were directed to take creatine daily for 8 weeks. At each 
study visit, study medication adherence was assessed. Participants were asked to maintain 
empty bottles of creatine and return them at weekly visits. Participants were informed to 
store creatine at room temperature. The half life of creatine is between 72 and 96 hours, 
and therefore, up to four doses of creatine could be missed before the participant was 
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Storage and Accountability  
The study drug was stored at room temperature in a locked room with access 
limited to authorized individuals. An inventory that includes a signed account of study 
drug received, dispensed to and returned by each participant was maintained. At the 
conclusion of the study, final drug supply (used and unused) inventory and reconciliation 
was conducted. A copy of the final inventory is filed in the regulatory binder.  
 
Data Analysis 
Power Analysis   
Based on prior clinical experience regarding treatment completion among female 
MA users, for this pilot study, a sample size of 10 was initially proposed. Considering a 
40% attrition rate, 14 participants were proposed to achieve a sample size of 10. To 
determine the minimum effect that would likely be detected with a sample size of 10, a 
nondirectional power analysis was performed with alpha = 0.05. Effect for the power 
analysis was specified as average baseline (over three measures) HAMD scores 
compared with average HAMD scores during active treatment (over eight measures). A 
gradual onset of effect during active treatment is assumed, starting with an effect of 0 and 
ending with an effect of 0.5, resulting in an average effect during treatment of 0.25. The 
effect to be tested was treated as a linear combination of the separate measures (y*), and 
a pattern of correlation of 0.5 was used. This generated a standard deviation (SD) for y* 
that will be different from the within-occasion SD for Y itself. Then the effect magnitude 
specified was divided by the SD(y*) to generate an “effective” or de facto effect size, 
which resulted in an effect size of 1.09 with a power of 0.87.  
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Statistical Analyses   
To address the primary hypothesis that there would be a decrease in HAMD 
scores over time with creatine treatment, change from baseline over time was analyzed 
using linear mixed effect model repeated measures (MMRM) with maximum likelihood 
estimation. Likelihood based mixed effect models provide an overall framework to 
analyze longitudinal data that include data that are missing at random (MAR) by 
estimating the individual slope to summarize each participant’s response (Mallinckrodt et 
al., 2003). Hamilton Depression Rating Scale scores from the baseline period were 
averaged and compared with the mean HAMD scores from the treatment period.  
 To address the secondary hypothesis that compared to baseline, PCr levels would 




 The investigative team comprised of the PI, a PhD candidate from the College of 
Nursing, clinical research coordinators and research faculty from the Diagnostic 
Neuroimaging group of the Department of Psychiatry. The PI had primary responsibility 
for screening participants for study eligibility, data collection and analysis and 
manuscript preparation. The PI trained the three clinical research coordinators on all 
aspects of the study and data collection, including administration of the HAMD and BAI, 
to assist when the PI was unavailable. Dr. Kelly Posner, creator of the C-SSRS, by way 
of an instructional DVD, provided C-SSRS training. The research faculty were 
responsible for the MRS methods, acquisition and analysis.  
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Human Subjects and Data and Safety Monitoring  
Plan 
Description of Protocol and Participants 
 The purpose of this feasibility study was to evaluate changes in depression rating 
scores and brain PCr levels in female MA users who took creatine for 8 weeks. The 
sample consisted of 14 females between the ages of 18 and 64 of age who signed the 
consent form and took the first dose of creatine (see Table 1 study eligibility criteria). 
The sample was primarily recruited from ARS, the substance abuse evaluation clinic that 
is part of the University of Utah’s Department of Psychiatry. The investigative team 
comprised of faculty and staff from the Department of Psychiatry and College of 
Nursing. The PI was a PhD candidate in the College of Nursing. 
 Study participants were asked to attend an informed consent process and 
screening visit, precreatine MRS visit, twice weekly treatment period visits for 8 weeks, a 
postcreatine treatment MRS visit and three follow up visits. The HAMD was collected 
once per week, whereas urine sample for drug screen testing, self-report substance use 
and the C-SSRS were collected twice weekly. Finally, 5 grams of daily creatine was 
dispensed weekly for 8 weeks.  
 
Investigational New Drug 
 This study was conducted under IND application 114316, which was issued to Dr. 
Perry Renshaw by the Division of Psychiatry of the FDA in January 2012. In December 
2013, the current study was submitted as a subprotocol of the IND, and after the 30 day 
FDA review period and the University of Utah Institutional Review Board (IRB) 
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approval was issued, the study was started. Regulations under Section 21, Part 312 of the 
Code of Federal Regulations (CFR; Food and Drug Administration, 2014) were followed 
for this IND study  
 
Risks to Study Participants   
Methamphetamine using females with depression were proposed for this study. 
Pregnant females and nursing mothers were excluded from participation since the effects 
of MRS and creatine exposure on a fetus or developing child are unknown. Pregnancy 
testing was administered at every visit, and if a female became pregnant during the 
course of the study, she would have been withdrawn and referred to obstetrics and 
gynecology care. 
The following are risks that could have resulted from study participation. During 
the screening visit, participants could have become emotionally upset when asked about 
their psychiatric history including suicide attempts, or physical and sexual abuse. It was 
also possible for participants to experience discomfort or swelling when blood was drawn 
for laboratory tests. Rarely, infection can result from blood draws, and if an infection had 
occurred, the participant would have been referred for appropriate care. Further, 
intravenous drug users could have experienced a trigger to use drugs during the blood 
draw. Counseling about the trigger would have been offered at the time of blood draw as 
necessary. It is possible that a participant’s illness could have worsened during the study. 
If the participant’s illness worsened to the point that they were a danger to herself or 
others, she would have been referred for appropriate care. If the participant were 
hospitalized for worsening illness, she would have been withdrawn from the study.  
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As a requirement by the Division of Psychiatry of the FDA, the C-SSRS was 
collected at every visit, and if a female had endorsed current serious suicide risk, she 
would have been referred by a phone call from the PI to psychiatric care with her primary 
psychiatrist. In the case of no primary psychiatrist or the inability to contact the primary 
psychiatrist, the female would have been referred to emergency care at UNI.  
Magnetic resonance imaging/magnetic resonance spectroscopy scans do not use 
ionizing radiation. Instead, magnetic fields and radio waves are used to take pictures. 
There are no known risks related to MRI scans other than the risk of injury when metallic 
objects are brought into the scanning room by mistake. Serious injury can occur during 
an MRI scan to persons who have a cardiac pacemaker, metal clips on blood vessels (also 
called stents), artificial heart valves, artificial limbs, brain stimulator devices, implanted 
drug pumps, cochlear implants, ocular implants or known metal fragments in eyes, 
exposure to shrapnel or metal fillings, other metallic surgical parts, orthodontic braces, 
body jewelry or piercings that cannot be removed for the scan, and certain transdermal 
patches. Participants were screened for these items before they were cleared for the 
MRI/MRS scans. Participants could have experienced claustrophobia, dizziness, 
headaches, or a metallic taste in the mouth while inside the scanner. These symptoms are 
temporary, and would have stopped when the participant left the scanner.  
Other than to comply with FDA regulations, information obtained about 
participants in the course of the study did not leave the University of Utah in any form 
that would identify participants. Confidentiality was assured by locking all consent forms 
and case report forms in locked cabinets located in a locked office. Participants were 
assigned a code (i.e., participant ID) for all documentation and data analysis files.  
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Benefits to Study Participation 
 There were no guaranteed benefits to participation in this research. However, 
potential benefits to participants included a comprehensive psychiatric and medication 
evaluation, treatment and close monitoring by study personnel at no cost and a copy of 
their magnetic resonance imaging (MRI) scan. If a participant seemed to truly benefit 
from the study medication and wished to continue it after the study ended, the PI would 
make an effort to provide information about creatine that is available as a nutritional 
supplement in the United States.  
 
Data Safety and Monitoring 
 Clinical data were collected using standardized paper CRFs and were only 
identified with the study’s ID of the participants. The codes that link the name of the 
participant and the study ID were kept confidential by the investigative team on a 
password protected, encrypted, electronic file. Collected CRFs were securely transported 
to the PI’s data entry center. The PI was responsible for entering the data into SPSS® 
version 20 for Macintosh computer. The PI monitored data on a continuous basis and the 
PI’s dissertation committee chair, Gwen Latendresse, and committee member, Perry 
Renshaw, provided oversight.  
 
Reporting Mechanisms  
Adverse events (AEs), which are discussed in detail in Chapter 6, were reported 
to the University of Utah Institutional Review Board (IRB) and FDA in the annual 
request for study continuation report. There were no Serious Adverse Events (SAEs) 
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reported in this study.  
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A REVIEW OF TREATMENT OPTIONS FOR COMORBID  




 Comorbid methamphetamine (MA) use and depression interferes with treatment 
outcomes. Female MA users are known to have higher rates of depression than male MA 
users, although this is also true for the general population. There are limited treatment 
options for the management of depression among MA users. In this integrative review, 
data on treatment strategies for comorbid depression and MA use disorders is 
summarized. English-language articles were identified from PsychINFO, CINAHL, 
PubMed, and Medline as well as from reference lists of key articles. Search terms 
included methamphetamine, depression, and treatment. Research articles describing 
psychological (n = 3), pharmacological (n = 6), nutritional supplement (n = 1), and 
psychological combined with pharmacological (n = 3) approaches for the treatment of 
MA use or withdrawal and/or depression are included in this review. Psychological and 
combination psychological with pharmacological approaches have not been shown to be 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 This chapter was coauthored with Kelly J. Lundberg and Perry F. Renshaw and was 
accepted by the Journal of Addictions Nursing on September 8, 2014. 
   
 
73
effective in treating these comorbid conditions. Antidepressants have been determined to 
be ineffective and/or to introduce side effects. Gender differences with response to 
treatment were examined in only one of the published studies. There is a large gap in 
knowledge regarding treatment of comorbid MA use disorders and depression. 
Considering that female MA users experience higher rates of depression than male MA 
users, a focus on gender specific treatment approaches is warranted.  
 
Introduction 
Methamphetamine, a derivative of amphetamine, is a potent stimulant that affects 
the brain and central nervous system. Methamphetamine use results in increased 
dopamine release in the brain, as well as reduction of dopamine uptake, causing feelings 
of pleasure, increased energy, and greater alertness, and as a result, MA has high abuse 
potential. Methamphetamine use rates have fluctuated over the past decade in the United 
States with more stable rates over the past 4 years. In 2013, the National Survey on Drug 
Use and Health reported that 595,000 Americans 12 years or older reported using MA in 
the past month (Substance Abuse and Mental Health Services Administration 
[SAMHSA], 2014). In comparison, in 2005 and 2006, past month MA initiates reached 
2.4 million in Americans older than 12 years of age (SAMHSA, 2012). Even though rates 
of MA use have declined nationally, the consequences of MA abuse are still a public 
health concern. Both acute and chronic MA abuse have serious medical, psychiatric and 
dental repercussions. Short- and long-term health effects of MA abuse include stroke, 
(Perez et al., 1999), cardiac arrhythmia (Haning & Goebert, 2007), depression (McKetin, 
Lubman, Lee, Ross, & Slade, 2011; Thomas et al., 2010), anxiety (Glasner-Edwards et 
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al., 2010), insomnia, paranoia (McGregor et al., 2005), and structural and chemical 
changes to the brain (Sekine et al., 2003; Yoon et al., 2010). Depression, in particular, is 
a public health concern because cost-of-illness research has indicated that depression is 
associated with considerable economic burden, with the majority of the burden deriving 
from lost work productivity (Wang, Simon, & Kessler, 2003). Along those same lines, 
depression also impacts our healthcare system as nearly 70% of patients seen in a primary 
care setting present with symptoms consistent with depression (Robinson, Geske, Prest, 
& Barnacle, 2005), but accurate depression diagnoses are often delayed by comorbid 
medical conditions (Katon, 2004). Finally, with respect to MA dependency and comorbid 
depression, research shows that this dual diagnosis worsens the overall prognosis and 
confounds treatment outcomes (Glasner-Edwards et al., 2010). 
 
Comorbid Methamphetamine Use and Depression 
 It is not uncommon for depression and substance use to occur simultaneously 
(McKetin et al., 2011; Thomas et al., 2010). The association between the two conditions 
is likely bidirectional, with short- and long-term substance use resulting in mood changes, 
and substance use being a compensatory behavior to alleviate symptoms of depression 
(Koob et al., 2013). Methamphetamine has unique effects as its chronic use is known to 
reduce brain concentrations of dopamine and serotonin, which predisposes MA users to 
depression (Sekine et al., 2003; Thomas et al., 2010). Moreover, MA directly influences 
brain monoamine regulation resulting in a state that includes several of the features of 
major depression, including mood, sleep and appetite disturbances (London et al., 2004). 
However, symptoms of depression are not exclusive to MA use. Studies of other 
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substances of abuse, such as cocaine, heroin, alcohol, and nicotine, have documented 
increased rates of depression that exceed general population estimates. Similarly, a 
pattern of elevated comorbid substance use disorders and depression generally involves 
more females than males. For example, in a study of adults seeking treatment for cocaine 
abuse, 34.8% (n = 32) of females versus 28.6% (n = 59) of males, also met criteria for 
lifetime major depression (McCance-Katz, Carroll, & Rouansaville, 1999). Findings from 
large survey studies are similar for both opioid use disorders and major depression as 
well as alcohol dependence and major depression. Rates have been documented as 63.5% 
(n = 141) of females compared to 45.7% (n = 162) of males (Grella, Karno, Warda, Niv, 
& Moore, 2009), and 48.5% (n = 102) of females compared to 24.3% (n = 86) of males, 
respectively, meeting criteria for comorbid depression and an opioid use disorder or 
alcohol dependence (Kessler, Crum, Warner, Nelson, Schulenberg, & Anthony, 1997). 
The prevalence of daily nicotine use and comorbid depression, on the other hand, appears 
to be higher in males (36.8%; n = 326) compared to females (33.6%; n = 674; Husky, 
Mazure, Paliwal, & McKee, 2008).  
 Several studies have shown that depression rates are higher in MA using females 
compared to males (Glasner-Edwards, Mooney, et al., 2008a, 2008b; Semple et al., 
2007). With that said, it is unclear if this is a result of an existing gender difference, a 
type of self-medication, or a consequence of MA use, however, the prevalence of pre-
morbid depressive disorders in MA users has been documented to be high, with a 
majority reporting a significant lifetime history of depression (Drake, Kaye, McKetin, & 
Duflou, 2008; Hall, Andrus, Oostveen, Althaus, & VonVoigtlander, 1996; Zweben et al., 
2004). For example, in one study, MA users had a 62% (n = 187) rate of depression and a 
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23% (n = 69) rate of suicidality prior to initiating MA use, and after MA use was 
initiated, depression rates increased by nearly 20% (Hall et al., 1996). Further, using the 
Beck Depression Inventory (BDI) Semple and colleagues (2007) noted that 60% (n = 88) 
of MA using females in their study met criteria for moderate to severe depression, and 
these females were three times more likely to have used MA “to cope with mood” 
compared to females with lower levels of depressive symptoms. Moreover, in a 
longitudinal study of MA dependent adults participating in the Methamphetamine 
Treatment Project, 70% (n = 368) of the females who met criteria for major depressive 
disorder at study initiation still met criteria for depression at a 3 year follow up visit 
(Glasner-Edwards, Mooney, et al., 2008a). In contrast, in one study of MA dependent 
adults, rates of depression were noted as higher in males (31%; n = 32) than females 
(28%; n = 7), but as the authors noted, the instrument used, the Psychiatric Diagnostic 
Screening Questionnaire, does not indeed detect DSM criteria, but rather, serves as a 
screening tool (Polcin, Buscemi, Nayak, Korcha, & Galloway, 2012). Nonetheless, the 
majority of these findings highlight that females in general are more likely than males to 
have depression, and with substance use disorders, gender differences are underscored in 
ways that suggest greater rates of comorbid depression in females relative to males.  
 
Diagnosing and Treatment of Depression Among  
Methamphetamine Users 
 The diagnosis and treatment of depression among MA users is problematic 
because intoxication and withdrawal symptoms mirror symptoms of depression. There 
are at least three distinct syndromes to consider when assessing MA users: 1) expected 
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effects from MA use and symptoms of withdrawal when MA use is discontinued; 2) 
depressive symptoms that develop during periods of active MA use; and 3) a depressive 
disorder that is independent from MA use. The Diagnostic and Statistical Manual of 
Mental Disorders (DSM-5) offers guidelines for discerning independent depressive 
disorders and substance induced disorders. According to the DSM-5, if depressive 
symptoms develop before substance use was initiated or if symptoms occur and persist 
for 4 weeks or longer after substance use is terminated, criteria are met for an 
independent depressive disorder (American Psychiatric Association [APA], 2013). Also, 
based on DSM-5 criteria, depressive symptoms that manifest during a period of substance 
use that is insufficient to attain intoxication or withdrawal effects would be a diagnosis of 
an independent depressive disorder (APA, 2013). Conversely, criteria for substance 
induced depression are met when depressive symptoms occur during or soon after 
intoxication or withdrawal from a substance that is capable of producing the symptoms 
(APA, 2013). Yet, there are no published studies that have addressed the reliability of 
DSM-5 criteria for differentiating between substance intoxication and withdrawal 
symptoms versus an independent depressive disorder.  
There is some evidence, though, of acceptable reliability (kappa = 0.75) for a 
current independent diagnosis of depression among substance users as well as reliability 
(kappa = 0.66) for current substance induced depression in a study evaluating the 
Psychiatric Research Interview for Substance and Mental Disorders for DSM-IV 
(PRISM; Hasin, Samet, Nunes, Meydan, Matseoane, & Waxman, 2006), although these 
measures of reliability are limited to one report and it is not well documented if the 
PRISM is widely used. It is also noteworthy that time constraints in a clinical setting may 
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not permit for rigorous patient interviewing to separate substance induced symptoms 
from more enduring symptoms. In the face of these challenges with distinguishing 
between an independent depressive disorder and a substance induced depressive disorder, 
the significance of these differential diagnoses is centered on treatment planning and 
improving outcomes. 
Despite the evidence regarding depression rates in MA users, little is known about 
treatment options for depression among MA users. Treatment approaches for MA 
dependence have been recently reviewed (Ciketic, Hayatbakhsh, Doran, Naiman, & 
McKetin, 2012; Lee & Rawson, 2008), but the issue of managing comorbid conditions 
has not been examined closely. Therefore, the purpose of this paper is to summarize 
published reports on treating depression in MA users with a particular focus on treatment 
response differences by gender. Evaluating treatment response by gender is important 
since rates of MA use among males and females approach nearly equal proportions 
(Durell, Kroutil, Crits-Christoph, Barchha, & Van Brunt, 2008). This use rate pattern is 
unlike that observed with many other drugs of abuse, which typically demonstrate men 
using more than females (Durell et al., 2008). Given the paucity of information with 
regard to treating comorbid MA use disorders and depression, this chapter will help 
provide a review of treatment approaches and their outcomes. 
 
Methods 
Following Whittemore and Knafl’s (2005) guidelines, an integrative review was 
conducted with a specific focus on treatment approaches for depression in MA use 
disorders. Methods were used to identify relevant literature included searching electronic 
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databases and searching the reference lists of key papers. The electronic databases 
searched included: PsychINFO, CINAHL, PubMed, and Medline. The key search terms 
included in the search were “methamphetamine,” “depression,” and “treatment.” Next, 
data were evaluated for inclusion. Articles were selected for their relevance to the 
research focus. Publications reporting findings from preclinical or animal studies were 




There is very little documentation available regarding the treatment of comorbid 
MA use and depression. The peer reviewed publications selected for this integrative 
review included empirical research reports that described findings from randomized 
controlled trials and nonrandomized trials. Publications emerged beginning in the early to 
mid-1990s. The search yielded three articles reporting psychological approaches for 
managing comorbid depression and MA dependence. There were six articles found 
reporting findings from studies evaluating pharmacological approaches to treating MA 
dependence or withdrawal, and even though the primary outcome of these studies was not 
to treat comorbid depression and MA dependence, they were included in this review 
because depression was a secondary outcome measure. There was one article reporting 
the results of a nutritional supplement trial of comorbid unipolar or bipolar depression 
and MA dependence identified in the search. Finally, three articles were found reporting 
findings from a study investigating the combination of a pharmacological and 
psychological approach for the treatment of MA dependence. 




All of the studies evaluating psychological approaches to treating comorbid 
depression and MA use investigated cognitive behavioral therapy (CBT) as an 
intervention (see Table 4). During the last 3 decades, CBT has been considered one of the 
most effective types of therapy for treatment of alcohol and drug dependencies (Anton et 
al., 2005; DeRubeis & Crits-Christoph, 1998; Mattick & Heather, 1993), but little 
evidence exists regarding the use of CBT for treating comorbid depression and MA use. 
In fact, Peck and colleagues (2005) compared 16 weeks of CBT, contingency 
management (CM), CBT plus CM, and gay specific CBT, and noted a 75% decrease in 
MA use across all groups randomized to the four difference conditions, but no 
statistically significant changes in depression were detected. In another study, participants 
assigned to CBT reported nearly 50% less amphetamine use over 6 months, but CBT had 
only a short-term effect on depression rating scores (Baker et al., 2004). Baker and 
colleagues (2004) did not separate the findings by type of amphetamine so changes 
specific to MA use are unknown. Collectively, these findings suggest that CBT is useful 
for reducing MA use but not for the treatment of comorbid MA use and depression.  
Stepped-care, which is a health care model that supports starting with a less 
intensive approach to treatment and transitioning to more intensive therapy if indicated 
(Murphy, Lynch, Oslin, McKay, & TenHave, 2007), has also been evaluated for 
treatment of alcohol and drug use disorders. As with CBT, there are limited reports of 
stepped-care being effective for comorbid depression and MA use. In a feasibility study, 
a stepped-care approach was shown to be effective in reducing depressive symptoms 
(Kay-Lambkin, Baker, McKetin, & Lee, 2010), however, these findings warrant further  
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exploration and replication in a larger sample of MA users. Two of the studies evaluating 
psychological approaches to the treatment of MA included participants of both genders 
(Baker et al., 2004; Kay-Lambkin et al., 2010), whereas one of the studies included male 
homosexual participants only (Peck et al., 2005). Of the two studies that included both 
males and females, treatment response results were not separated by gender. However, 
even though there was a gender bias favoring the enrollment of males, 62.6% (n = 134; 
Baker et al., 2004) and 56% (n = 11; Kay-Lambkin et al., 2010), more females (83.3%; n 




There is one published study on the use of an antidepressant for the management 
of MA withdrawal, four published studies on the utilization of antidepressants in treating 
MA dependence, one published study evaluating a stimulant for the treatment of MA 
dependence, and one published study on the utility of a nutritional supplement in treating 
comorbid depression and MA use (see Table 5). In the studies evaluating the use of 
antidepressants, the authors also compared differences in depressive symptoms between 
the groups randomized to an antidepressant or placebo. The findings consistently 
demonstrated no significant changes in depressive symptoms (Cruickshank et al., 2008; 
Elkashef et al., 2008; Galloway, Newmeyer, Knapp, Stalcup, & Smith, 1994; Galloway, 
Newmeyer, Knapp, Stalcup, & Smith, 1996; Shoptaw et al., 2008). 
Brown and Gabrielson (2012) reported findings from a randomized controlled 
trial of the nutritional supplement citicoline or placebo for bipolar or unipolar depression  
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among MA dependent adults. Their study results demonstrated a 33% improvement in 
depression rating scores measured by the Inventory of Depressive Symptomatology-
Clinician Rated (IDS-C) in the citicoline group, whereas the placebo group demonstrated 
a 13% improvement in IDS-C scores (Brown & Gabrielson, 2012). It is worth noting that 
citicoline (generic name for CDP-choline when used as a supplement) is a 
complementary and alternative medicine approach for the treatment of depression. In the 
United States, citicoline, which is a natural occurring compound, is sold as a nutritional 
supplement over the counter (Adibhatla & Hatcher, 2005). Apart from the mood finding, 
self-report MA use and urine drug screen findings indicated no significant differences in 
MA use from study entry to study completion (Brown & Gabrielson, 2012). Finally, there 
were no significant differences noted with regard to frequency and amount of MA use for 
the duration of the study between groups  (Brown & Gabrielson, 2012). These findings 
suggest that citicoline is not effective in the treatment management of comorbid MA 
dependence and depression, although the study needs to be replicated in a larger sample 
focused solely on either unipolar or bipolar depressed participants.  
In an open label study evaluating a nonamphetamine stimulant, modafinil, for the 
treatment of MA dependence, the authors reported a statistically significant decrease in 
Hamilton Depression Rating Scale (HAMD) scores from beginning of the study to 
completion (McGaugh et al., 2009). However, there was no change in the number of 
positive urine drug screens during the course of the 6 week trial (McGaugh et al., 2009). 
These findings should be interpreted with caution considering the sample size at study 
initiation was eight and only four participants remained at study completion. 
Furthermore, the choice of a parametric statistical method may not have been appropriate 
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based on the small sample size.  
Only one of the published findings of pharmacological approaches to treating 
either MA dependence or depression among MA users separated results by gender 
(Elkashef et al., 2008). All of the studies enrolled more males than females with the 
exception of the open label modafinil study, which enrolled four females and three males 
(McGaugh et al., 2009).  
 
Pharmacological and Psychological Approaches 
There are three published studies regarding the combination of pharmacological 
and psychological approaches to the treatment of MA dependence (see Table 6). The 
majority of the studies suggest that pharmacological and psychological studies are not 
effective for treatment of MA dependence (Heinzerling et al., 2010; Shoptaw et al., 2006) 
and/or the participants experienced undesirable side effects (Shoptaw et al., 2006). 
Indeed, in the placebo controlled trial of the selective serotonin reuptake inhibitor (SSRI) 
sertraline, the researchers found that participants randomized to the SSRI experienced 
sustained craving and had an increased rate of relapse (Shoptaw et al., 2006). On the 
other hand, in a sample of HIV positive MA abusing males, in a single blind study of 
modafinil combined with CBT, medication responders experienced a decrease in 
depressive symptoms over 12 weeks, with medication response being defined as a greater 
than 50% reduction in the number of days of self-report MA use (McElhiney, Rabkin, 
Rabkin, & Nunes, 2009). Since 55% of the males were on antiretroviral therapy 
(McElhiney et al., 2009), it is possible that there was an interaction between the 
antiretroviral medication and modafinil resulting in changes in mood. Nonetheless, the  
















































































































































































































































































































































































































































































































































































































































































   
 
87
results of this study are not generalizable when taking into account the small homogenous 
sample (n = 10 completers). 
Of the three studies evaluating the combination of pharmacological and 
psychological interventions for the treatment of MA dependence, one of them included 
only males (McElhiney et al., 2009). The other two studies did not separate the findings 
by gender, and both studies enrolled more males than females (Heinzerling et al., 2010; 
Shoptaw et al., 2006). 
 
Discussion 
This review explored treatment approaches for the management of comorbid 
depression and MA use. The results yielded a total of 13 publications. Studies evaluating 
psychological approaches, such as cognitive behavioral therapy, are limited, and results 
suggest that psychological interventions may be useful in treating MA dependence but 
not depression among MA users. In studies of antidepressants for treatment of MA 
withdrawal, dependence and comorbid mood disorders, findings have suggested that 
antidepressants are ineffective.  
However, results from a randomized control trial of the nutritional supplement 
citicoline demonstrate that citicoline may be effective in reducing depressive symptoms 
in a sample of unipolar and bipolar depressed MA using adults, but not effective in 
reducing MA dependence. Citicoline is an endogenous intermediate in the biosynthetic 
pathways of structural membrane phospholipids. Of relevance, citicoline increases brain 
dopamine and norepinephrine levels, presumably by increasing the activity of tyrosine 
hydroxylase (Secades and Lorenzo, 2006). Considering that chronic MA use results in 
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disturbances in the dopaminergic systems, perhaps citicoline administration helps correct 
these disturbances, and in turn, mood is improved.  
In a small open label study of a nonamphetamine stimulant, modafinil, for the 
treatment of MA dependence, depressive symptoms improved over the course of the 
study, but concerns of a small sample size (n = 4 completers) needs to be examined when 
evaluating these results. Moreover, in a small (n = 10 completers) study of modafinil 
combined with CBT in HIV positive males, depressive symptoms improved and self-
report MA use was reduced over the 12 week treatment period. Modafinil has stimulant-
like effects, which may explain lower depression rating scores while taking it (Price & 
Taylor, 2005). Finally, studies investigating a nonamphetamine stimulant or 
antidepressant in addition to psychological approaches in treating MA dependence have 
demonstrated to be ineffective, have undesirable side effect profiles, or enrolled a small 
homogenous sample, which limits generalizability of the study results. Only one of the 
published reports separated treatment response results by gender. Overall, there were a 
higher percentage of males enrolled in each study, which is not too surprising considering 
that several of the studies enrolled HIV positive males only.   
 The main finding from this review, that treatment options are scarce for comorbid 
depression and MA use disorders, was anticipated given that there is little evidence based 
research guiding the management of comorbid mood and substance use disorders. 
Findings from RCT of pharmacotherapy for a comorbid substance use disorder, with 
alcohol being the primary substance evaluated, and bipolar disorder consistently reveal 
that there are no changes in either depressive or manic symptoms (Brown, et al., 2009; 
Salloum, Cornelius, Daley, Kirisci, Himmelhoch, & Thase, 2005; Stedman, Pettinati, 
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Brown, Kotz, Calabrese, & Raines, 2010; Tolliver, Desantis, Brown, Prisciandaro, & 
Brady, 2012) or reductions in alcohol use (Brown, et al., 2009; Stedman, et al., 2010; 
Tolliver, et al., 2012).  
Results, however, are inconsistent from RCT studies of pharmacotherapy 
management of comorbid substance use disorders, with opiates, alcohol or cocaine 
largely investigated, and unipolar depression. Studies demonstrate either a reduction in 
cocaine or alcohol use but no changes in depressive symptoms (Ciraulo, et al., 2005; 
Hernandez-Avila, Modesto-Lowe, Feinn, & Kranzler, 2004; Pettinati, et al., 2010), 
reduced alcohol use and depressive symptoms (Moak, Anton, Latham, Voronin, Waid, & 
Durazo-Arvizu, 2003), or no changes in opiate, alcohol, or cocaine use and/or depressive 
symptoms (Carpenter, Brooks, Vosburg, & Nunes, 2004; Petrakis, Carroll, Nich, Gordon, 
Kosten, & Rounsaville, 1998; Pettinati, Volpicelli, Luck, Kranzler, Rukstalis, & Cnaan, 
2001; Schmitz, Averill, Stotts, Moeller, Rhoades, & Grabowski, 2001). Moreover, 
experimental and nonexperimental studies evaluating psychological approaches for the 
treatment of comorbid mood disorders and substance use disorders show varying results, 
but overall demonstrate that MI combined with CBT may result in short-term reduced 
substance use and improvements in mental status (Cleary, Hunt, Matheson, & Walter, 
2008).  
 One of the goals of this review was to investigate if treatment response differs by 
gender. However, reporting results by gender was not common, and more males 
compared to females were enrolled in most of the studies. Because rates of substance use 
overall generally favors males, (Durell et al., 2008), this finding was expected. 
Nonetheless, barriers to seeking substance abuse treatment and treatment retention that 
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are specific to females are worth considering. For instance, substance abusing females 
worry about losing custody of their children if they seek services for substance related 
issues (Brady & Ashley, 2005). Further, limited access to and lack of financial support 
for childcare services in addition to responsibilities as a mother are frequently reported as 
obstacles to females seeking substance abuse treatment (Brady & Ashley, 2005; van 
Olphen & Freudenberg, 2004). Lastly, reports suggest that females experience greater 
social stigma and guilt than males do, which may serve as an additional impediment to 
females seeking substance abuse treatment (Booth & McLaughlin, 2000; Brady & 
Ashley, 2005). 
 Studies of comorbid depression and substance use disorders are faced with 
particular challenges. Notably, attrition rates are remarkably high (Gelkopf, Weizman, 
Melamed, Adelson, & Bleich, 2006; Sayre, Schmitz, Stotts, Averill, Rhoades, & 
Grabowski, 2002), and teasing apart symptoms of depression as a primary diagnosis from 
substance withdrawal symptoms can be difficult. Along those same lines, measuring the 
severity of depression in substance abusing and dependent populations is not easy. The 
oscillation between intoxication with and withdrawal from substances may artificially 
drive depression rating scores up or down. Even though depression is common with 
abuse or dependence in all classes of substances, the distinct pharmacological effects of 
MA are unique. During periods of intoxication, by way of increased synaptic dopamine 
concentrations, MA may exert mood elevating effects, however, once MA use is stopped, 
the “crash” or “come down” results in symptoms of depression.  
 
 




The findings of this review demonstrate the limitations of treatment options for 
the management of comorbid depression and MA use disorders. Even though 
investigations of modafinil should be interpreted cautiously due to small, heterogeneous 
samples sizes, clinicians might consider prescribing it for patients with depression and 
MA use disorders. Also, detailed psychiatric and substance use histories should be 
collected for making a distinction between a primary diagnosis of depression versus 
substance induced depression.  
 Until there is a broader evidence based foundation for the treatment of comorbid 
depression and MA use disorders, attention should be focused on designing and 
conducting high quality clinical trials. Future studies should include larger sample sizes 
in addition to standardized outcome measures. Also, standardized treatment and follow 
up periods would be advantageous for understanding treatment effects. Lastly, as 
clinicians and clinical investigators investigate new strategies for treating comorbid 
depression and MA use disorders, more gender specific attention is warranted.   
 
Conclusions 
No clear treatment model exists to suggest how to optimally manage comorbid 
depression and MA use disorders. Several studies have shown that female MA users 
experience depression at rates higher than males MA users, although this is also true in 
the general population. Investigating treatment options for MA users that have greater 
efficacy and/or safer side effect profiles is an important next step. Also, standardizing 
measurement and reporting for future studies in this area (e.g., using the same depression 
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rating scale and reporting outcomes by gender) would be useful for interpreting results 
and understanding additional gaps in our knowledge of comorbid MA use and 
depression. High quality studies of comorbid depression and MA use disorders are 
required for building a more expansive foundation of evidence based practice to guide 
clinical and research recommendations. 
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THE UTILITY OF MRS FOR UNDERSTANDING  
SUBSTANCE USE DISORDERS1 
 
Abstract 
Magnetic resonance spectroscopy (MRS), a noninvasive and nonionizing imaging 
technique, is being widely used in substance abuse research. It provides useful 
information with regard to brain metabolism, neuronal health, neurotransmission and 
cellular membrane integrity and the effects substances have on these processes. Both 
proton (1H) and phosphorus (31P) MRS have been applied to evaluate substance induced 
injury within the brain, recovery from substance use disorders as well treatment response 
to medication. A search of the literature published during the past decade resulted in 
nearly 50 publications that utilized MRS to investigate brain chemistry changes 
associated with substance use disorders. While methamphetamine (MA) use disorders 
received the most attention in the last 10 years, information from all drug classes 
demonstrated quantitative correlates of injury relevant to substance use. The most 
consistent finding noted was decreased content of N-acetylaspartate (NAA), a marker of 
neuronal vitality. The relationship between brain chemistry changes with substance use 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 This chapter was coauthored with Xianfeng Shi, Gwen Latendresse and Perry F. 
Renshaw and was submitted to the Journal of American Psychiatric Nurses Association 
on October 15, 2014. 
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and the impact on cognition was understudied over the past 10 years. The few studies that 
have been published in this area suggest a negative correlation between changes in 
neurochemistry and measures of attention, but continued work needs to be conducted to 
gain a better understanding of the effects of substances on cognition. The concern of 
small sample sizes in addition to low statistical power needs to be considered when 
evaluating reports of MRS substance abuse studies. At the same time, the potential 
impact of continued MRS application in the field of substance abuse is profound when 
considering its ability to investigate treatment response and potentially predict relapse.  
 
Introduction 
Magnetic resonance spectroscopy is gaining popularity in substance abuse 
research as a tool for identifying brain biomarkers and monitoring response to treatment. 
This noninvasive imaging technique does not use ionizing radiation making it low-risk 
for research on a number of populations including children. Magnetic resonance 
spectroscopy provides in vivo data on the concentration of neurometabolites, which can 
be used to track diseases and assist in developing novel treatments targeted at 
bioenergetics. The utility of MRS in substance use disorders is providing important 
insights into the cerebral consequences and etiology of drug abuse in addition to 
observing changes over time during abstinence.  
 
Magnetic Resonance Spectroscopy Technique 
 Similar to magnetic resonance imaging (MRI), the fundamentals of MRS are 
based on nuclear magnetic resonance (Castillo, Kwock, & Mukherji, 1996). Chemists 
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have applied in vitro spectroscopy as a technique for evaluating compounds in a solution 
since around the 1950s, but the application of MRS to study humans is relatively new. 
The Food and Drug Administration (FDA) approved the use of MRS as a clinical tool in 
1995 (Gujar, Maheshwari, Bjorkman-Burtscher, & Sundgren, 2005), and while data can 
be collected from human tissue in nearly any part of the body, the brain has been most 
frequently studied. Most published studies of human brain biochemistry report findings 
using two MRS-visible nuclei: 1H and 31P; however, other methods include carbon-13 
(13C) and fluorine (19F; Lyoo & Renshaw, 2002).  
Proton MRS has the advantage over other MR active nuclei of utilizing the same 
hardware that is used for routine clinical MRI, and consequently, it is readily accessible 
and the associated costs are relatively low (Barker & Lin, 2006). Due to the high 
sensitivity of the proton nucleus, and its ubiquitous presence in a range of compounds 
found in human tissue, information from 1H MRS is relatively straightforward to obtain 
and interpret. An advantage to 31P MRS is the extensive information it provides with 
regard to bioenergetics, cellular membrane precursors and break down products (Reddy 
& Keshavan, 2003). On the other hand, technical aspects of 31P MRS, such as low spatial 
resolution and signal-to-noise ratios (SNR), limit its clinical applicability (Barker & Lin, 
2006), but 31P MRS is gaining popularity in research. Along those same lines, the main 
advantage of utilizing 13C MRS is the rich information it offers about glial-neuronal 
interactions (Mason & Krystal, 2006), but because it requires particular hardware, 13C-
labeled substrate infusions, and specialized expertise, it is not commonly used clinically 
or in research (Barker & Lin, 2006).  
Finally, advantages to using 19F MRS is that it offers the ability to detect 
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fluorinated medications in the brain (Mason & Krystal, 2006) and its sensitivity to motion 
is less than other MRS techniques (Strauss, Unis, Cowan, Dawson, & Dager, 2002). 
However, as with 13C MRS, it requires specialized hardware and expertise, and its 
applicability is limited to research focused on studies of drug distribution and/or 
pharmacokinetics.   
 There are different field strengths for human brain MRS, ranging from 0.5 Tesla 
(T) to 7 T (Barker & Lin, 2006). Higher field strengths have the advantage of increased 
SNR, enhanced signal detection and better spatial resolution (Lyoo & Renshaw, 2002). In 
substance abuse research, field strengths of 1.5 – 4 T are commonly used.  
 A superconducting magnet creates a strong magnetic field and serves as the 
common factor in both MRI and MRS. The set up for MRS studies is similar to MRI with 
the exception of extra steps required for data acquisition and analysis. Shimming, the first 
step in acquiring clinical data from MRS, is a process used to achieve homogeneity of the 
magnetic field (Gujar et al., 2005). As the concentration of water far exceeds the 
concentration of neurometabolites by a factor of more than 10,000, a second important 
step in spectroscopy is suppression of the water signal. Other MRS considerations 
include application of specific acquisition methods such as single-voxel (SV) versus 
chemical shifting imaging (CSI) and repetition and echo time parameters; however, it is 
beyond the scope of this paper to discuss details with regard to these methods (see de 
Graaf, 2007). Importantly, planning and performing MRS research differs from MRI 
research. Further, it requires knowledge of biophysics and an understanding of which 
acquisition methods to use to answer a research question. 
 




In MR imaging, the signal, primarily from hydrogen atoms of water, is displayed 
as images. In MRS imaging, the signal derives from much less concentrated compounds, 
and results are represented as a collection of peaks referred to as a resonance within a 
spectrum (Gujar et al., 2005). Measured in parts per million (ppm), the peaks are 
distributed along the x-axis, and the intensity of the peaks is represented on an arbitrary 
scale along the y-axis (see Figure 2). In brain MRS, the most commonly observed 
resonance peaks are NAA, creatine (Cr), choline (Cho), and myo-inositol (mI). Peaks that 
are also detected, but not as commonly, include gamma-aminobutyric acid (GABA), 
glutamate (Glu) and glutamine (Gln). The spectrum of resonances provides information 
about the function of neuronal structure, phospholipid metabolism and cellular membrane 






Figure 2. Proton magnetic resonance spectrum from human anterior cingulate cortex 
using a short TE (30s). Metabolites are labeled total creatine (tCr), glutamine + glutamate 
(Glx), myo-inositol (mI), total choline (tCho), N-acetylaspartate (NAA). Figure from 
Xianfeng Shi. 
 









Table 7. Metabolites displayed in a resonance of spectrum 
 
Metabolite Spectrum location (ppm) Role Physiologic Significance 
N-acetylaspartate 
(NAA) 2.02 
Marker of neuronal 
integrity 
Lower concentrations are 
considered a sign of neuronal 
loss or damage 
Creatine (Cr) and 
phosphocreatine (PCr) 3.03 & 3.94 
Brain energy 
metabolism 
Decreased Cr seen in liver 
disease and decreased PCr seen 
in depression 
Choline (Cho) 3.20 Cell membrane turnover 
Higher levels of Cho with 
demyelination and tumors 
Myo-inositol (mI) 3.56 Glial marker 
Increased mI seen in 
Alzheimer’s disease, diabetes 
mellitus and multiple sclerosis 
& decreased mI in chronic 
hepatic & hypoxic 
encephalopathies, stroke, 
Graves’ disease & lymphoma 
Glutamate (Glu) and 
glutamine (Gln) 2.40 Brain metabolism 





acid (GABA) 3.03 Neuronal control 
Decreased GABA may be 













N-acetylaspartate is observed at 2.02 ppm in the spectrum and is the most 
prominent signal in the water suppressed proton spectrum. The precise physiological role 
of NAA is not known, but one of its functions relates to neuronal and axonal integrity 
while another role involves mitochondrial bioenergetics (Gujar et al., 2005). Lower 
concentrations of NAA have been interpreted as a sign of neuronal loss or damage in 
neurological (Achtnichts et al., 2013; Verma et al., 2013), sleep (Yadav et al., 2014) and 
psychiatric disorders (Kraguljac et al., 2012; Maltezos et al., 2014). 
 
Creatine 
 The creatine resonance is a composite peak consisting of both Cr and 
phosphocreatine (PCr), and is observed at 3.03 and at 3.94 ppm. Creatine and PCr are 
believed to be sensitive to changes in brain energy metabolism. Similar to NAA, 
alterations in brain Cr concentrations are considered to reflect mitochondrial dysfunction 
(Sung et al., 2013) as well as changes in cerebral energy metabolism (Iosifescu et al., 
2008). The energy buffering system in the brain is made up of PCr and adenosine 
triphosphate (ATP), and a phosphate group is transferred from PCr to adenosine 
diphosphate (ADP) by the enzyme creatine kinase, thereby replenishing ATP. Given that 
there are changes in neuronal energy requirements, mitochondrial dysfunction causes 
reductions in the formation of PCr transferred by mitochondrial creatine kinase (Sung et 
al., 2013). Lower concentrations of Cr have been seen in liver disease (Barker & Lin, 
2006), and reduced levels of  PCr have been noted in depression (Forester et al., 2009; 
Iosifescu et al., 2008; Kondo et al., 2011; Moore, Christensen, Lafer, Fava, & Renshaw, 






 The Cho containing compounds glycerophosphocholine and phosphocholine 
contribute to the Cho peak observed at 3.20 ppm. Concentrations of 
glycerphosphocholine and phosphocholine vary depending on brain region with higher 
levels found in myelin (Licata & Renshaw, 2010). Choline containing compounds play an 
important role in the synthesis and degradation of cellular membranes and are considered 
sensitive to changes in membrane turnover (Gujar et al., 2005). Therefore, an increase in 
Cho levels, as seen in neurodegenerative disorders (Bustillo, 2013) and with 
demyelination and tumors (Gujar et al., 2005) may reflect an increase in cellular 
production (Castillo et al., 1996; Gujar et al., 2005).  
 
Myo-inositol 
 The mI peak occurs at 3.56 ppm. The exact role of mI within the brain is not 
clear, but it is considered to be a glial marker with its function relating to osmoregulation. 
For example, it maintains osmotic balance through regulation of plasma membrane mI 
transport (Haris, Cai, Singh, Hariharan, & Reddy, 2011). Elevated mI content has been 
seen in Alzheimer’s disease, diabetes mellitus and multiple sclerosis, whereas decreased 
mI has been observed in chronic hepatic and hypoxic encephalopathies, stroke, Graves’ 
disease and lymphoma (Haris et al., 2011). 
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Glutamate and Glutamine 
 Both Glu and Gln resonate closely together as peaks located between 2.10 and 
2.50 ppm. The peak seen at 2.40 ppm is typically referred to as a combined Glu and Gln 
resonance and is referred to as Glx (Licata & Renshaw, 2010). These metabolites make 
up the glutamate glutamine cycle, which plays a central role in brain metabolism. Injury 
to the brain may result in impaired transportation of Glu and as a result, increased values 
may be detected (Shutter, Tong, & Holshouser, 2004).  
 
Gamma-Aminobutyric Acid 
 Gamma-aminobutyric acid, or GABA, is detected as a peak at 3.03 ppm. As the 
primary inhibitory neurotransmitter in the central nervous system, GABA plays an 
important role in neuronal control. Decreased brain GABA concentrations may suggest 
neuronal dysfunction (Long et al., 2013). Glutamate, Gln and GABA are notorious for 
being difficult to measure, and despite developments to improve obtaining data from 
these metabolites, they are not as commonly reported as other neurometabolites. 
 
A Decade of MRS Studies in Substance Use Disorders 
Alcohol  
Seven 1H MRS studies have been conducted over the past decade to evaluate the 
effects of alcohol use on brain chemistry. With the exception of two studies (Hermann et 
al., 2011; Yeo et al., 2013), all of the studies employed scanners with a field strength of 
1.5 T (Bartsch et al., 2007; Ende et al., 2005; Gazdzinski, Durazzo, Weiner, & 
Meyerhoff, 2008; Meyerhoff et al., 2004; Miese et al., 2006). Magnetic resonance 
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spectroscopy studies of alcohol use over the past decade appear to be largely consistent 
with reports of an association between long-term alcohol use and neuronal injury in a 
variety of brain regions (Gazdzinski et al., 2008; Meyerhoff et al., 2004; Yeo et al., 
2013). For instance, Meyerhoff and colleagues (2004) noted that levels of frontal white 
matter (WM) NAA were lower in heavy drinkers when compared to light drinkers. 
Moreover, the damage caused by alcohol use appears to persist after 1 week of abstinence 
(Gazdzinski et al., 2008), but there is evidence of at least partial recovery after 2 to 3 
months of abstinence (Bartsch et al., 2007; Ende et al., 2005). For example, Ende et al. 
(2005) found increased concentrations of Cho in the superior frontal gyrus, cerebellar 
vermis and dentate nucleus compared to baseline Cho measurements in alcoholic 
dependent individuals who were abstinent for 12 weeks.  
Along side neuronal injury, changes in glutamatergic neurotransmission have also 
been reported with higher concentrations of Glu noted in treatment seeking alcohol users 
during acute alcohol withdrawal but not in healthy comparison participants (Hermann et 
al., 2011). Lastly, differences in mI levels were also noted in alcohol users versus 
comparison participants with reports of lower mI with alcohol use (Gazdzinski et al., 
2008). Taken together, these findings highlight the neurotoxicity of chronic alcohol 
consumption with the potential for sustained short-term effects but the possibility of 
recovery with abstinence over time.  
While changes in neurochemistry with alcohol use have been well documented 
over the past 10 years, less is known about how these alterations influence cognition. One 
study employed neuropsychological testing to understand the association between brain 
chemistry and attention and concentration in alcohol users (Bartsch et al., 2007). The 
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authors reported an increase in frontomesial NAA with 6-7 weeks of abstinence 
accompanied by improvements in attention, but no correlation between cognitive 
function and cerebral Cho levels, or between long-term memory, nonverbal and verbal 
cognitive abilities and NAA or Cho (Bartsch et al., 2007). These findings suggest that the 
relationship between brain chemistry and cognition may be region specific and perhaps 
provide evidence of repair to neuronal viability with abstinence. More work in this area, 
though, would be able to provide a better understanding of these relationships.  
 
Methamphetamine  
It is not surprising that there are more MRS studies of MA (n = 9) use published 
in the last 10 years than any other substance of abuse in light of the public health 
concerns surrounding MA use (Nicosia, Pacula, Kilmer, Lundberg, & Chiesa, 2009). The 
majority of published studies have utilized 1H MRS at 1.5 T (Ernst & Chang, 2008; 
Nordahl et al., 2005; Salo, Buonocore, et al., 2011; Salo, Nordahl, et al., 2011; Salo et al., 
2007) or 3 T (Cloak, Alicata, Chang, Andrews-Shigaki, & Ernst, 2011; Howells et al., 
2014; Y. H. Sung et al., 2007) while one study reported findings from a 13C MRS study 
using a 1.5 T field strength scanner (Sailasuta, Abulseoud, Harris, & Ross, 2010) and 
another study used 31P MRS imaging at 3 T (Sung et al., 2013).  
Results from 1H MRS studies have noted that MA use is associated with lower 
levels of NAA in the frontal lobe (n = 30) and anterior cingulate cortex (ACC; n = 70) 
but not in the occipital cortex (n = 36; Howells et al., 2014; Nordahl et al., 2005; Salo et 
al., 2007; Sung et al., 2007). Further, concentrations of Glu in frontal white matter have 
been reported to be significantly higher in female MA users (n = 5) abstinent for at least 7 
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days compared with healthy controls (n = 6; Sailasuta, Abulseoud, Hernandez, Haghani, 
& Ross, 2010), which is consistent with MA induced neurotoxicity.  
Further, a 31P MRS study noted that PCr levels in MA users (n = 51) were 
significantly decreased when compared to values observed in healthy controls (n = 23), 
and this effect was greater in females (n = 23) than males (n = 28; Sung et al., 2013). 
Lastly, longitudinal studies of 5 months of abstinence in MA users provide evidence for 
normalization of brain chemistry with reports of frontal GM Glx decreasing after 1 month 
of abstinence as well as a negative correlation between abstinence and Glx concentrations 
5 months later (Ernst & Chang, 2008). Moreover, ACC Cho concentrations were noted to 
be elevated with short-term abstinence (n = 25; Nordahl et al., 2005; Salo et al., 2011), 
suggesting that the rate of cell membrane turnover is high in the early stages of brain 
recovery from MA use. The findings from these studies join evidence implicating serious 
consequences of MA use, and since there are no pharmacological therapies approved by 
the FDA for the treatment of MA abuse or dependence, these findings draw attention to 
the need to develop treatment options aimed at brain bioenergetics.  
 The association between changes in brain chemistry in MA users and its effect on 
cognition is also under studied. Since 2004, one study used a neuropsychological test, the 
Spatial Stroop Attention Test (Stroop, 1935), to evaluate the relationship between 1H 
MRS findings and selective attention. Findings from this study indicate that ACC 
NAA/Cr values negatively correlated with measures of attentional control in MA users (n 
= 36) while healthy volunteers (n = 16) did not exhibit a correlation between attentional 
control and ACC NAA/Cr ratios (Salo et al., 2007). Given the implications of the ACC’s 
role in attention, it is not surprising to observe neuronal injury combined with decreased 
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attention in MA users.  
 
3,4-methylenedioxymethamphetamine 
The main neurometabolites of interest in 1H MRS studies of MDMA, or 3,4-
methylenedioxymethamphetamine (commonly known as “Ecstasy”) have been NAA and 
mI concentrations. Findings from these studies (n = 7) over the last decade have not 
demonstrated a consistent pattern of MDMA effects on the brain (Daumann et al., 2004; 
de Win, Jager, Booij, Reneman, Schilt, Lavini, Olabarriaga, den Heeten, et al., 2008; de 
Win, Jager, Booij, Reneman, Schilt, Lavini, Olabarriaga, Ramsey, et al., 2008; de Win et 
al., 2007), even when employing higher field strengths at 3 or 4 T (Cowan et al., 2007; 
Cowan, Joers, & Dietrich, 2009).  
Only one study reported significant differences in neurometabolites in MDMA 
users relative to healthy volunteers, and in this study, the authors noted elevated basal 
ganglia mI with MDMA use (n = 31) but not in a non-MDMA using comparison group (n 
= 33; Liu et al., 2011). It is not clear why reports over the past 10 years have produced 
conflicting results that were reported in prior decades, which do suggest that MDMA has 
possible neurotoxic effects (Chang, Ernst, Grob, & Poland, 1999). One possibility for this 
discrepancy is the challenges associated with studying pure MDMA users. The majority 
of MDMA users are polysubstance users with concurrent marijuana use reported more 
frequently than other drugs of abuse (Singer, Linares, Ntiri, Henry, & Minnes, 2004), and 
it has been suggested that marijuana may provide neuroprotective effects (Costa, 2007). 
Another consideration is the potential that 1H MRS is not sensitive enough to detect 
changes in brain chemistry related to MDMA use. None of the published studies over the 
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last decade utilized neuropsychological testing as a method to understand the relationship 
between brain chemistry and cognition in MDMA users. 
 
Cocaine   
Magnetic resonance spectroscopy studies of cocaine are limited to 1H MRS since 
2004. Of the five published reports, two of them evaluated changes in specific 
neurometabolites following pharmacological treatment, and the findings suggest that 
cocaine induced injury may normalize with pharmacotherapies targeting brain 
bioenergetics (Schmaal, Veltman, Nederveen, van den Brink, & Goudriaan, 2012; 
Streeter et al., 2005). For instance, Schmaal and colleagues (2012) administered a 
potential glutamatergic drug, N-acetylcysteine (NAC) 1 hour prior to a 1H MRS scan, and 
they documented a significant increase in dorsal anterior cingulate cortex (dACC) Glu 
after a single oral dose (n = 10). Support for the need to target the glutamatergic system 
in cocaine users is found in a cross sectional 1H MRS study that demonstrated lower 
levels of Glu in chronic crack cocaine users (n = 14) when compared to noncrack cocaine 
using controls (n = 14; Yang et al., 2009).  
Adding to the evidence that cocaine induces injury to the brain, GABA 
concentrations in the left prefrontal lobe have been found to be significantly lower in 
cocaine users with and without a history of comorbid alcohol use (n = 23), but not in a 
healthy comparison group (n = 20; Ke et al., 2004). On the whole, results from these 1H 
MRS studies of cocaine users demonstrate the need for further development of treatments 
focused on repairing glutamatergic injury and disruptions of GABA pathways. 
 Consistent with other drugs of abuse and MRS studies, there is limited published 
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information regarding brain chemistry alterations from cocaine use and the influence of 
these changes on cognition. Indeed, in the last 10 years, there are no reports of studies 
employing concurrent neuropsychological testing and MRS methods in cocaine users.  
 
Opiates 
 Over the past decade, comparatively fewer studies have employed MRS methods 
to investigate opiate induced changes in neurometabolites. The few studies (n = 3) that 
have been conducted have primarily been focused on opiate maintenance therapy in 
opiate users by conducting 1H (Hermann et al., 2012) and 31P (Silveri et al., 2004) MRS. 
Results from the 1H MRS study using a 3 T field strength suggest an imbalance of the 
glutamate system with higher levels of ACC Glx noted in older opiate users (number of 
older opiate users not provided) relative to nonopiate users (n = 20), as well as increased 
Cho concentrations in left frontal WM observed across all age groups of opiate users (n = 
17) compared to controls (Hermann et al., 2012). Alterations in brain bioenergetics were 
indicated in the 1.5 T 31P MRS study of methadone maintenance therapy initiation in 
heroin users with reduced levels of PCr found in the orbitofrontal and occipital cortices 
with heroin use (n = 43) but not in a healthy comparison group (n = 15; Silveri et al., 
2004). Because of the limited number of MRS studies in opiate use, it is difficult to 
definitively assess the impact of opiate use on the brain; however, the few published 
reports provide some evidence that there are differences in neurochemistry in opiate users 
starting opiate maintenance therapy in comparison to nonopiate users. Finally, none of 
these studies evaluated the effects of changes in neurochemistry related to opiate use on 
cognition. 




The effects of marijuana use on brain chemistry have been well studied over the 
past decade. Eight reports have been published and the findings suggest that marijuana 
use results in altered brain metabolites. Nearly all of the published studies described 
higher field strength 1H MRS studies at 3 T (Muetzel et al., 2013; Prescot, Locatelli, 
Renshaw, & Yurgelun-Todd, 2011; Prescot, Renshaw, & Yurgelun-Todd, 2013; Sung, 
Carey, et al., 2013) or 4 T (Chang, Cloak, Yakupov, & Ernst, 2006; Mashhoon, Jensen, 
Sneider, Yurgelun-Todd, & Silveri, 2013; Silveri, Jensen, Rosso, Sneider, & Yurgelun-
Todd, 2011). Disturbances of ACC glutamatergic neurotransmission, suggested by 
reduced Glu levels, appear to be a consistent finding in marijuana users (n = 30; Prescot 
et al., 2011; Prescot et al., 2013) in addition to evidence of alterations in neuronal 
integrity (e.g., lower NAA concentrations) in recreational and chronic marijuana users (n 
= 43; Hermann et al., 2007; Prescot et al., 2011; Prescot et al., 2013) and comorbid 
marijuana and methamphetamine users (n = 8; Sung et al., 2013).  
Moreover, decreased concentrations of NAA and Glu in the basal ganglia were 
seen in regular marijuana users (N = 45: Chang et al., 2006). Changes in the thalamus 
have also been noted with increased mI (n = 13; Mashhoon et al., 2013) and increased 
mI/Cr (n = 15; Silveri et al., 2011) documented in chronic marijuana users with respect to 
healthy volunteers. A less consistent finding involves reports of possible changes in Cr. 
For example, Prescot and colleagues (2011) found decreased ACC Cr in marijuana users 
(n = 17) compared to healthy controls (n = 17), whereas Chang et al. (2006) demonstrated 
increased thalamic Cr in marijuana users (n = 45) relative to nonmarijuana users (n = 30).  
Even though alterations in brain metabolism and neuronal integrity are 
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consistently reported in 1H MRS studies of marijuana, the clinical implications of these 
findings are not as well known. In the single study that examined the association between 
neurochemistry and cognition in marijuana users, the authors reported a positive 
correlation between basal ganglia mI and simple reaction time in nonmarijuana users (n = 
30) and poorer performance on the simple reaction time and psychomotor tests for both 
nonmarijuana users (n = 30) and marijuana users with lower basal ganglia mI (n = 45; 
Chang et al., 2006). Interestingly, with the exception of memory testing, marijuana users 
outperformed the comparison group in all cognitive domains, but these results were not 
compared with neurometabolites (Chang et al., 2006). Because both of the groups 
demonstrated substandard performance on some cognitive testing and the marijuana users 
overall performed better than the nonmarijuana users, the impact of marijuana use on 
brain chemistry is inconclusive.  
 
Nicotine 
 Magnetic resonance spectroscopy studies of nicotine use over the last 10 years 
have mostly targeted the ACC utilizing field strength of at least 3 T. The main 
neurometabolites of interest have been GABA, Glu and Glx, and although there are 
inconsistencies noted in the findings, they generally suggest that nicotine use results in 
brain chemistry changes. To illustrate, when compared to former nicotine users (n = 9) 
and nicotine naïve adults (n = 16), there were no differences in ACC or left hippocampus 
Glu concentrations in chronic nicotine users (n = 16; Gallinat & Schubert, 2007), 
whereas, in nicotine using females who relapsed during nicotine replacement therapy (n = 
5), dACC Glu/Cr levels were found to be reduced relative to a nicotine abstinent group (n 
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= 4; Mashhoon et al., 2011).  
It is possible that Glu serves as a biomarker for relapse considering changes in 
Glu were not found in treatment naïve nicotine users yet were identified in females 
seeking treatment. As an alternative, perhaps gender influences Glu since reduced 
concentrations were noted in a female specific group only. Along the same lines of the 
Glu finding, alterations in cortical GABA concentrations were also noted in nicotine 
using females (n = 6) versus nicotine using males (n = 10; Epperson et al., 2005), 
suggesting that GABA levels may also vary by gender.  
Magnetic resonance spectroscopy studies of nicotine have also evaluated changes 
in NAA and Cho, and these findings indicate the possibility of nicotine use resulting in 
neurotoxicity as evidenced by reduced NAA levels in the left hippocampus among 
nicotine users (n = 13) compared to nonnicotine users (n = 13), as well as higher ACC 
Cho concentrations with increased lifetime nicotine exposure (Gallinat et al., 2007). The 
association between Cho and lifetime nicotine use suggests that nicotine use may cause 
changes in cell density or accelerate the rate of cortical membrane turnover (Gallinat et 
al., 2007). Because nicotine is widely used across the world and commonly used by most 
other substance users, furthering our understanding of its effects on the brain is important 
for educational and treatment approach purposes. Findings from these studies suggest that 
gender specific treatment approaches targeted on glutamatergic system and focusing on 
neuronal repair may be important. 
 Translating the clinical implications related to MRS and nicotine use is difficult 
given the paucity of research on the effects of changes in brain chemistry on cognitive 
function. However, the findings from the single published report suggest a negative 
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correlation between dACC GABA/Cr concentrations and attentional bias toward smoking 
cues in 15 smokers, which the authors interpreted as the dACC having an important 
function in overall cognitive control (Janes et al., 2013).     
 
A Synthesis of Research Efforts During the Last Decade 
 Using MRS imaging, there has been considerable progress over the last decade in 
understanding how substances of abuse impact brain chemistry. Proton MRS was 
ubiquitous among the reports, whereas 31P and 13C MRS studies were less common. 
There were not any studies that evaluated changes in every peak of the spectrum, but 
rather, studies largely appeared to focus on specific visible metabolites that were known 
for being altered by the drug of interest.  Additionally, field strength also plays a role in 
determining which neurometabolites are measurable, as field strengths of at least 3 T are 
recommended for evaluating Glu, Gln and GABA (Di Costanzo et al., 2003).    
The MRS studies of drug abuse disorders over the last 10 years demonstrate an 
inconsistent overlap in brain chemistry changes across drug classes, thus suggesting that 
changes in neurometabolites may be substance of abuse specific rather than a universal 
impact from drug use. The most consistent findings were lower NAA levels associated 
with alcohol, MA, marijuana and nicotine use and reduced mI content in alcohol, MDMA 
and marijuana users, indicating that use of these substances may result in decreased 
neuronal health. Moreover, the report of increased Cho values with abstinence was 
consistent among alcohol and MA users, therefore suggesting that the rate of cellular 
membrane production may increase with brain recovery.  
Fewer consistent findings were noted from studies of Glu, Glx and GABA 
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concentrations. Increased Glu levels and decreased Glx concentrations were documented 
in abstinent alcohol users and MA users, whereas crack cocaine, marijuana and nicotine 
users were found to have decreased Glu concentrations and cocaine and nicotine use were 
associated with lower GABA levels. The increase in Glu together with the decrease in 
Glx in abstinent drug users raises the possibility of persistent neurotoxicity, while 
decreases in Glu and GABA concentrations may reflect alterations in neurotransmission. 
Finally, reports of Cr were limited to studies in marijuana, which demonstrated an 
inconsistent pattern of changes in Cr, and one possible explanation for this inconsistency 
is the variation in brain regions examined. However, reports from 31P MRS studies 
consistently indicate reductions in PCr content, suggesting brain energy metabolism 
alterations in drug users. 
 
What Are The Gaps? 
 The majority of the studies used 1H MRS methodology to attempt to understand 
changes in brain chemistry among drug users. However, there is a gap in knowledge with 
respect to how substances of abuse impact brain metabolic energy. Brain energy 
metabolism can be quantified using 31P MRS imaging, and the major peaks identified in 
the 31P spectra include PCr, inorganic phosphate (Pi), phosphomonoesters (PMEs), 
phosphodiester (PDE), the α-, β- and γ-nucleotide triphosphates (NTPs) and diphosphates 
(NDPs). Only two of the 45 published articles over the last decade applied 31P MRS 
imaging, and while the findings from these studies suggest that substance use 
compromises high energy phosphate metabolism, the small number of publications and 
small sample sizes limit generalizability.  
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 There is limited information regarding how changes in neurochemistry relate to 
cognitive function. Four of the studies published since 2004 conducted 
neuropsychological testing in conjunction with MRS scanning. Since NAA has been 
identified as a marker of neuronal integrity, it is not surprising that there is a relationship 
between improvements in attention with increasing NAA levels in abstinent alcohol 
users. On the other hand, the finding from Chang et al. (2006) which demonstrated higher 
performance in marijuana users was not expected considering several neurometabolites, 
including NAA, were noted to be lower in marijuana users. The inconsistencies and lack 
of information with respect to the relationship between brain chemistry and cognition 
underscore the need for more attention in this area.  
 Studies of MRS and substance abuse are notorious for small sample sizes. The 
largest sample size noted in the review of articles from the last decade involved 231 
treatment-seeking and nontreatment seeking alcohol users (Yeo et al., 2013). This is a 
remarkably large sample size compared to the majority of other studies, which on average 
included approximately 30 participants. Concerns regarding external validity and low 
statistical power is raised with a small sample size. In fact, in a review of neuroimaging 
meta-analyses, the median statistical power of 461 individual studies was 8% (Button et 
al., 2013). If low statistical power is typical in neuroimaging research, the likelihood of 
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Where We Are Headed? 
 Information gleaned from MRS studies of substance users has provided useful 
insight on the neurobiological effects of substance use and abstinence. Because MRS 
scans reveal concentrations of target chemicals in brain regions, its utility is becoming 
more widespread in examining pharmacological treatment approaches. With respect to 
MRS substance abuse studies, two of the 47 studies published since 2004 focused on 
investigating neurometabolite changes with the treatment of medications focused on 
repairing glutamateric and GABA pathway disruptions caused by cocaine use (Schmaal 
et al., 2012; Streeter et al., 2005).  
If future pharmacological development studies adapt the approach of including 
MRS, our understanding of how medications work in the brain of drug users may allow 
for more targeted treatment modalities. In addition to pharmaceutical development, MRS 
may be used in the specialty of substance abuse for diagnostic purposes. Overall, in 
psychiatry research, the diagnostic potential of MRS remains unfulfilled, but the recent 
advances in MRS offers the possibility of identifying brain biomarkers for disease. For 
instance, in Parkinson’s disease, reduced cingulate NAA/Cr ratios have been noted in 
individuals with Parkinson’s disease, and thus, identified as a clinical biomarker of 
disease progression (Sharma et al., 2013).  
Finally, future uses of MRS also include evaluating treatment response, and a 
study by Kondo et al. (2011) demonstrates an application of this approach. Phosphorus 
MRS was conducted before and after depressed adolescents were treated with an 
investigational medication, creatine, which was hypothesized to increase brain PCr 
content. The researchers noted a significant increase in PCr concentrations at the end of 
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treatment scan in parallel with a decrease in reported depressive symptoms (Kondo et al., 
2011). The results from this study offer the opportunity for drug addiction researchers to 
consider study designs that take the neurobiology of addiction coupled with targeted 
treatment approaches into consideration.  
 
Conclusions 
 Proton and 31P MRS has provided a window into the brain and the effects 
substances have on neurometabolites. In the last decade, the consistent finding of reduced 
NAA concentrations across several classes of substances of abuse may offer a biomarker 
of substance abuse. As seen in treatment studies of cocaine use disorders, MRS is also a 
useful tool for gaining insight into treatment response. The potential impact of 
developing treatments intended to repair neuronal and brain pathways is profound in 
substance abuse research as there are limited approved treatment options for substance 
use disorders. Even though there are limitations of MRS in substance abuse research, 
such as small sample size and low statistical power, this methodology could continue as a 
pivotal role for improving treatment outcomes, but further improvements in design and 
analysis are recommended.  
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WITHIN SUBJECTS STUDY OF CREATINE IN DEPRESSED  
FEMALES WHO USE METHAMPHETAMINE1 
 
Abstract 
Depression among methamphetamine (MA) users is more prevalent in females 
than males, but gender specific treatment options for this comorbidity have not been 
described. Reduced brain phosphocreatine (PCr) levels have been shown to be lower in 
female MA users compared to males, and, of relevance, studies have demonstrated an 
association between treatment resistant depression and reduced brain PCr concentrations. 
The nutritional supplement creatine monohydrate has been shown to reduce symptoms of 
depression in female adolescents and adults taking selective serotonin reuptake inhibitors 
as well as to increase brain PCr in healthy volunteers. Therefore, a study of creatine 
monohydrate for the treatment of depression in female MA users was proposed.  
Fourteen females with major depressive disorder (MDD) and comorbid MA 
dependence were enrolled in an 8 week open label trial of 5 grams of daily creatine 
	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
1 This chapter was coauthored with Young-Hoon Sung, Xianfeng Shi, Marjorie Pett, 
Gwen Latendresse, Rebekah Huber, Jubel Morgan, Danielle Kuykendall, Kelly J. 
Lundberg, and Perry F. Renshaw 
   
 
131
monohydrate and of these 14, 11 females completed the study. Depression was measured 
using the 17-item Hamilton Depression Rating Scale (HAMD) and PCr levels were 
measured using phosphorus (31P) magnetic resonance spectroscopy (MRS) pre- and 
postcreatine treatment. Secondary outcome measures included anxiety symptoms, 
measured with the Beck Anxiety Inventory (BAI), and MA use, monitored by twice 
weekly urine drug screens and self-report MA use. The results of a linear mixed effects 
repeated measures model analysis showed reduced HAMD scores as early as week 2 
when compared to baseline. This improvement was maintained through study 
completion. Brain PCr concentrations were shown to be higher at the 31P MRS scan 
compared to the baseline scan; Mbaseline = 0.223 (SD = 0.013) versus Mpost treatment = 0.233 
(SD = 0.009), t(9) = 2.905, p < .01, suggesting that creatine might increase PCr levels. 
Moreover, average BAI scores were reduced as early as week 1 and remained lower 
through study completion. Finally, a reduction in MA positive urine drug screens by 
greater than 50% was observed by week 6 (baseline: 50% MA positive urine drug 
screens; week 6: 21.4%).  
Creatine was well tolerated, and adverse events that were reported, such as cold 
and flu symptoms (n =10), indigestion (n = 1), flank pain (n = 1), polydipsia (n = 1), 
headache (n = 3), swelling in hands (n = 4), diarrhea (n = 4), stomach discomfort (n = 3), 
numbness and tingling in hands (n = 1), muscle cramps (n = 2), blurry vision (n = 1), 
lightheaded (n = 1) and nausea (n = 1) were not related to study participation. The current 
study suggests that creatine treatment may be a promising therapeutic approach for 
comorbid depression and anxiety in MA dependence in females.  
 




 Depression and MA use disorders are highly comorbid. In a number of studies, 
rates of depression among MA users are consistently documented as greater than 35% 
(Dyer & Cruickshank, 2005; Kay-Lambkin, Baker, Lee, Jenner, & Lewin, 2011;  
McKetin, Lubman, Lee, Ross, & Slade, 2011; Sutcliffe et al., 2009). In contrast, 
according to a survey conducted by the Centers for Disease Control and Prevention 
(CDC), general population rates for current depression are 9.0%, including 3.4% for 
major depressive disorder (Centers for Disease Control and Prevention, 2010). Among 
MA users and the general population, females are more likely than males to have 
depression, but the gender differences in MA use disorders are substantially higher. For 
example, findings from the CDC survey suggested that 4.0% of females compared to 
2.7% of males met criteria for current depression (Centers for Disease Control and 
Prevention, 2010), whereas rates as high as 70% in females compared to 30% in males 
have been documented in MA users (Glasner-Edwards et al., 2008).  
There are no clear pharmacological treatment modalities for comorbid depression 
and MA use disorders (Hellem, Lundberg, & Renshaw, 2014). In fact, there is limited 
available data on medication treatment options for MA dependence and/or withdrawal. 
For example, investigations of antidepressants as a treatment option for MA dependence 
(Colfax et al., 2011; Elkashef et al., 2008; Galloway, Newmeyer, Knapp, Stalcup, & 
Smith, 1996; Heinzerling et al., 2010; Shoptaw et al., 2008; Shoptaw et al., 2006) or 
withdrawal (Cruickshank et al., 2008) have reported that antidepressants are not an 
effective treatment option. Notably, in a randomized controlled trial, MA dependent 
adults (n = 120) assigned to 100 milligrams of the selective serotonin reuptake inhibitor 
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(SSRI) sertraline daily for 12 weeks had no change in self-report MA use and had more 
MA positive urine drug screens compared to the placebo group (n = 109; Shoptaw et al., 
2006).  
Neuroimaging findings from studies on both depression and MA use disorder are 
associated with changes in brain energy metabolism (Forester et al., 2009; Iosifescu et al., 
2008; Kondo et al., 2011; Sung, Yurgelun-Todd, et al., 2013). Phosphorus MRS is the 
only method available to measure in vivo brain chemistry changes. Because of its role in 
adenosine (ATP) production, PCr is one of the main neurometabolites of interest in 
psychiatry neuroimaging research, and it has been found to be decreased in depressive 
(Forester et al., 2009; Iosifescu et al., 2008; Moore, Christensen, Lafer, Fava, & 
Renshaw, 1997) and MA use disorders (Sung et al., 2013). Interestingly, this effect was 
shown to be greater in female MA users (n = 32) than male MA users (n = 28; Sung et 
al., 2013), and, like depression rates among MA users, these findings highlight the 
differences between male and female MA users. Clinically, lower concentrations of brain 
PCr have been associated with poorer treatment outcomes (Iosifescu et al., 2008; 
Renshaw, Parow, Hirashima, Ke, Moore, Frederick, et al., 2001), and thus, novel 
treatment approaches aimed at moderating this brain energy deficiency, particularly in 
females, are warranted.  
Due to its critical role in bioenergetic metabolism, creatine monohydrate has 
shown promise in treating a number of disorders. For example, creatine has been reported 
to be neuroprotective in neurodegenerative disorders such as Parkinson’s and 
Huntington’s disease (Adhihetty & Beal, 2008), improve neurological symptoms in rats 
with traumatic brain and spinal cord injury (Hausmann, Fouad, Wallimann, & Schwab, 
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2002; Rabchevsky, Sullivan, Fugaccia, & Scheff, 2003; Sullivan, Geiger, Mattson, & 
Scheff, 2000) and have gender specific antidepressant effects in rats (Allen et al., 2010; 
2012). For example, when male and female rats were administered creatine, the female 
rats’ performance improved on the forced swim test, a tool to measure depression in rats, 
whereas the male rats’ performance declined (Allen et al., 2010). Along those same lines 
of creatine’s gender dependent antidepressant effects, adjunctive oral creatine use has 
been associated with reduced depressive symptoms in female adolescents (Kondo et al., 
2011) and adults (Lyoo et al., 2012) taking an SSRI. Also of relevance, creatine 
administration has been shown to increase brain PCr concentrations (Dechent, Pouwels, 
Wilken, Hanefeld, & Frahm, 1999; Lyoo et al., 2003). 
On the basis of these preliminary findings, this pilot study was focused on female 
MA users diagnosed with comorbid depression in an open label study of stand alone 
creatine treatment for comorbid depression and MA use disorders. In this clinical trial, it 
was hypothesized that there would be a decrease in depressive symptoms as well as an 
increase in brain PCr levels with 8 weeks of creatine treatment. Because co-occurring 
anxiety is highly prevalent among depressed substance users (Grant et al., 2004; Lubman, 
Allen, Rogers, Cementon, & Bonomo, 2007) and among depressed individuals in the 










Recruitment and Consent  
 A total of 21 females were screened for study participation and 14 females 
completed the baseline assessments and were enrolled in this open label study of creatine 
(see Figure 3). Of these 14 females, 11 completed the study. Females were informed of 
the study by recruitment flyers and staff referrals from a clinic that provides substance 
abuse assessment and referrals for adults with substance abuse and/or mental health 
issues. The inclusion criteria for study entry were: 1) female gender, ages 18 – 64 years 
inclusive, 2) diagnosis of major depressive disorder (MDD) with a current major 
depressive episode as determined by the Structured Clinical Interview for DSM-IV 
Disorders (SCID-I/P; First et al., 2007), 3) a score of greater than or equal to 15 on the 
17-item HAMD (Hamilton, 1960), 4) identification of MA as primary drug of choice and 
5) a SCID-I/P diagnosis of MA dependence or abuse within the last 12 months. The 
exclusion criteria included: 1) a SCID-I/P diagnosis of bipolar disorder, 2) known or 
suspected diagnosis of schizophrenia or schizoaffective disorder, 3) a diagnosis of renal 
disease, type I or II diabetes mellitus, colitis, diverticulitis or seizure disorder, 4) human 
immunodeficiency virus (HIV) seropositive status or elevated liver enzymes by lab 
determination, 5) current treatment with an antidepressant, mood stabilizer or 
antipsychotic medication, 6) current serious suicide risk identified by the Columbia 
Suicide Severity Rating Scale (C-SSRS), 7) positive urine pregnancy test and 8) 
contraindication to magnetic resonance scan. Gift card compensation to locations with 
alcohol and cigarette sale restrictions was offered to participants after each completed 
visit. If each visit was attended, participants were compensated a total of $290.  
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Prior to obtaining written informed consent, the study was fully explained to potential 
participations. The study was conducted in accordance with the Declaration of Helsinki 
and was approved by the University of Utah Institutional Review Board. The study was 
conducted under investigational new drug Investigational New Drug (IND) number 
114,316. 
 
Study Design and Procedures 
In this within subjects design, each enrolled participant was treated with fixed 
dose Creapure® brand of creatine (Alzchem, LLC, Trostberg, Germany) 5 grams by 
mouth daily for 8 weeks. Prior to and following the 8 week treatment phase, baseline and 
follow up phases were conducted, each of which were comprised of three visits. To 
determine study eligibility, the same researcher administered the SCID-I/P for each 
participant after consent was obtained. During the baseline phase, a complete blood 
count, comprehensive metabolic panel, including liver enzymes to assess for active liver 
disease, and HIV testing were obtained. Laboratory studies, with the exception of HIV 
testing, were repeated at the conclusion of treatment, to prospectively identify 
abnormalities associated with creatine administration. At each study visit, vital signs and 
concomitant medications were collected in addition to self-report drug use (e.g., 
cigarettes, alcohol, cocaine, MA, THC, heroin and nonprescribed prescription opiates) 
over the past 48 hours and adverse events were monitored twice weekly using a 
medication adverse effect checklist during the 8 week intervention period. Participants 
completed the medication adverse effect checklist, and the principal investigator (PI) 
reviewed each adverse effect to determine expectedness and relationship to study 




Attendance in outpatient treatment and/or 12 step programs (e.g., Narcotics or 
Alcoholics Anonymous) was also assessed at each study visit. A member of the 
investigative team completed the C-SSRS at every study visit as well as weekly HAMD 
and BAI assessments. Since four researchers administered the HAMD on different 
participants throughout the study, an interrater reliability analysis using the Kappa 
statistic was performed to determine consistency among raters. The intraclass correlation 
coefficient for the HAMD raters was determined to be 0.98. Urine samples were 
collected twice weekly for testing of MA, opiates, benzodiazepines, THC and cocaine in 
addition to pregnancy testing. Finally, creatine adherence was assessed weekly as well as 
collection of used and unused creatine bottles. If participants missed more than three 
daily doses of creatine, they were withdrawn from the study for protocol noncompliance. 
Similarly, if participants missed more than three consecutive study visits, they were 
withdrawn from the study for protocol noncompliance. 
 Phosphorus MRS scans were acquired using a Siemens 3 T MRI scanner 
(Siemens AG, Munich, Germany) that is approved for clinical use. Two dimensional-
chemical shift imaging (2D-CSI) free induction decay pulse sequence was used with TR / 
TE = 3000 / 2.3 ms, number of average = 36, field of view = 20 cm × 20 cm, acquisition 
matrix 8 × 8, size of vector = 1024, voxel dimension=2.5 cm × 2.5 cm, flip angle = 90°, 
slice thickness = 2.5 cm, and bandwidth = 2.5 kHz. Advanced Method for Accurate, 
Robust and Efficient Spectral (AMARES; Vanhamme, van den Boogaart, & Van Huffel, 
1997) fitting routine within jMRUI software package (Naressi, et al, 2001) was used for 
quantitation of 31P metabolites of the frontal lobe. Phosphocreatine integral values were 
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expressed relative to the total phosphorus signal (Blumberg, et al, 1999).  
 
Outcome Measures 
 The primary outcome measure was the weekly change in HAMD scores from 
baseline. The secondary outcome measures were the weekly changes in BAI scores from 
baseline, postcreatine treatment changes in brain PCr values in addition to percent of 
weekly positive MA urine drug screens. Treatment response for the HAMD (Furukawa et 
al., 2007) and BAI (Leyer, Ruberg, & Woodruff-Borden, 2006) was defined a priori as a 
decrease of 50% or more from baseline. (Note: a discussion of HAMD and BAI 
reliability and validity can be found in Chapter 3). Because classical methods of 
reliability measurement are often not tenable with a longitudinal design (DeShon, 
Ployhart, & Sacco, 1998), within occasion reliability, using a linear mixed effects model 
with maximum likelihood, for the HAMD and BAI were calculated, and these results 
indicated an estimated reliability (Donaldson, 2008; Singer & Willet, 2003) of 0.52 for 
both scales. The HAMD reliability of 0.52 is similar with the only other published report 
(Laenen, Alonoso, Molenberghs, Vangeneugden, & Mallinckrodt, 2009) of within 
occasion reliability using a linear mixed effects model, and possible explanations for this 
low reliability are discussed in the Discussion section. There are no published reports of 




 Based on prior clinical experience regarding treatment completion among female 
MA users, for this pilot study, a sample size of 10 was initially proposed. A power 
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analysis was performed to determine the minimum effect that would be detected with 10 
completed participants. The HAMD scores from the first three visits were averaged and 
considered “baseline,” and the effect for the power analysis compared the average 
treatment HAMD scores with the baseline HAMD score. Assuming a gradual onset of 
effect during the treatment phase, an initial effect of 0 was used with an ending effect of 
0.5, resulting in an average treatment effect of 0.25. A linear combination of the separate 
measures (y*) was used to test the effect in addition to a 0.5 pattern correlation. Thus, a 
standard deviation (SD) for y* was generated and divided by the SD(y*) to calculate a de 
facto effect size, which resulted in a value of 1.09 for the effect size with a power of 0.87.  
 Descriptive statistics are reported for baseline demographic variables, retention 
and missed medication doses. Analyses for the primary outcome measure and change in 
BAI scores outcome were performed using a linear mixed effects model repeated 
measures analysis, which is capable of handling missing data and time varying covariates 
(Mallinckrodt et al., 2003). Time was included as a fixed factor and subject was treated as 
a random factor. Age was used a covariate. Sidak correction, a method to compensate for 
multiple comparisons, (West, Welch, & Gałecki, 2006) was used to control for Type I 
error. A paired t-test and Wilcoxon Signed Ranks test was conducted to evaluate changes 
in brain PCr levels. An alpha value of less than 0.05 was considered significant for one 










 Of the 21 females screened for participation, 14 (M = 37.4, SD = 9.9 years of age) 
were enrolled in the study (see Figure 3).  All of the participants met SCID-I/P criteria for 
MDD as a primary disorder. The average baseline HAMD score was 17.5 (SD = 2.7; see 
Tables 8 and 9), which suggests moderate illness with respect to severity of depression 
(Furukawa et al., 2007). All participants met SCID-I/P criteria for lifetime MA 
dependence and 57% of the sample met criteria for current MA dependence. Current 
comorbid substance use disorders included alcohol (7.1%), cannabis (7.1%) and opioid 
(28.6%), and current comorbid psychiatric disorders included social phobia (7.1%) and 
posttraumatic stress disorder (7.1%). On average, the participants used an estimated 
lifetime amount of 5,662.9 (SD = 9,671.0) grams of MA with a mean of 18.9 (SD = 9.4) 
years of total use. Concomitant medications reported at baseline included: Enalapril (n = 
1), vitamins (n = 1), Estridiol (n = 1), Proventil (n = 1), Aciphex (n = 1), Neurontin (for 
nerve pain) (n = 1), Methadone (n = 1) and Ambien (n = 1).  
 
Primary Outcome 
With respect to linear mixed model assumptions, visual inspection did not reveal 
any obvious deviations from linearity of the residual plot, homoscedasticity or normality 
of residuals. Significant improvements in depressive symptoms were found as early as 
week 2 (M = 10.04, SD = 1.19 days on creatine) and maintained through the follow up 
period (see Figure 4). There was not a significant age by time interaction, and thus, age  
 
   
 
142
Table 8. Baseline demographic characteristics (frequencies) 
  
 Characteristic n % 
 Race   
      Caucasian 13 92.9 
      American Indian 1 7.1 
 Ethnicity   
      Not Hispanic or Latino 14 100 
 Marital status   
      Married 2 14.3 
      Divorced 4 28.6 
      Never married 8 57.1 
 Education level   
      Did not graduate high school 5 35.7 
      Graduated high school or GED 3 21.4 
      Part college 4 28.6 
      Graduated 2 year college 2 14.3 
 Employment status   
      Employed full-time 2 14.3 
      Employed part-time 1 7.1 
      Unemployed  8 57.1 
      Student 1 7.1 
      Homemaker 2 14.3 
 Antidepressant treatment history 9 64 
 DSM-IV diagnoses   
      Major Depressive Disorder (MDD) 14 100 
      Alcohol use disorder, current 1 7.1 
      Stimulant use disorder, current 8 57.1 
      Cannabis use disorder, current 1 7.1 
      Opioid use disorder, current 4 28.6 
      Social phobia, current 1 7.1 
      PTSD, current 1 7.1 
      Substance induced anxiety, current 4 28.6 
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 Table 9. Baseline demographic characteristics (descriptive statistics) 
   
 Characteristic Mean SD Range 
 
Age in years 37.4 9.9 24 – 52 
 Estimated lifetime use of methamphetamine in 
grams 5,662.9 9,671.0 
10.5 – 
37,280.0 
 Abstinence from methamphetamine in days  52.9 94.6 0 – 363  
 Total years of methamphetamine use  18.9 9.4 4 – 35 
 Hamilton Depression Rating Scale score  17.5 2.7 13 – 22  

































HAMD = Hamilton Depression Rating Scale 
* Change in HAMD score statistically significant from baseline (p < .05). 
Error bars represent 95% confidence interval 
Red error bars indicate the treatment period 
 
Figure 4. Change in mean Hamilton Depression Rating Scale scores 
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was removed from the model. By visual inspection of individual HAMD scores (see 
Figure 5), it appears that scores improved relatively consistently with the exception of 2 
participants. One of these two outliers had a drastic increase in her HAMD score (30) at 
week 1, followed by a drastic decrease to a score of 13 at the next visit she attended 
(week 3). The other outlier’s HAMD score did not drop below 14, whereas all other 
participants scored below 14 by week 4. Differences in baseline characteristics, which are 
discussed in the Discussion section, might explain these outliers. Finally, change scores 




HAMD = Hamilton Depression Rating Scale 
Treatment period = weeks 2 – 9  
Treatment response = score of 8.75 or below 
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Secondary Outcomes  
Anxiety.  With respect to linear mixed model assumptions, visual inspection did 
not reveal any obvious deviations from linearity of the residual plot, homoscedasticity or 
normality of residuals. Significant improvements in anxiety symptoms were found as 
early as week 1 (M = 4.70, SD = 1.57 days on creatine) and maintained through the 
follow up period (see Figure 6. There was not a significant age by time interaction, and 
thus, age was removed from the model. By visual inspection of individual BAI scores 
(see Figure 7), it appears that scores improved relatively consistently with the exception 
of 1 participant. This 1 outlier had a higher baseline BAI score (39.0 compared to a range 
of 5.0 - 28.5), and her score increased at week 2 after a small decrease at week 1, whereas 
the remaining participants’ scores decreased at week 1 and continued to decrease. 
Differences in baseline characteristics, which are discussed in the Discussion section, 
might explain this outlier. Finally, percentage change scores are presented in Table 10. 
Phosphocreatine.  One of the enrolled participants was unable to complete the 
MRS scan, and therefore, there were a total of 10 scan completers. A paired t-test was 
used to evaluate pre- and postcreatine PCr values, and the results of the test indicated that  
after 8 weeks of creatine treatment, mean PCr values were significantly higher than 
baseline measures; Mbaseline = 0.223 (SD = 0.013) versus Mpost treatment = 0.233 (SD = 
0.009), t(9) = 2.905, p < .01, 95% CI [0.002, 0.019]. The standardized effect size, d, was 
0.92. Because of the small sample size and nonnormal distribution of the dependent 
variable (i.e., PCr), a Wilcoxon Signed Ranks test was also performed. The results of this 
test  were similar to the results from the paired t-test: median PCr values increased from 
the baseline scan; Mdbaseline = 0.226 versus Mdpost treatment = 0.236 (Z = 2.293, p = .01).  










BAI = Beck Anxiety Inventory 
* Change in BAI score statistically significant from baseline (p < .05). 
Error bars represent 95% confidence interval 
Red error bars indicate the treatment period 
 









BAI = Beck Anxiety Inventory 
Treatment period = weeks 2 – 9 
Treatment response = 9.8 
 
Figure 7. Change in individual Beck Anxiety Inventory scores 
 
The results of both the paired t-test and Wilcoxon Signed Ranks suggest that creatine 
treatment may increase brain PCr levels. A visual inspection of the individual PCr levels 
at the baseline to posttreatment scans demonstrate that all but 1 participant’s PCr 
appeared to consistently increase by the second scan. The outlier’s PCr decreased by the 
posttreatment scan (0.22 compared to 0.23 at baseline; see Figure 8), and noncompliance 
with taking creatine daily may explain why her values did not increase. 
Methamphetamine use.  At baseline, 50% of the urine drug screens were positive 
for MA. By week 6, the percentage of urine drug screens positive for MA was reduced by 
more than half (21.4%). The percentage of urine drug screens positive for MA remained 









































PCr = phosphocreatine 
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MA = methamphetamine 
Figure 9. Percentages of positive methamphetamine urine drug screens from baseline 
through follow up 
 
also reduced throughout the course of the study. At baseline, a mean of 0.26 (SD = 0.02) 
grams of daily MA was reported, and by the end of 8 weeks of creatine treatment a mean 
of 0.13 (SD = 0.03) grams of daily MA was reported.  
 
Retention and Missed Visits 
  
A total of 11 participants (78.6%) completed the study from baseline through 
follow up. Three participants dropped out of the study: 1 participant was admitted to 
inpatient substance abuse treatment during the first week of creatine treatment, another 
participant was considered lost to follow up after missing three consecutive study visits 
during weeks 3 and 4 of creatine treatment and the third drop out was due to the 
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time commitment (see Figure 3). On average, there were a total of two missed visits per  
participant.    
 
Medication Adherence, Safety and Tolerability 
Medication adherence was monitored by counting returned used and unused vials 
of creatine. Participants took on average 83.3% of dispensed study medication. A paired 
t-test was used to evaluate pre- and postserum creatinine values as an indicator of 
medication adherence. The results of the test suggested that the 11 participants who 
completed the 8 weeks of creatine administration increased their mean serum creatinine 
values from pretreatment (M = 0.76, SD = 0.09) to posttreatment (M = 0.89, SD = 0.14), 
t(10) = 4.11, p = .002, 95% CI [0.060, 0.202]). 
Creatine appeared to be well tolerated, and none of the participants withdrew due 
to adverse effects from creatine. Using the medication adverse effect checklist, 
participants reported a total of 32 adverse effects during the treatment phase of the study 
(see Table 11). The investigator reviewed each adverse effect, and because there is 
inconsistent published data regarding adverse effects of creatine, none of the events were 
considered related to study participation. All of the reported adverse effects were mild in 
severity and resolved without intervention. Adverse events included: cold and flu 
symptoms (n =10), indigestion (n = 1), flank pain (n = 1), polydipsia (n = 1), headache (n 
= 3), swelling in hands (n = 4), diarrhea (n = 4), stomach discomfort (n = 3), numbness 
and tingling in hands (n = 1), muscle cramps (n = 2), blurry vision (n = 1), lightheaded (n 
= 1) and nausea (n = 1). There were no abnormalities detected on laboratory assessments 
that were drawn at end of treatment.  
























































































































































































































































































































































































































































































































































































































































































































 The current study is the first open label trial of 5 grams of daily creatine for the 
treatment of depression in female MA users. This study demonstrated improvements in 
depressive symptoms, measured by the HAMD, as early as the second week of creatine 
treatment and maintained through study completion. Further, anxiety symptoms,  
measured by the BAI, were reduced as early as the first week of study participation and 
also maintained throughout the study. Urine drug screens positive for MA were reduced 
from 50% to 21.4% by the sixth week of creatine treatment and were maintained until the 
end of the study, and 8 weeks of creatine treatment was associated with a mean increase 
in brain PCr concentrations. Finally, creatine was well tolerated with few reported 
adverse effects. In summary, this study shows positive effects from creatine treatment on 
depression, anxiety, MA use and brain bioenergetics in female MA users with comorbid 
depression.  
 The finding related to reduced HAMD scores is consistent with other studies of 
creatine in depressed females. In fact, both Lyoo and colleagues (2012) and Kondo et al. 
(2011) noted decreased HAMD and CDRS scores, respectively, with 8 weeks of creatine 
augmentation. The exact antidepressant mechanism of creatine is not clear, but one 
possible explanation involves its role in cellular energy metabolism. As a guanidine 
compound, the liver, kidney or pancreas endogenously produces creatine, and 
exogenously it is found in products containing meat (Adhihetty & Beal, 2008). Cellular 
entry of creatine into the brain, heart and skeletal muscle is reliant on the sodium chloride 
dependent creatine transporter (Adhihetty & Beal, 2008; Brown et al., 2014), and it exists 
as both intracellular free creatine and PCr, which is referred to as the total creatine pool 
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(Adhihetty & Beal, 2008).  
Several lines of evidence suggest mitochondrial dysfunction in the 
pathophysiology of depression (Jou, Chiu, & Liu, 2009; Rezin, Amboni, Zugno, 
Quevedo, & Streck, 2008; Streck et al., 2014) and with MA neurotoxicity (Sung, 
Yurgelun-Todd, et al., 2013; Yamamoto, Moszczynska, & Gudelsky, 2010). As a key 
regulator of energy production, one of the consequences of mitochondrial dysfunction is 
reduced ATP production (Streck et al., 2014). The role of the creatine-PCr system is to 
provide an intracellular buffer against ATP depletion. Creatine treatment may increase 
brain intracellular PCr, and this might explain why reduced depressive symptoms are 
associated with oral creatine treatment. Further, this may also explain our finding of 
increased brain PCr levels, which is consistent with other creatine neuroimaging studies. 
Kondo and colleagues (2011) reported a significant increase in PCr values in participants 
treated with 8 weeks of daily creatine compared to untreated controls and Lyoo et al. 
(2003) showed an increase in brain PCr concentrations in participants treated with daily 
creatine for 2 weeks compared to a placebo group.  
There were 2 outliers with respect to change in HAMD scores. As descried in the 
results section, one of these two outliers had a drastic increase in her HAMD score at 
week 1 (score of 16 at baseline and score of 30 at week 1) followed by a drastic decrease 
to a score of 13 at the next visit she attended (week 3). This particular participant’s 
SCID-I/P diagnoses were similar to the other participants with diagnoses of recurrent 
major depressive disorder and current stimulant use disorder. Her estimated total amount 
of lifetime MA use, however, was higher (37,280 grams) than the other participants 
(range 10.5 – 13,440). It is possible that the increased amount of total lifetime MA use 
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played a role in the severity and fluctuation of symptoms. 
The other outlier’s HAMD score did not drop below 14, whereas all other 
participants scored below 14 by week 4. In addition to SCID-I/P diagnoses of recurrent 
major depressive disorder and current stimulant use disorder, she also met criteria for a 
current opioid use disorder and current substance induced anxiety disorder. In fact, she 
was taking methadone and started a methadone taper during the fourth week of study 
participation. Tapering from methadone may explain why her HAMD score never 
dropped below 14, as it is possible that she was experiencing symptoms from the taper 
that resulted in symptoms of depression. However, since variables that relate to changes 
in methadone doses were not collected in the present study, this is merely a speculation. 
The BAI score outlier was the female tapering from methadone. She presented 
with high anxiety symptoms at baseline (score = 39) after a small decrease at week 1 
(score = 16); her symptoms increased at week 2 (score = 34), whereas the remaining 
participants’ scores (range of scores = 0 – 18) continued to decrease at week 2. She was 
prescribed methadone for chronic pain, and it is possible that pain symptoms and the 
anticipation of the upcoming methadone taper, which started during the fourth week of 
study participation, explain why her anxiety scores were higher in the beginning of the 
study than the other participants’ scores. Her BAI scores steadily decreased from week 2 
to week 7 (score = 8), and then increased each week from week 7 through study 
completion (final score = 18). However, as mentioned above, since variables that relate to 
changes in methadone doses were not collected in the present study, this is merely a 
speculation. 
 In this study, a decrease in the number of positive urine drugs for MA and self-
   
 
156
report amount of daily MA use throughout the course of the study was observed. By 
week 6, the percentage of positive MA urine drugs screens was less than almost half of 
the positive drugs screen for MA that were observed at baseline, and by the end of the 
treatment period, the amount of self-reported MA use was reduced by half. In agreement 
with the self-medication hypothesis of drug use, which suggests that individuals use 
substances in an effort to cope with mood symptoms (Khantzian, 1985), it is possible that 
as the severity of depressive and anxiety symptoms were reduced, MA use was also 
reduced.  
However, it is worth pointing out that the 3 participants who dropped out of the 
study were actively using MA, whereas nearly half  (45.5%) of the study completers 
maintained abstinence from MA from study entry through study completion. 
Nonetheless, this is the first monotherapy study that reports a decrease in the number of 
positive MA urine drug screens. There have been studies that have investigated a 
medication versus placebo in conjunction with usual care in an outpatient psychiatric 
clinic setting (e.g., cognitive behavioral therapy, counseling or contingency 
management). For example, Shoptaw et al. (2009) evaluated bupropion compared to 
placebo for MA dependence in an outpatient treatment clinic where participants also 
received CBT and CM. While the percent of positive MA urine drug screens decreased 
over the course of the 12 week medication period, the difference in percent of positive 
MA urine drug screens between the placebo and bupropion groups was not significant 
(Shoptaw et al., 2008). Therefore, it is possible that CBT or CM had an effect on MA use 
or CBT or CM coupled with study participation had an effect on MA use. Regardless, the 
results from this study suggest that creatine, without standard of care treatment, might be 
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effective at reducing MA use.   
 The reliability estimate, using a linear mixed effects model with maximum 
likelihood (Donaldson, 2008; Singer & Willet, 2003) for the HAMD and BAI reported in 
this study is not commonly reported, but it is a more appropriate reliability measure for 
longitudinal data (DeShon, Ployhart, & Sacco, 2010; Donaldson, 2008; Laenen et al., 
2009) Laenen and colleagues (2009) calculated a reliability estimate of the HAMD from 
two clinical trials evaluating the efficacy of two antidepressants using a linear mixed-
effects model analysis. The results from their study are similar to the results from the 
current study with average reliability estimates around 0.50 and 0.60 (Laenen et al., 
2009). The Laenen et al. study and the present study analyzed reliability from a 
homogenous sample, which, because reliability is a population dependent concept 
(Laenen et al., 2009), may explain lower reliability estimates than what we are used to 
seeing with classical reliability measurements. Further, as Laenen and colleagues pointed 
out, the Pearson correlation coefficient is commonly reported, which does not take into 
account patients evolving with time, and an overestimation of reliability is calculated.  
There are not any published studies of within occasion reliability of the BAI to 
compare the reliability estimate from the present study with. The same rationale 
explained for the low reliability estimate of the HAMD, however, also applies to the low 
reliability estimate of the BAI in the present study.  
It is noteworthy that psychometric studies require much larger sample sizes than 
the sample of this study. With that said, the reliability estimate of 0.52 for both the 
HAMD and BAI was not surprising because the present study did not have an adequate 
number of participants to calculate reliability measures. Cronbach’s alpha is the most 
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ubiquitous reported reliability estimate as a measure of internal consistency, but it is not 
mathematically possible to calculate Cronbach’s alpha for the present study considering 
the small sample size. Both the HAMD (Hamilton, 1960) and BAI (Beck et al., 1988) 
evolved from clinical classifications, and Feinstein (1987) refers to research scales based 
on clinical symptoms of disease as clinimetric (as opposed to psychometric).  
The difference between psychometric and clinimetric scales are that the former 
are based on variables that are selected according to their relationship to an underlying 
construct, whereas clinimetric scale items are deliberately chosen according to how the 
variables relate to symptoms (Fayers and Hand, 2002). Despite the popularity of using 
traditional psychometric approaches to evaluating scale reliability, Fayers and Hand 
(2002) question the appropriateness of using these traditional approaches with clinimetric 
scales.  
Nonetheless, considering the sample of depressed MA users included in the 
present study, concern of reliability and validity in the traditional psychometric sense 
should not go unnoticed. Because the effects of MA use and/or withdrawal from MA 
mimic symptoms of depression and anxiety, further psychometric studies that consider 
clinimetric ideas (Fayers and Hand, 2002) with adequate sample sizes should be 
considered.  
 This study has limitations that merit consideration. First, the lack of a placebo 
group makes it difficult to know if creatine, as opposed to the Hawthorne effect 
(McCarney, Warner, Iliffe, van Haselen, Griffin, & Fisher, 2007), played a role in 
reducing depressive and anxiety symptoms and MA use. Three of the participants were 
homeless and may have benefited from the individual attention from the research team as 
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well as the gift card compensation. Future studies with a placebo group and/or a control 
group that does not receive creatine but is assessed over time are warranted.  
Another limitation to consider is that this study recruited a small sample, but it is 
note worthy that the a priori power analysis resulted in a power of 0.87 and effect size of 
1.09 for a sample of 10 completers for the primary outcome measure, and our total 
sample size included 11 participants for the primary outcome. In addition, as the first 
study of creatine in depressed female MA users, the feasibility of recruiting and retaining 
participants needed to be established. An attrition rate of 21.4% is lower than most other 
treatment trials of MA dependence, as rates are commonly reported as 45% - 67% 
(Brown & Gabrielson, 2012; Cruickshank et al., 2008; Elkashef et al., 2008; McGaugh et 
al., 2009; Shoptaw et al., 2008).  
Finally, this study was limited to females with comorbid depression and MA 
dependence because of preclinical studies that suggest creatine has antidepressant effects 
in female but not male rodents (Allen et al., 2010). Consequently, gender effects of 
creatine were not evaluated in this study; and therefore, future studies with male MA 
users included are necessary. Finally, HAMD criteria of 15 and above was used even 
though a score of greater than 15 suggests moderate illness (Furukawa et al., 2007). A 
score of 15 or greater was selected to capture females with dysthymia in addition to 
moderate to severe depression since dysthymia is also associated with poor treatment 
outcomes (Katon et al., 2002); however, none of the enrolled participants’ baseline 
HAMD scores were less than 16. 
 
 




The present study suggests that creatine provides a promising therapeutic 
approach for comorbid depression and MA dependence in females with regard to its 
tolerability, safety profile and easy attainability. Depression is a mediator and moderator 
of MA use, and comorbid depression among MA users confounding treatment outcomes 
and worsening overall prognosis is well documented. If creatine can help address the 
symptoms of depression among MA users, it would improve treatment outcomes and 
reduce the risk of relapse.  
 
Conclusions 
The present study showed that creatine as a stand alone treatment may be 
beneficial for treating depressive and anxiety symptoms, MA dependence and increasing 
brain PCr concentrations in females. Creatine was well tolerated with minimal adverse 
events and is an inexpensive, easily attainable product. Replication of the current study in 
a larger sample with depressed male and female MA users is required. Importantly, 
though, given that there are not any FDA approved treatments for either MA dependence 
or comorbid depression and MA use disorders, interventions with the potential to reduce 
mood symptoms, improve brain bioenergetics and reduce MA use are urgently required.  
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 This appendix contains regulatory materials such as the Investigational New Drug 
(IND) application and safe to proceed letter from the Food and Drug Administration 
(FDA); Institutional Review Board (IRB) approved informed consent form and IRB 
approval letters. 





Drug information:  
AlzChem will provide creatine monohydrate to the Brain Institute at the University of 
Utah for drug abuse research.  (Please refer to AlzChem’s Drug Master File (DMF) 
16538).  The active ingredient, creatine monohydrate (a-methyl guandino-acetic acid), is 
considered a dietary supplement according to the Dietary Supplement Health Education 
Act that was passed in 1994 by the Food and Drug Administration (FDA) Act.  The 
following is the formula of creatine monohydrate: 











The formulation of the dosage that will be used is 4-10 grams per day and the product 
will be administered orally.  We propose to investigate creatine monohydrate’s potential 
role in drug abuse research over the course of the next 5-7 years.   
 
Previous Human Experience with Creatine: 
A French scientist Michel Eugene Chevreul first described creatine as a nitrogenous 
organic acid that occurs naturally in vertebrate animals in the 1830s.  The capacity for 
creatine biosynthesis via the creatine-kinase-phosphocreatine energy buffering system 
was established early in the evolutionary history of life on Earth [1].  Acting as a 
substrate for hydrogen ions, creatine facilitates the production of adenosine triphosphate 
(ATP) from adenosine diphosphate (ADP), thus increasing the amount of free energy 
available within cells [2].  
Creatine is under investigation as a treatment for neuromuscular and 
neurodegenerative diseases.  Walter et al. [3] administered creatine to treat Muscular 
Dystrophy in a double-blind placebo-controlled trial.  The study enrolled 32 participants 
and 5 grams/day of creatine was administered [3].  The researchers noted a significant 
improvement in muscle strength and daily activities in the creatine group and there were 
no reported side effects from creatine use [3].   
Creatine supplementation has also been used for the treatment of Huntington’s 
Disease (HD).  Study findings suggest that phosphocreatine (PCr) and inorganic 
phosphate are reduced in resting muscles of HD patients [4].  Creatine supplementation 
in animal models of HD has been shown to improve motor performance, extend survival, 
attenuate the loss in body and brain weight, reduce neuron atrophy, and lower the 
number of Huntington-positive aggregates [5-7].  Moreover, creatine supplementation 
has been shown to be neuroprotective and reduce lesion volume in mitochondrial toxin 
models of HD [8].  Hersch and colleagues [9] conducted a double-blind placebo-
controlled trial testing the safety and tolerability of creatine adminstration in a HD 
population.  In addition, they evaluated brain and serum biomarkers of creatine 
availability and activity [9].  Subjects were instructed to take 8 grams of creatine daily for 
16 weeks, which was well tolerated and safe [9].  The researchers noted increased brain 
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and serum creatine concentrations in the creatine-treated group, which returned to 
baseline after a washout period [9].   
There is strong evidence that mitochondrial impairment plays a role in the 
pathogensis of Parkinson’s disease (PD) [10], and due to this bioenergetic impairment, 
creatine has been explored as a treatment option.  Matthews et al. [8] noted that oral 
creatine supplementation resulted in protection against an electron transport chain of 
mitochondria called 3-nitropropionic acid, 1-methyl-4-phenyl-2,3,6-tetrahydropyridine 
(MPTP) induced dopamine depletion in mice.  In a randomized double-blind clinical trial 
of creatine in early PD patients, researchers reported that creatine delayed increases in 
the Unifed Parkinson’s Disease Scale by as much as 50% [11].  Creatine is currently 
under investigation in a phase III trial examining 1,720 patients with early stage PD 
(http://clinicaltrials.gov/ct2/show/NCT00449865?term=NET-PD&rank=1).  
Creatine supplementation has been studied as a treatment intervention for 
schizophrenia.  Kapstan and colleagues [12] enrolled 12 patients in a placebo-controlled 
study of creatine supplementation. Creatine was administered at a dose of 3-5 
grams/day for three months, and found to be safe.  Adverse effects were limited to 
nausea reported by one female subject, and vomiting in one male subject [12]. 
Amital et al. (2006) treated ten Post-Traumatic Stress Disorder (PTSD) patients with 
with creatine in an open-label study [13].  Participants were treated with creatine 
monohydrate 3 grams/day for one week, then 5 grams/day for an additional three weeks.  
Notably, average Hamilton Depression Rating Scale [14] (HAM-D) score was reduced 
from 24.1 + 5 at study entry to 20.4 + 6 after one month of creatine treatment (p=0.006) 
[13].  Total scores on the HAM-D, Hamilton Anxiety Rating Scale [15] and Clinician 
Administered PTSD Scale [16] showed greater improvement for patients with co-morbid 
major depressive disorder (N=6) compared with scores for patients without psychiatric 
co-morbidity [13]. 
Also, relevant to consideration of creatine as a treatment for mental disorders is the 
work of Rae and colleagues, who showed that creatine supplementation improves both 
working memory and intelligence testing scores in adults [17].  Forty-five adults were 
treated with 5 grams/day for six weeks in a double-blind, placebo-controlled design.  
Creatine supplementation had a significant positive effect (p=0.0001) on subjects’ 
working memory (backward Digit Span Recall) and intelligence test scores (Raven’s 
Advanced Progressive Matrices). 
Kondo and colleagues [19] conducted a study under IND 104,586 examining the 
possible role creatine could play in treating female adolescents with major depressive 
disorder (MDD).  Five female adolescents who had been taking fluoxetine (Prozac®) for 
over eight weeks and still met diagnostic criteria for MDD were treated with 4 grams of 
creatine daily for eight weeks.  Mean depression rating scores measured by the Children 
Depression Rating Scale decreased by 56% and no serious adverse events occurred 
[19].   
Sakellaris and colleagues [20] facilitated an open label pilot study to examine creatine 
acting as a neuroprotectant for children and adolescents with traumatic brain injury 
(TBI).  39 subjects were enrolled in the study and were given 0.4g/kg oral creatine for six 
months. They noted that creatine decreased the duration of posttraumatic amnesia, 
intubation, and intensive care unit stay. Significant improvement was recorded in the 
categories of headache (p < 0.001), dizziness (p = 0.005) and fatigue (p < 0.001). No 
side effects were seen due to creatine administration [20]. 
 
There have not been any reports of creatine being withdrawn from the market for any 
reason to date. 
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General Investigational Plan: 
Rationale for the drug or research plan:  
Methamphetamine (MA) is a derivative of an amphetamine and is a powerful 
stimulant that affects the brain and central nervous system. Even though rates of MA use 
are declining nationally [21], the consequences of MA dependence are still a public health 
concern.  MA dependence is a highly refractory condition, which results in serious 
impairment of social and occupational functioning [22].  Long-term MA use may result in 
persistent psychiatric symptoms including drug-induced psychosis [23].  Additionally, MA 
users often report previous suicide attempts and violent behavior changes [24].   
MA use is of great concern in the state of Utah because it’s the primary drug of 
threat in the state, and accounts for 15.6% of substance abuse treatment admissions [25, 
found at http://www.dsamh.utah.gov/].  Of those in treatment, nearly 75% are women and 
mothers [25].  The Utah Division of Substance Abuse and Mental Health indicates that MA 
peaked in Utah in 2006, and regardless of use rates, MA remains more widely abused 
than heroin, cocaine, or prescription drugs (Health, 2010).  In addition, Utah state data 
indicates that within Salt Lake County, MA is the primary drug of choice among females 
between the ages of 18 and 24 [25].  
Consistent study findings suggest that approximately twice as many females are 
depressed as men [26-29].  By the middle teenage years, females experience more than 
double the rate of depressive disorders found in males [30, 31].  This approximate 2:1 
gender difference in depression continues throughout the reproductive years [32].  In 
addition to increased incidence, initial episodes of depression are longer in duration and 
more severe in symptomatology in females compared to males [33].  Females are more 
likely than males to have atypical symptoms of depression, such as hypersomnia and 
hyperphagia, to have co-morbid anxiety disorders, and to attempt suicide [34].  Globally, 
depression is among the most common disorders affecting females throughout their lives, 
and is the leading cause of disability among women between the ages of 15 and 44 years 
[35].  Moreover, depression is associated with high-risk behavior such as illicit drug use 
[36].  
Recently the Utah Department of Health published a report on depression and 
antidepressant use in Utah [37].  Using health insurance claims from 899,323 Utah 
residents, antidepressant use was examined, and over six million pharmacy claims from 
2009 were reviewed.  Of interest, they reported that 84,000 individuals were prescribed 
antidepressants, resulting in antidepressants being the most widely prescribed medication 
in the state.  When comparing antidepressant utilization by gender, researchers noted that 
females are prescribed antidepressants at a rate of more than twice that of males.  A 
recent study by Mental Health America ranked Utah the most depressed state in the 
nation [38].  Their results indicated that among adults, 10.1% experienced a depressive 
episode in the past year [38].	  	   	  
Kalechstein and colleagues [39] examined the association between psychiatric 
symptoms and MA dependence in a sample of 1,580 substance-using individuals.  They 
assessed demographics, history of substance dependence and psychiatric 
symptomatology.  170 participants self-reported MA dependency, and of these 170, 
29.4% reported needing psychiatric services, 49.4% reported a previous suicide attempt, 
and 57.1% reported presence of depressive symptoms in the past year [39].  Moreover, 
the researchers noted a prevalence of depression in females as being two to three times 
greater than depression in males [39].  Researchers from the Methamphetamine 
Treatment Project noted that 68% of all women reported a history of feeling depressed at 
some point in their lifetime, whereas 50% of all men reported a history of feeling 
depressed at some point in their lifetime [24].  Likewise, 28% of MA dependent women 
reported a suicide attempt during their lifetime, compared to only 13% of men [24].  
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There is no clear treatment model recommending how depression and MA use 
cormorbidity is best managed.  Stepped-care is a model of healthcare delivery that 
facilitates the integration of evidence-based treatments into clinical practice, and it has 
been recommended in the alcohol and drug field [40].  Kay-Lambkin et al. [40] explored 
the effectiveness of stepped-care in a sample of depressed MA users, and their findings 
indicate improvement in depression.  However, they noted their pilot study is the first to 
examine the efficacy of stepped-care in depressed MA users, and stepped-care is not 
commonly utilized as a treatment option for this population [40].  
The causal nature of the association between depression and MA use continues 
to be debated in the literature.  Some authors argue that MA use results in biological and 
psychological changes that increase an individuals risk for depression [41].  Others have 
proposed that substance use in general is a compensatory behavior to alleviate symptoms 
of an underlying mental illness, which is referred to as the self-medication hypothesis [42].   
Data from preclinical animal studies suggest that creatine has sex-dependent 
antidepressant properties.  The Prosolt Forced Swim Test (FST) is the most widely 
employed experimental animal model of depression.  Fed to rates, diets enriched with 4% 
creatine for six weeks confer a longer latency to immobility in female rats compared with 
rats fed 0% creatine.  In male rats, however, creatine has the opposite effect [43].  
Moreover, supplementation with 4% creatine in female rats was of greater benefit for 
reducing depression-like behavior than 10mg/kg of fluoxetine (Allen, 20110, unpublished 
findings).  The gender-specific nature of these findings may be due to the fact that 
estrogen receptors are quite common on mitochondria [44].  Estrogen has potent effects 
on mitochondria, particularly in times of mitochondrial stress [45].  Estrogen has cell-
specific effects on a variety of physiologic endpoints, including regulation of mitochondrial 
biogenesis and activity [46].   
In an eight-week open label study of creatine augmentation in female adolescents 
who failed to respond to an SSRI, Children Depression Rating Scores (CDRS) were 
reduced by 44% [19].  Moreover, the researchers noted that brain PCr concentrations 
increased with eight-weeks of creatine use when compared to a comparison group [19].  
To date, no studies have examined the effect of creatine supplementation in female MA 
users.  Given the gender-specific effects of creatine in animal models [43], clinical trials in 
males should be deferred until efficacy and safety has been shown.  
 
The indication(s) to be studied: 
We propose to investigate creatine monohydrate’s potential role in drug abuse 
research. As an initial step in testing the antidepressant and neuroprotective effects of 
creatine supplementation, we propose an open-label clinical trial of creatine 
administration in female MA users.  
 
The general approach to be followed in evaluating the drug: 
The general approach includes creatine supplementation in a methamphetamine 
using population. 
 
Kinds of clinical trials to be conducted in the first year: 
As an initial step, we propose an open-label clinical trial of creatine administration 
in female MA users.  Female MA users will be recruited for study participation, and once 
eligibility is determined, study participants will undergo baseline neuroimaging (magnetic 
resonance spectroscopy (MRS)) and then begin creatine supplementation at 5 grams 
per day for 8 weeks.  Study participants will undergo a second MRS scan after 
completing 8 weeks of creatine supplementation.  Depression will be measured using 
two reliable scales: Hamilton Depression Rating Scale (HAM-D) and Montegomery-
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Asberg Depression Rating Scale (MADRS).  Adverse event monitoring will occur at each 
study visit. Upon completion of the open-label trial, we will propose a randomized control 
trial design involving placebo and creatine in depressed female MA users.  
 
The estimated number of patients to be given the drug in those studies: 
We will request approval to recruit 20 participants in the open-label trial and 
up to 100 participants in the double-blind placebo controlled trial.   
 
Any risks of particular severity or seriousness anticipated on the basis of the toxicology 
data in animals or prior studies in humans with the drug or related drugs: 
There are not any concerns of severity of seriousness anticipated.  Creatine  
supplementation has been studied in animals and humans and adverse events are 
limited to mild gastrointestinal discomfort.   
 
Investigator’s Brochure:  
There is not an investigator’s brochure for creatine monohydrate.   
 
Protocol: 
Please see the protocol attached to the 1572. 
 
Chemistry, Manufacturing, and Control Information: 
Please refer to AlzChem’s DMF 16538 for information regarding chemistry,  
manufacturing and control information.  Note a placebo is not proposed for the initial 
study.  If a placebo-controlled trial is proposed later, information regarding the placebo 
will be provided.  
  
 Labeling: 
  See attached drug label.  
 
 Environmental analysis requirements: 
  Please refer to AlzChem’s DMF 16538. 
 
Pharmacology and Toxicology Information: 
Please refer to AlzChem;s DMF 16538. 
 
Previous Human Experience with the Investigational Drug: 
See section ii. Previous Human Experience with Creatine 
 
Additional Information: 
Drug dependence and abuse potential: N/A 
Radioactive drugs: N/A 
Pediatric studies: N/A 
Other information: N/A 






1. Ellington, W.R. and T. Suzuki, Early evolution of the creatine kinase gene family 
and the capacity for creatine biosynthesis and membrane transport. Subcell Biochem, 
2007. 46: p. 17-26. 
2. Kamber, M., et al., Creatine supplementation--part I: performance, clinical 
chemistry, and muscle volume. Med Sci Sports Exerc, 1999. 31(12): p. 1763-9. 
3. Walter, M.C., et al., Creatine monohydrate in muscular dystrophies: A double-
blind, placebo-controlled clinical study. Neurology, 2000. 54(9): p. 1848-50. 
4. Jenkins, B.G., et al., Evidence for impairment of energy metabolism in vivo in 
Huntington's disease using localized 1H NMR spectroscopy. Neurology, 1993. 43(12): p. 
2689-95. 
5. Ferrante, R.J., et al., Neuroprotective effects of creatine in a transgenic mouse 
model of Huntington's disease. J Neurosci, 2000. 20(12): p. 4389-97. 
6. Andreassen, O.A., et al., Creatine increase survival and delays motor symptoms 
in a transgenic animal model of Huntington's disease. Neurobiol Dis, 2001. 8(3): p. 479-
91. 
7. Dedeoglu, A., et al., Creatine therapy provides neuroprotection after onset of 
clinical symptoms in Huntington's disease transgenic mice. J Neurochem, 2003. 85(6): p. 
1359-67. 
8. Matthews, R.T., et al., Creatine and cyclocreatine attenuate MPTP neurotoxicity. 
Exp Neurol, 1999. 157(1): p. 142-9. 
9. Hersch, S.M., et al., Creatine in Huntington disease is safe, tolerable, 
bioavailable in brain and reduces serum 8OH2'dG. Neurology, 2006. 66(2): p. 250-2. 
10. Beal, M.F., Therapeutic approaches to mitochondrial dysfunction in Parkinson's 
disease. Parkinsonism Relat Disord, 2009. 15 Suppl 3: p. S189-94. 
11. Investigators, N.N.-P., A randomized, double-blind, futility trial of creatine and 
minocucline in early Parkinson disease. Neurology, 2006. 66: p. 664-671. 
12. Kaptsan, A., et al., Lack of efficacy of 5 grams daily of creatine in schizophrenia: 
a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry, 2007. 68(6): p. 
881-4. 
13. Amital, D., et al., Open study of creatine monohydrate in treatment-resistant 
posttraumatic stress disorder. J Clin Psychiatry, 2006. 67(5): p. 836-7. 
14. Faries, D., et al., The responsiveness of the Hamilton Depression Rating Scale. J 
Psychiatr Res, 2000. 34(1): p. 3-10. 
15. Hamilton, M., The assessment of anxiety states by rating. Br J Med Psychol, 
1959. 32(1): p. 50-5. 
16. Blake, D.D., et al., The development of a Clinician-Administered PTSD Scale. J 
Trauma Stress, 1995. 8(1): p. 75-90. 
17. Rae, C., et al., Oral creatine monohydrate supplementation improves brain 
performance: a double-blind, placebo-controlled, cross-over trial. Proc Biol Sci, 2003. 
270(1529): p. 2147-50. 
18. Kondo, D.G., et al., Open-label adjunctive creatine for female adolescents with 
SSRI-resistant major depressive disorder: A 31-phosphorus magnetic resonance 
spectroscopy study. J Affect Disord, 2011. 
19. Sakellaris, G., et al., Prevention of traumatic headache, dizziness and fatigue 
with creatine administration. A pilot study. Acta Paediatr, 2008. 97(1): p. 31-4. 
20. Administration, S.A.a.M.H.S., Results from the 2010 National Survey on Drug 
Use and Health (NSDUH), 2010. 
   
 
174
21. Homer, B.D., et al., Methamphetamine abuse and impairment of social 
functioning: a review of the underlying neurophysiological causes and behavioral 
implications. Psychol Bull, 2008. 134(2): p. 301-10. 
22. Durell, T.M., et al., Prevalence of nonmedical methamphetamine use in the 
United States. Subst Abuse Treat Prev Policy, 2008. 3: p. 19. 
23. Zweben, J.E., et al., Psychiatric symptoms in methamphetamine users. Am J 
Addict, 2004. 13(2): p. 181-90. 
24. Utah Department of Human Services Substance Abuse & Mental Health., Annual 
Report, 2010, Utah Department of Human Services. Retrieved from: 
http://www.dsamh.utah.gov/. 
25. Hankin, B.L., et al., Development of depression from preadolescence to young 
adulthood: emerging gender differences in a 10-year longitudinal study. J Abnorm 
Psychol, 1998. 107(1): p. 128-40. 
26. Piccinelli, M. and G. Wilkinson, Gender differences in depression. Critical review. 
Br J Psychiatry, 2000. 177: p. 486-92. 
27. Weissman, M.M. and M. Olfson, Depression in women: implications for health 
care research. Science, 1995. 269(5225): p. 799-801. 
28. Andersen, I., et al., Increasing prevalence of depression from 2000 to 2006. 
Scand J Public Health, 2011. 
29. Wade, T.J., J. Cairney, and D.J. Pevalin, Emergence of gender differences in 
depression during adolescence: national panel results from three countries. J Am Acad 
Child Adolesc Psychiatry, 2002. 41(2): p. 190-8. 
30. Garrison, C.Z., et al., Incidence of major depressive disorder and dysthymia in 
young adolescents. J Am Acad Child Adolesc Psychiatry, 1997. 36(4): p. 458-65. 
31. Kessler, R.C., et al., Sex and depression in the National Comorbidity Survey. I: 
Lifetime prevalence, chronicity and recurrence. J Affect Disord, 1993. 29(2-3): p. 85-96. 
32. McCauley, E., et al., Depression in young people: initial presentation and clinical 
course. J Am Acad Child Adolesc Psychiatry, 1993. 32(4): p. 714-22. 
33. Gorman, J.M., Gender differences in depression and response to psychotropic 
medication. Gend Med, 2006. 3(2): p. 93-109. 
34. Murray, C.J.L. and A.D. Lopez, The global burden of disease, 1996, Cambridge, 
MA: Harvard University Press. 
35. Marmorstein, N.R., W.G. Iacono, and S.M. Malone, Longitudinal associations 
between depression and substance dependence from adolescence through early 
adulthood. Drug Alcohol Depend, 2010. 107(2-3): p. 154-60. 
36. Health, U.D.o., Utah atlas of healthcare: antidepressant use in Utah, 2010, Utah 
Department of Health. 
37. Healthcare, T., Ranking America's mental health: an analysis of depression 
across the states, 2007, Mental Health America: Washington, DC. 
38. Kalechstein, A.D., et al., Psychiatric comorbidity of methamphetamine 
dependence in a forensic sample. J Neuropsychiatry Clin Neurosci, 2000. 12(4): p. 480-
4. 
39. Kay-Lambkin, F.J., et al., Stepping through treatment: reflections on an adaptive 
treatment strategy among methamphetamine users with depression. Drug Alcohol Rev, 
2010. 29(5): p. 475-82. 
40. Hallfors, D.D., et al., Which comes first in adolescence--sex and drugs or 
depression? Am J Prev Med, 2005. 29(3): p. 163-70. 
41. Khantzian, E.J., The self-medication hypothesis of addictive disorders: focus on 
heroin and cocaine dependence. Am J Psychiatry, 1985. 142(11): p. 1259-64. 
   
 
175
42. Allen, P.J., et al., Chronic creatine supplementation alters depression-like 
behavior in rodents in a sex-dependent manner. Neuropsychopharmacology, 2010. 
35(2): p. 534-46. 
43. Renshaw, P.F., et al., Multinuclear magnetic resonance spectroscopy studies of 
brain purines in major depression. Am J Psychiatry, 2001. 158(12): p. 2048-55. 
44. Simpkins, J.W., et al., Estrogen actions on mitochondria--physiological and 
pathological implications. Mol Cell Endocrinol, 2008. 290(1-2): p. 51-9. 
45. Klinge, C.M., Estrogenic control of mitochondrial function and biogenesis. J Cell 
















 Food and Drug Administration 





 STUDY MAY PROCEED 
 
Perry F. Renshaw, M.D., Ph.D., M.B.A 
The Brain Institute 
The University of Utah 
383 Colorow Drive 
Salt Lake City, UT 84108 
 
 
Dear Dr. Renshaw: 
 
Please refer to your Investigational New Drug Application (IND) submitted under section 505(i) 
of the Federal Food, Drug, and Cosmetic Act for creatine. 
 
We have completed our 30-day, safety review of your application and have concluded that you 
may proceed with your proposed clinical investigation for Improvements in depression scores in 
female methamphetamine users. 
 
In addition, we have the following Clinical comment for your consideration: 
 
• We understand that you will propose a randomized, double-blind, placebo control trial 
involving creatine treatment in depressed female MA users after you have completed this 
open-label trial. Please submit the detailed protocol of the randomized double-blind, 
placebo control trial design to FDA for review 
 
As sponsor of this IND, you are responsible for compliance with the FDCA 
(21 U.S.C. §§ 301 et. seq.) as well as the implementing regulations [Title 21 of the Code of 
Federal Regulations (CFR)].  A searchable version of these regulations is available at 
http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm.  Your responsibilities 
include: 
 
• Reporting any unexpected fatal or life-threatening adverse experiences associated with use 
of the drug by telephone or fax no later than 7 calendar days after initial receipt of the 
information [21 CFR 312.32(c)(2)];  
 
• Reporting any serious, unexpected adverse experiences, as well as results from animal 
studies that suggest significant clinical risk, in writing to this Division and to all 
investigators within 15 calendar days after initial receipt of this information 
[21 CFR 312.32(c)(1)]; and  
 
Reference ID: 3084559








• Submitting annual progress reports within 60 days of the anniversary of the date that the 
IND went into effect (the date clinical studies were permitted to begin) [21 CFR 312.33].    
 
Cite the IND number listed above at the top of the first page of any communications concerning 
this application.  Each submission to this IND must be provided in triplicate (original plus two 
copies).  Please include three originals of all illustrations that do not reproduce well.  Send all 
submissions, electronic or paper, including those sent by overnight mail or courier, to the 
following address: 
 
Food and Drug Administration 
Center for Drug Evaluation and Research 
Division of Psychiatry Products 
5901-B Ammendale Road 
Beltsville, MD 20705-1266 
 





{See appended electronic signature page} 
 
Thomas Laughren, M.D. 
Director 
Division of Psychiatry Products 
Office of Drug Evaluation I 
Center for Drug Evaluation and Research 
Reference ID: 3084559








This is a representation of an electronic record that was signed
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Consent and Authorization Document 
 
BACKGROUND 
You are being asked to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it involves. Please take 
time to read the following information carefully and discuss it with friends and relatives if 
you wish. Ask the research doctor or staff if there is anything that is not clear or if you 
would like more information. Take time to decide whether or not to volunteer to take part 
in this research study.  
 
Dr. Perry Renshaw is the physician who helps oversee this study. He is a Psychiatrist at 
the University of Utah School of Medicine in the Department of Psychiatry.  
 
The purpose of the study is to see if the investigational medication creatine helps reduce 
symptoms of depression in female methamphetamine (MA) users. Another purpose of 
the study is to see if the use of creatine results in changes in brain chemistry.  
 
You are being asked to participate in this study because you have used 
methamphetamine within the past twelve months, methamphetamine is your preferred 
drug of choice, and you have depression. If you decide you would like to take part in the 
study, you will first undergo a screening visit to see if you qualify for the study. If the 
screening requirements are met you can enroll in the study if you choose. 
 
The study drug creatine is found naturally throughout your body. Creatine has a role in 
transferring energy during skeletal muscle contraction and maintaining energy balance in 
cells with intermittently high energy requirements. In humans, brain and muscle are two 
such tissue types. Previous creatine studies suggest that its neuroprotective benefits 
would be useful for protecting the brain from damage associated with drug use. There is 
also evidence of creatine providing treatment similar to anti-depressants. The current 
study will provide more information on how effective creatine is in reducing depression in 
methamphetamine users. Other studies using creatine have shown it to be effective in 
treating patients suffering from Muscular Dystrophy, depression, Parkinson’s disease, 
Huntington’s disease, and brain trauma. Creatine has been studied extensively at doses 
ranging from 4 g daily to 25 g daily with a very safe side effect profile. This study will 
require the use of 5 g daily of creatine. 
 
This study will use rating scales and questionnaires to understand your mood. In 
addition, the study will use Magnetic Resonance Imaging (MRI) and Magnetic 
Resonance Spectroscopy (MRS) brain scans to see if the structure and/or chemicals in 
the brain change when you are treated with creatine.  
 
STUDY PROCEDURES 
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This research study is called an open label trial. This means that everyone will receive 
creatine. In other words, there is no placebo involved.  
 
There will be 21 visits in the study over 12-14 weeks. You will be asked to schedule 3 
weekly visits for the first 3 weeks, and then twice weekly for the 8 weeks while you are 
taking creatine, and then 3 additional visits approximately 7 days apart after you finish 
taking creatine. Your twice-weekly visits must be at least 48-72 hours apart. You will be 
asked to take part in the following procedures during your study visits: 
• Vitals: Your vitals will be checked at each visit. Vitals include your blood pressure, 
pulse, and your weight.  
• Medical History and Physical: This is similar to what your doctor does at your 
yearly checkup. The study team will ask you questions about your medical history 
and a study clinician will give you a complete physical exam. 
• Blood Draw (venipuncture): We will draw about 2 tablespoons of your blood at two 
study visits. We will run tests on your blood to check for systemic medical illnesses. 
We will do an HIV test. If you are found to be HIV positive, you will be referred to the 
Utah AIDS foundation for a full evaluation and treatment referral. We will run the 
following tests on your blood: 
o Complete blood count (CBC) 
o Comprehensive metabolic panel (CMP) 
o HIV test 
• *Additional tests may be ordered if we believe they are necessary. This means that 
you may have up to 4 blood draws total.  
• Urine Sample: We will ask you to provide a urine sample at each visit.  We will run 
the following tests on your urine: 
o Pregnancy test. Participants who are pregnant will not be enrolled in the 
study, due to the unknown effects of creatine and MRI scans on a developing 
fetus.  Participants will be informed if their pregnancy test is positive. 
o Drug screen for marijuana, cocaine, benzodiazepines, methamphetamine, 
and opiates. 
• Structured Clinical Interview for DSM-IV Disorders: We will administer this 
interview at the screening visit.  
• Drug History Questionnaire (DHQ): During your initial screening we will ask you 
questions about your drug and alcohol history. 
7. Drug intake Diary: We will ask you a series of questions about your current drug 
and alcohol use at each visit. 
8. Hamilton Depression Rating Scale: We will administer a depression rating 
scale once a week. 
9. Columbia-Suicide Severity Rating Scale: We will administer a suicide rating 
scale at each visit.  
10. Beck Anxiety Scale: We will administer an anxiety rating scale once a week. 
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11. Concomitant Mediations: Concomitant medications are any medications other 
than the study drug that you may be taking. We will ask you if you started taking 
any new medications at each visit. 
12. Side Effects Monitoring: After you start the study drug you will be asked 
questions regarding any possible side effects you may experience at each visit. 
13. MRI Brain Scan: You will have two MRI/MRS (magnetic resonance imaging and 
magnetic resonance spectroscopy) brain scans. Total time in the MRI machine 
could last up to 120 minutes for each MRI/MRS visit. These scans take pictures 
of the structure and chemical make up of your brain. They do not cause pain and 
do not use radiation. The MRI scanner looks like a large cylinder with a tube in 
the middle. You will be asked to lie down on your back on a foam-padded table, 
and put your head into a special holder. The table slides inside the “hole” of the 
scanner. Soft foam rubber sponges may be placed on both sides and under your 
head for comfort. The foam will also help keep your head still. You will hear 
different sounds while the pictures are taken. These sounds can be loud. The 
sounds change depending on the type of picture that is being taken. Some 
examples are scans that sound like: a hammer hitting a piece of wood, an electric 
saw, loud beeping or clicking, or buzzing noises. These sounds may be repeated 
several times.  We will provide you with a copy of your MRI/MRS scan and you 
can also request a copy of the scan interpretation.  
• Study Medication: Study medication will be given to you after you have completed 
the first brain scan. You will be asked to bring back your unused study medication at 
each visit. You will be asked to mix the creatine in at least 4 ounces of water or juice, 
and then you will drink it. 
 
Visit Schedule: 
Screening Visit:  
During the screening you be evaluated to see if you meet study inclusion criteria. 
1. We will collect your demographic information. 
2. Vital signs. 
3. A trained individual will administer the Structured Clinical Interview for DSM-IV 
Disorders (SCID), the Hamilton-Depression Rating Scale (HAM-D), and the Beck 
Anxiety Inventory (BAI). 
4. We will administer the Columbia-Suicide Severity Rating Scale (C-SSRS). 
5. We will obtain a urine sample for a pregnancy test and a drug of abuse test. We 
will test for drugs such as marijuana, cocaine, benzodiazepines, 
methamphetamine, and opiates.  
6. We will write down all the medications you are taking, including vitamins and 
over-the-counter remedies.  
7. We will ask you if you have any medical conditions.  
8. We will collect a detailed drug use history using the Drug History Questionnaire.  
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9. You will be asked to describe your recent drug use (past 2 days) including 
caffeine, nicotine, alcohol, and illegal street drugs. 
10. Medical history and physical exam (the physical exam may take place at the first 
brain scan visit or visit one). 
11. *Phlebotomy for comprehensive metabolic panel (electrolytes and liver function 
tests), complete blood count, HIV. 
*Additional tests may be ordered if we believe they are necessary for determining study 
eligibility 
 
If you do not qualify for the study because of the following disqualifications, you will not 
be able to enter the study: 
§ Pregnancy 
§ Major medical illness 
§ Bipolar disorder, schizophrenia, or schizoaffective disorder 
§ Positive HIV test 
§ Taking medications for depression 
 
First Brain Scan Visit: 
1. Vital signs. 
2. Physical exam (if it did not occur at the first visit). 
3. We will administer the HAM-D, C-SSRS and BAI. 
4. We will obtain a urine sample for a pregnancy test and a drug of abuse test. We 
will test for drugs such as marijuana, cocaine, benzodiazepines, 
methamphetamine, and opiates.  
5. We will write down all the medications you are taking, including vitamins and 
over-the-counter remedies. 
6. You will be asked to describe your recent drug use (past 2 days) including 
caffeine, nicotine, alcohol, and illegal street drugs. 
7. Brain scan. 
 
Visits 3-16 (occur twice weekly for 8 weeks): 
1. Vital signs. 
2. Physical exam (if it did not occur at the first two visits). 
3. We will administer the C-SSRS 
4. We will administer the HAM-D and BAI at one of the twice weekly visits. 
5. We will obtain a urine sample for a pregnancy test and a drug of abuse test. We 
will test for drugs such as marijuana, cocaine, benzodiazepines, 
methamphetamine, and opiates.  
6. We will write down all the medications you are taking, including vitamins and 
over-the-counter remedies. 
7. You will be asked to describe your recent drug use (past 2 days) including 
caffeine, nicotine, alcohol, and illegal street drugs. 
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8. We will assess for possible side effects of creatine. 
9. We will dispense the study medication. 
10. You will return unused and used bottles of creatine. 
 
Visit 17/18 (Second Brain Scan Visit): 
1. Vital signs. 
2. We will administer the HAM-D, C-SSRS and BAI. 
3. We will obtain a urine sample for a pregnancy test and a drug of abuse test. We 
will test for drugs such as marijuana, cocaine, benzodiazepines, 
methamphetamine, and opiates.  
4. We will write down all the medications you are taking, including vitamins and 
over-the-counter remedies. 
5. You will be asked to describe your recent drug use (past 2 days) including 
caffeine, nicotine, alcohol, and illegal street drugs. 
6. *Phlebotomy for comprehensive metabolic panel (electrolytes and liver function 
tests) and complete blood count. 
7. We will assess for possible side effects of creatine. 
8. You will return unused and used bottles of creatine. 
9. Brain scan. 
*Additional follow-up tests may be ordered if we believe they are necessary 
 
Follow-up (weeks 10, 11, 12): 
1. Vital signs. 
2. We will administer the HAM-D, C-SSRS, and BAI. 
3. We will obtain a urine sample for a pregnancy test and a drug of abuse test. We 
will test for drugs such as marijuana, cocaine, benzodiazepines, 
methamphetamine, and opiates.  
4. We will write down all the medications you are taking, including vitamins and 
over-the-counter remedies. 
5. You will be asked to describe your recent drug use (past 2 days) including 
caffeine, nicotine, alcohol, and illegal street drugs. 
6. We will assess for possible side effects of creatine. 
 
RISKS 
During your screening visit, you may become emotionally upset when asked about your 
psychiatric history including suicide attempts, or physical and sexual abuse.   
 
You may experience discomfort or swelling when blood is drawn for laboratory tests. 
Rarely, infection can result from blood draws.   
 
It is possible that treatment with creatine will not be effective in treating your depression.   
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The researchers will take precautions to safeguard your confidentiality, but it is possible 
that a breach of confidentiality could occur. 
 
Creatine has been studied extensively since the 1980’s and previous studies have 
shown it to be a very safe drug. Creatine overall has a safe side effect profile. You may 
experience mild GI discomfort from taking creatine. We will be monitoring you closely for 
potential side effects. 
 
MRI/MRS scans do not use ionizing radiation like x-rays or CT scans. Instead, magnetic 
fields and radio waves are used to take the pictures. There are no known risks related to 
MRI/MRS scans – other than the risk of injury when metallic objects are brought into the 
scanning room by mistake. Serious injury can occur during an MRI/MRS scan to persons 
who have:   
§ Cardiac (heart) pacemakers. 
§ Metal clips on blood vessels (also called stents). 
§ Artificial heart valves. 
§ Artificial arms, hands, legs, etc. 
§ Brain stimulator devices. 
§ Implanted drug pumps. 
§ Cochlear (ear) implants. 
§ Ocular (eye) implants or known metal fragments in eyes. 
§ Exposure to shrapnel or metal fillings  
§ Other metallic surgical parts. 
§ Orthodontic braces on the teeth. 
§ Body jewelry or piercings that cannot be removed for the scan. 
§ Certain tattoos with metallic ink (please tell us if you have a tattoo) 
§ Certain transdermal (skin) patches such as NicoDerm (nicotine for tobacco 
dependence), Transderm Scop (scopolamine for motion sickness), or Ortho Evra (birth 
control) 
 
If you have any such devices, or have had a surgery where metal devices were placed in 
your body, you cannot take part in the study unless cleared for MRI/MRS scanning by 
the surgeon who implanted the medical device(s). 
 
Serious risks also exist if ferromagnetic objects (things that stick to magnets) are brought 
into the scanning area. These items can become dangerous flying objects, and are not 
allowed near the MRI scanner. 
 
The Food and Drug Administration (FDA) has approved the 3.0T scanner for routine 
clinical studies in adults. Although the scans we are using in this study have no known 
risks, there could be ill effects that are delayed, such that they have not yet been 
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recognized by the FDA. The MRI/MRS scans do not cause pain. Apart from the scanner 
noise, you will not know the scan is taking place. 
 
Inside the scanner, some people experience claustrophobia (fear of being in small 
spaces), dizziness, headaches, or a metallic taste in the mouth. Some people 
experience double vision or see flashing lights. These symptoms are temporary, and will 
stop when you leave the scanner.   
 
You may feel cramped inside the scanner. There is a mirror placed inside the scanner so 
that you can see your face, and look out into the scanning room. The technologist will be 
able to hear you at all times, and will be able to talk to you during the scan. 
 
Very rarely, someone having an MRI/MRS scan feels a tingling sensation in his or her 
back. This is due to the magnetic field changing quickly during the scan. If you feel a 
tingling during the scan, you should let us know right away so that the scan can be 
changed. 
 
The sounds made by the scanner can be annoying, but the noise is not harmful to your 
hearing.  You will be given earplugs or headphones to muffle the noise. 
 
The precautions taken will avoid all the known risks related to MRI/MRS scans.  You can 
stop the scan at any time. 
 
Many people with positive or indeterminate HIV test results will experience stress, 
anxiety, or depression. You may feel sad, depressed, angry or anxious if you learn you 
are infected with HIV. Some persons with negative tests may continue or increase 
unsafe behaviors, which would increase the risk of HIV infection. Some persons are 
afraid that their test results will get into the wrong hands, and that discrimination might 
result. Although people who are infected with HIV may not feel sick and often live for 
many years, they are sometimes treated unfairly, badly, or in extreme cases, with 
violence by others who learn they have HIV or AIDS. For these reasons, you should 
consider your social supports (such as family and friends) and your insurance needs 
before you are tested. Among the possible legal consequences in Utah is that a 
diagnosis of AIDS disease must be reported to the State Health Department. It is 
possible that your HIV information can be released to health providers caring for you or 
your exposed child; to health officials when required by law; to insurers to permit 
payment; to persons involved in foster care or adoption; to official correctional, probation 
and parole staff; to emergency or health care staff who are accidentally exposed to your 
blood; or by special court order.    
 
REPRODUCTIVE RISKS 
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The effect of creatine on the fetus is unknown. Pregnant women cannot take part in this 
study, nor should women who plan to become pregnant during the study. Women who 
are at risk of pregnancy will be asked to have a pregnancy test before taking part to 
exclude the possibility of pregnancy. You will also be tested for pregnancy at each visit 
by urine sample.  
If you become pregnant while taking part in the study, you must immediately tell your 
research doctor. Because the effects of creatine on the fetus are unknown, you will be 




In addition to the risks listed above, you may experience a previously unknown risk or 
side effect.  
 
BENEFITS 
We cannot promise any benefits to you from being in the study. However, there are 
some possible benefits if you participate in this study: 
 
§ You will receive a thorough medical and psychiatric evaluation including basic 
laboratory blood tests. 
§ We hope that you will benefit if you take oral creatine, but this cannot be 
guaranteed.   
§ Other than direct benefits to you, there are possible indirect benefits: 
o Results from the study will help doctors understand how and if creatine 
helps female methamphetamine users with depression. 
The MRI part of the study may improve our understanding of the biology of 
methamphetamine use. However, this understanding will not directly benefit you. 
 
ALTERNATIVE PROCEDURES 
You may choose not to participate in this study. 
 
HIV TESTING 
As part of the study you will be tested for HIV also called Human Immunodeficiency 
Virus. The HIV testing is required as part of the study. If the HIV test is positive, the 
study doctor will inform you immediately of the result by contacting you through the 
phone number you provide. We will refer you to the Utah AIDS foundation to meet with 
their case management workers for counseling and treatment referral. A positive HIV 
test result would make you ineligible to participate in the study due to effect it may have 
on the brain.   
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We are required by Utah state law to report the results of a positive HIV test to the Utah 
Department of Health. Information required includes your name, age, sex, address, 
phone number and date of positive test.   
 
You will be offered counseling before undergoing HIV testing. 
 
PERSON TO CONTACT 
If you have questions, complaints or concerns about this study, you can contact Tracy 
Hellem at (801) 386-4773 or Danielle Kuykendall at (801) 450-2196 during any hours of 
the day or night. If you think you may have been injured from being in this study, please 
call Tracy Hellem. 
 
Institutional Review Board: Contact the Institutional Review Board (IRB) if you have 
questions regarding your rights as a research participant. Also, contact the IRB if you 
have questions, complaints or concerns which you do not feel you can discuss with the 
investigator. The University of Utah IRB may be reached by phone at (801) 581-3655 or 
by e-mail at irb@hsc.utah.edu.   
 
Research Participant Advocate:  You may also contact the Research Participant 




If you are injured from being in this study, medical care is available to you at the 
University of Utah, as it is to all sick or injured people. The University of Utah has not set 
aside any money to pay the costs for such care. The University will work with you to 
address costs from injuries. Costs would be charged to you or your insurance company 
(if you have insurance), to the study sponsor or other third party (if applicable), to the 
extent those parties are responsible for paying for medical care you receive. Since this is 
a research study, some health insurance plans may not pay for the costs. By signing this 
consent form you are not giving up your right to pursue legal action against any parties 
involved with this research. 
 
The University of Utah is a part of the government. If you are injured in this study, and 
want to sue the University or the doctors, nurses, students, or other people who work for 
the University, special laws may apply. The Governmental Immunity Act of Utah is a law 
that controls when a person needs to bring a claim against the government, and limits 
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It is up to you to decide whether or not to take part in this study. If you decide to take part 
you are still free to withdraw at any time and without giving a reason. Refusal to 
participate or the decision to withdraw from this study will involve no penalty or loss of 
benefits to which you are otherwise entitled. If you don’t take part, you can still receive all 
standard care that is available to you. This will not affect the relationship you have with 
your doctor or other staff, nor decrease the standard of care that you receive as a 
patient.  
 
RIGHT OF INVESTIGATOR TO WITHDRAW 
The investigator can withdraw you from the study without your approval. Possible 
reasons for withdrawal include:  a positive pregnancy test, inability to comply with the 
study protocol or comply with attending the study visits (if you miss more than three 
visits, you will be withdrawn from the study), or worsening of your condition that requires 
hospitalization for safety. Other reasons for withdrawal include suicidal intent, 
incarceration, intolerable psychotic or mood symptoms, or adverse effects or toxicity 
from study drug.  
 
COSTS AND COMPENSATION TO PARTICIPANTS 
The study visits, study medication, laboratory tests, and brain scans will be provided to 
you at no cost. You will be compensated for your time and the amount of compensation 
is outlined below. Payment will be received in the dollar amounts listed below in the form 
of gift cards to a variety of local businesses including, but not limited to: restaurants, 
grocery stores, bookstores, and coffee shops. You can choose to receive gift cards at 
each visit or save them to receive larger amounts at one time. 
 
10. $25 - Screening   
11. $25 - Baseline neuroimaging 
12. $25 - Visit 1 (initiation of study drug) 
13. $10 - First weekly visits for weeks 2-8 (total = $70) 
14. $5 - Second weekly visits for weeks 2-8 (total = $35) 
15. $25 - Week 9 (end-of-treatment neuroimaging) 
16. $25 - Week 10 
17. $10 - Week 11 
18. $50 - Week 12 
 
NEW INFORMATION 
Sometimes during the course of a research study, new information becomes available 
about the treatment that is being studied. If new information comes out about creatine 
over the course of this study, the study team will tell you about it and discuss with you 
whether or not you want to continue in the study.  
 
NUMBER OF PARTICIPANTS 
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We expect to enroll a total of 30 women in this study. 
 
AUTHORIZATION FOR USE OF YOUR PROTECTED HEALTH INFORMATION  
Signing this document means you allow us, the researchers in this study, and others 
working with us to use some information about your health for this research study. 
 
This is the information we will use and include in our research records:  
- Demographic and identifying information like your name, address, date of 
birth and telephone number 
- Social Security Number – we will ask you for the last 4 digits of your Social 
Security Number for MRI registration purposes 
- Related medical information about you like your medical history, allergies, 
current and past medications or therapies, drug use history, and information 
from physical examinations, such as blood pressure reading, heart rate, and 
lab results and results from the brain scans 
- All tests and procedures that will be done in the study 
How we will protect and share your information: 
• We will do everything we can to keep your information private but we cannot 
guarantee this. Study information will be kept in a secured manner and electronic 
records will be password protected. Study information may be stored with other 
information in your medical record. Other doctors, nurses, and third parties (like 
insurance companies) may be able to see this information as part of the regular 
treatment, payment, and health care operations of the hospital. We may also 
need to disclose information if required by law. 
 
• We are required by Utah state law to report the results of a positive HIV test to 
the Utah Department of Health. Information required includes your name, age, 
sex, address and date of positive test.   
 
• To help us protect your privacy, we have obtained a Certificate of Confidentiality 
from the FDA. With this Certificate, the researchers cannot be forced to disclose 
information that may identify you, even by a court subpoena, in any federal, state, 
or local civil, criminal, administrative, legislative, or other proceedings. The 
researchers will use the Certificate to resist any demands for information that 
would identify you, except as explained below. 
 
The Certificate cannot be used to resist a demand for information from personnel 
of the United States Government that is used for auditing or evaluation of 
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federally funded projects or for information that must be disclosed in order to 
meet the requirements of the FDA. 
 
You should understand that a Certificate of Confidentiality does not prevent you 
or a member of your family from voluntarily releasing information about yourself 
or your involvement in this research. If an insurer, employer, or other person 
obtains your written consent to receive research information, then the 
researchers may not use the Certificate to withhold that information. 
 
The Certificate of Confidentiality does not prevent the researchers from 
disclosing voluntarily, without your consent, information that would identify you as 
a participant in the research project under the following circumstances: child 
abuse or intent to hurt self or others. The Certificate of Confidentiality also does 
not prevent the researchers from disclosing positive HIV tests to the Utah State 
Health Department as required by law.  
 
• A description of this clinical trial will be available on http://www.ClinicalTrials.gov, 
as required by U.S. Law.  This website will not include information that can 
identify you.  At most, the website will include a summary of the results.  You can 
search this website at any time. 
 
• In order to conduct this study and make sure it is conducted as described in this 
form, the research records may be used and reviewed by others who are working 
with us on this research: 
o Members of the research team and University of Utah Health Sciences 
Center 
o The University of Utah Institutional Review Board (IRB), who reviews 
research involving people to make sure the study protects your rights; 
o Alzchem, the company that makes the creatine that is being used in this 
study; and 
o The Food and Drug Administration 
 
• If we share your information with groups outside of University of Utah Health 
Sciences Center, we will not share your name or identifying information.  We will 
label your information with a code number, so they will not know your identity. 
 
• As previously mentioned, we are required by Utah state law to report the results 
of a positive HIV test to the Utah Department of Health. Information required 
includes your name, age, sex, address, phone number and date of positive test.   
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• If you do not want us to use information about your health, you should not be part 
of this research.  If you choose not to participate, you can still receive health care 
services at University of Utah Health Sciences Center  
 
What if I decide to Not Participate after I sign the Consent and Authorization 
Form? 
You can tell us anytime that you do not want to be in this study and do not want us to 
use your health information.  You can also tell us in writing.  If you change your mind, we 
will not be able to collect new information about you, and you will be withdrawn from the 
research study. However, we can continue to use information we have already started to 
use in our research, as needed to maintain the integrity of the research.   
 
This authorization does not have an expiration date.   
 
CONSENT 
I confirm that I have read this consent and authorization document and have had the 
opportunity to ask questions. I will be given a signed copy of the consent and 
authorization form to keep. 
 
I agree to take part in this research study and authorize you to use and disclose 







________________________     ____________ 
Participant’s Signature  Date 
 
________________________ 
Name of Person Obtaining Authorization and Consent 
 
________________________     ____________ 
Signature of Person Obtaining Authorization and Consent  Date 
 
 














































































 This appendix includes the instruments, such as the Hamilton Depression Rating 
Scale (HAMD), Beck Anxiety Inventory (BAI), Drug Health Questionnaire (DHQ), 
Columbia Suicide Severity Rating Scale (C-SSRS) and Structured Clinical Interview for 
DSM-IV Disorders (SCID) that were used for data collection in this study. 









1.   Depressed Mood      
      (sadness, hopeless, helpless, worthless) 
0     Absent 
1     These feeling states indicated only on questioning 
2     These feeling states spontaneously reported verbally 
3     Communicates feeling states nonverbally, i.e., through facial  
        expression, posture, voice and tendency to weep 
4      Patient reports VIRTUALLY ONLY these feeling states in his  
    spontaneous verbal and nonverbal communication 
 
2. Feelings of Guilt 
0     Absent 
1     Self-reproach, feels he has let people down 
2 Ideas of guilt or rumination over past errors or sinful deeds 
3 Present illness is a punishment.  Delusions of guilt 
4 Hears accusatory or denunciatory voices and/or experiences 
threatening visual hallucinations 
 
3. Suicide 
0     Absent 
1     Feels life is not worth living 
2 Wishes he were dead or any thoughts of possible death to self 
3 Suicide ideas or gesture 
4 Attempts at suicide (any serious attempt rates 4) 
 
4.    Insomnia - Early 
0 No difficulty falling asleep 
1 Complains of occasional difficulty falling asleep i.e., more than 
½ hour 
2 Complains of nightly difficulty falling asleep 
 
5.    Insomnia - Middle  
0 No difficulty 
1 Patient complains of being restless and disturbed during the 
night 
2 Waking during the night – any getting out of bed rates 2 
(except for purposes of voiding) 
 
6.    Insomnia - Late 
0 No difficulty 
1 Waking in early hours of the morning but goes back to sleep 
2 Unable to fall asleep again if gets out of bed 
 
7.    Work and Activities 
0 No difficulty 
1 Thoughts and feelings of incapacity, fatigue or weakness 
related to activities; work or hobbies 
2 Loss of interest in activity; hobbies or work – either directly 
reported by patient, or indirect in listlessness, indecision and 
vacillation (feels he has to push self to work or activities) 
3 Decrease in actual time spent in activities or decrease in 
productivity.  In hospital, rate 3 if patient does not spend at 
least three hours a day in activities (hospital job or hobbies) 
exclusive of ward chores. 
4 Stopped working because of present illness.  In hospital, rate 4 
if patient engages in no activities except ward chores, or if 
patient fails to perform ward chores unassisted. 
 
8.    Retardation 
       (slowness of thought and speech; impaired ability to concentrate;  
       decreased motor activity) 
0 Normal speech and thought 
1 Slight retardation at interview 
2 Obvious retardation at interview 
3 Interview difficult 







9.   Agitation 
0 None 
1 “Playing with” hand, hair, etc. 
2 Hand-wringing, nail-biting, biting of lips 
 
10.  Anxiety - Psychic 
0 No difficulty 
1 Subjective tension and irritability 
2 Worrying about minor matters 
3 Apprehensive attitude apparent in face or speech 
4 Fears expressed without questioning 
 
11.  Anxiety - Somatic 
       0     Absent      Physiological concomitants of anxiety such as:  
       1     Mild      Gastrointestinal - dry mouth, wind, indigestion, 
    2     Moderate      diarrhea, cramps, belching 
       3     Severe      Cardiovascular – palpitations, headaches 
4     Incapacitating  Respiratory - hyperventilation, sighing 
                                Urinary frequency 
                                Sweating 
 
12.  Somatic Symptoms - Gastrointestinal 
0 None 
1 Loss of appetite but eating without staff encouragement.  
Heavy feelings in abdomen.   
2 Difficulty eating without staff urging.  Requests or requires  
laxatives or medications for bowels or medication for G.I.  
symptoms.  
 
13.  Somatic Symptoms - General 
0 None 
1 Heaviness in limbs, back or head, backaches, headache, 
muscle aches, loss of energy and fatigability 
2 Any clear-cut symptom rates 2 
 
14.  Genital Symptoms 
       0     Absent          0     Not ascertained 
       1     Mild                      Symptoms such as:  loss of libido, 
       2     Severe                 menstrual disturbances 
 
15.  Hypochondriasis 
0 Not present 
1 Self-absorption (bodily) 
2 Preoccupation with health 
3 Frequent complaints, requests for help, etc. 
4 Hypochondriacal delusions 
 
16.  Loss of Weight 
       A.    When Rating by History: 
0      No weight loss 
1      Probable weight loss associated with present illness 
2      Definite (according to patient) weight loss 
 
   B.   On Weekly Ratings by Ward Psychiatrist, When Actual  
          Changes are Measured:  
0 Less than 1 lb. weight loss in week 
1 Greater than 1 lb. weight loss in week 
2 Greater than 2 lb. weight loss in week 
 
17.  Insight        
    0     Acknowledges being depressed and ill 
1 Acknowledges illness but attributes cause to bad food, 
climate, overwork, virus, need for rest, etc. 

















  Patient Name:______________________________________________________________                                              Date:_____________________ 
                                  
                                                  Hamilton Rating Scale for Depression (17-items) 
 
Instructions:  For each item select the “cue” which best characterizes the patient during the past week.   
 
                              










Beck Anxiety Inventory 
 
Below is a list of common symptoms of anxiety.   Please carefully read each item in the list.  Indicate how much you 
have been bothered by that symptom during the past month, including today, by circling the number in the 
corresponding space in the column next to each symptom. 
 
 
Not At All Mildly but it 
didn’t bother me 
much.  
Moderately - it 
wasn’t pleasant at 
times 
Severely – it 
bothered me a lot 
Numbness or tingling 0 1 2 3 
Feeling hot 0 1 2 3 
Wobbliness in legs 0 1 2 3 
Unable to relax 0 1 2 3 
Fear of worst 
happening 
0 1 2 3 
Dizzy or lightheaded 0 1 2 3 
Heart pounding/racing 0 1 2 3 
Unsteady 0 1 2 3 
Terrified or afraid 0 1 2 3 
Nervous 0 1 2 3 
Feeling of choking 0 1 2 3 
Hands trembling 0 1 2 3 
Shaky / unsteady 0 1 2 3 
Fear of losing control 0 1 2 3 
Difficulty in breathing 0 1 2 3 
Fear of dying 0 1 2 3 
Scared 0 1 2 3 
Indigestion 0 1 2 3 
Faint / lightheaded 0 1 2 3 
Face flushed 0 1 2 3 
Hot/cold sweats 0 1 2 3 
Column Sum     
 
Scoring - Sum each column.   Then sum the column totals to achieve a grand score.  Write that 
score here ____________ . 
Interpretation 
 
A grand sum between 0 – 21 indicates very low anxiety.  That is usually a good thing.  However, it is 
possible that you might be unrealistic in either your assessment which would be denial or that you have 
learned to “mask” the symptoms commonly associated with anxiety.   Too little “anxiety” could indicate that 
you are detached from yourself, others, or your environment.   
 
A grand sum between 22 – 35 indicates moderate anxiety.  Your body is trying to tell you something.  Look 
for patterns as to when and why you experience the symptoms described above.  For example, if it occurs 
prior to public speaking and your job requires a lot of presentations you may want to find ways to calm 
yourself before speaking or let others do some of the presentations.  You may have some conflict issues that 
need to be resolved.  Clearly, it is not “panic” time but you want to find ways to manage the stress you feel. 
 
A grand sum that exceeds 36 is a potential cause for concern.  Again, look for patterns or times when you 
tend to feel the symptoms you have circled.  Persistent and high anxiety is not a sign of personal weakness or 
failure.  It is, however, something that needs to be proactively treated or there could be significant impacts to 
you mentally and physically.  You may want to consult a counselor if the feelings persist. 
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PSYCHOACTIVE DRUG HISTORY QUESTIONNAIRE 
 
DRUG CATEGORY 
Note: First Use Card Sort With 
 Client To Determine  





1 = No 








Injection Drug Use 
 
1 =No 









c Frequency  




ALCOHOL   NA   
CANNABIS: 
Marijuana, hashish, hash oil 





     
STIMULANTS: 
Methamphetamine — speed, ice, crank 
     
AMPHETAMINES/OTHER STIMULANTS: 
Ritalin, Benzedrine, Dexedrine 
  NA   
BENZODIAZEPINES/ TRANQUILIZERS: 
Valium, Librium, Halcion, Xanax, Diazepam, “Roofies” 
  NA   
SEDATIVES/HYPNOTICS/BARBITURATES:  
Amytal, Seconal, Dalmane, Quaalude, Phenobarbital 
  NA   
HEROIN 
     
STREET OR ILLICIT METHADONE   NA   
OTHER OPIOIDS:  
Tylenol #2 & #3, 282’S, 292’S, Percodan, Percocet, Opium, 
Morphine, Demerol, Dilaudid 




LSD, PCP, STP, MDA, DAT, mescaline, peyote, 
mushrooms, ecstasy (MDMA), nitrous oxide 
















a If “EVER USED” is NO (1) for 
any given line, the remainder of 
the line should be left blank. 
 
b Code 87 = Infrequent Use 
 (≤ 2 x/year)   
 
Code 88 = Brief Experimental Use 
 (< 3 months lifetime use) 
 
c Frequency Codes: 
0 = no use 3 = 2 to 3x/mo. 6 = 4 to 6x/wk. 
1 = < 1x/mo. 4 = 1x/wk. 7 = daily 
2 = 1x/mo. 5 = 2 to 3x/wk  
 





















Since Last Visit 
 
  
Posner, K.; Brent, D.; Lucas, C.; Gould, M.; Stanley, B.; Brown, G.; Fisher, P.; Zelazny, 
J.; Burke, A.; Oquendo, M.; Mann, J.  
 
Disclaimer: 
This scale is intended for use by trained clinicians. The questions contained in the Columbia-Suicide Severity Rating 




Definitions of behavioral suicidal events in this scale are based on those used in The Columbia Suicide History 
Form, developed by John Mann, MD and Maria Oquendo, MD, Conte Center for the Neuroscience of Mental 
Disorders (CCNMD), New York State Psychiatric Institute, 1051 Riverside Drive, New York, NY, 10032. (Oquendo 
M. A., Halberstam B. & Mann J. J., Risk factors for suicidal behavior: utility and limitations of research instruments. 
In M.B. First [Ed.] Standardized Evaluation in Clinical Practice, pp. 103 -130, 2003.) 
 
 For reprints of the C-SSRS contact Kelly Posner, Ph.D., New York State Psychiatric Institute, 1051 Riverside Drive, 
New York, New York, 10032; inquiries contact posnerk@childpsych.columbia.edu  
 










SUICIDAL IDEATION  
Ask questions 1 and 2.  If both are negative, proceed to “Suicidal Behavior” section.  If the answer to 
question 2 is “yes,” ask questions 3, 4 and 5.   
Since Last 
Visit  
1.  Wish to be Dead  
Subject endorses thoughts about a wish to be dead or not alive anymore, or wish to fall asleep and not 
wake up.  
Have you wished you were dead or wished you could go to sleep and not wake up?  
 
Frequency of Ideation: ______ 
If yes, describe: 
 
 
Yes      No 
□   □ 
2.  Non-Specific Active Suicidal Thoughts 
General non-specific thoughts of wanting to end one’s life/commit suicide (e.g. “I’ve thought about killing 
myself”) without thoughts of ways to kill oneself/associated methods, intent, or plan during the 
assessment period.  
Have you actually had any thoughts of killing yourself? 
 
Frequency of Ideation: ______ 
If yes, describe: 
 
 
Yes      No 
□   □ 
3.  Active Suicidal Ideation with Any Methods (Not Plan) without Intent   
     to Act 
Subject endorses thoughts of suicide and has thought of at least one method during the assessment 
period. This is different than a specific plan with time, place or method details worked out (e.g.  
thought of method to kill self but not a specific plan).  Includes person who would say, “I thought about 
taking an overdose but I never made a specific plan as to when, where or how I would actually do it…..and I 
would never go through with it”.  
Have you been thinking about how you might do this? 
 
Frequency of Ideation: ______ 
If yes, describe:  
 
 
Yes      No 
□   □ 
4.  Active Suicidal Ideation with Some Intent to Act, without Specific   
     Plan 
Active suicidal thoughts of killing oneself and subject reports having some intent to act on such 
thoughts, as opposed to “I have the thoughts but I definitely will not do anything about them”. 
Have you had these thoughts and had some intention of acting on them?  
 
Frequency of Ideation: ______ 
If yes, describe:  
 
 
Yes      No 
□   □ 
5.  Active Suicidal Ideation with Specific Plan and Intent 
Thoughts of killing oneself with details of plan fully or partially worked out and subject has some intent 
to carry it out. 
Have you started to work out or worked out the details of how to kill yourself?  
Do you intend to carry out this plan? 
 
                                                                                   Frequency of Ideation: ______ 
If yes, describe:  
 
 
Yes      No 
□   □ 
 









INTENSITY OF IDEATION  
 Ideation Type                   Type # (1-5)                  Description of                                                                
                                                                             Ideation 
Most Common Ideation:      _____      _______________________________ 
 




Since Last Visit 
The following features should be rated with respect to both most common and most severe types of ideation 
experienced since last visit. Only rate most common if most severe and most common are different. 
    
Most  
Common     
     
Most Severe 
Frequency 
How many times have you had these thoughts? 
1. Less than once a week 
2. Once a week  
3. 2-5 times in week  
4. Daily or almost daily 












When you have the thoughts how long do they last? 
1. Fleeting - few seconds or minutes 
2. Less than 1 hour/some of the time 
3. 1-4 hours/a lot of time 
4. 4-8 hours/most of day 
       5. More than 8 hours/persistent or continuous 
____ ____ 
Controllability 
Could /can you stop thinking about killing yourself or wanting to die if you want to? 
1. Easily able to control thoughts 
2. Can control thoughts with little difficulty 
3. Can control thoughts with some difficulty 
4. Can control thoughts with a lot of difficulty 
5. Unable to control thoughts 
0. Does not attempt to control thoughts  
____ ____ 
Deterrents 
Are there things - anyone or anything (e.g. family, religion, pain of death) - that stopped you 
from wanting to die or acting on thoughts of committing suicide? 
1. Deterrents definitely stopped you from attempting suicide 
2. Deterrents probably stopped you  
3. Uncertain that deterrents stopped you  
4. Deterrents most likely did not stop you  
5. Deterrents definitely did not stop you  
0. Does not apply; wish to die only 
____ ____ 
Reasons for Ideation 
What sort of reasons did you have for thinking about wanting to die or killing yourself?  Was it to 
end the pain or stop the way you were feeling (in other words you couldn’t go on living with this 
pain or how you were feeling) or was it to get attention, revenge or a reaction from others? Or 
both? 
1. Completely to get attention, revenge or a reaction from others. 
2. Mostly to get attention, revenge or a reaction from others. 
3. Equally to get attention, revenge or a reaction from others and to end/stop the   
    pain  
4. Mostly to end or stop the pain (you couldn’t go on living with the pain or how   
         you were feeling). 
5. Completely to end or stop the pain (you couldn’t go on living with the pain or   






























(Check all that apply, so long as these are separate events; must ask about all types) 
Since Last 
Visit 
Actual Attempt:  
A potentially self-injurious act committed with at least some wish to die, as a result of act. Behavior was in part 
thought of as method to kill oneself. Intent does not have to be 100%.  If there is any intent/desire to die 
associated with the act, then it can be considered an actual suicide attempt. There does not have to be any 
injury or harm, just the potential for injury or harm. If person pulls trigger while gun is in mouth but gun is broken 
so no injury results, this is considered an attempt.   
Inferring Intent: Even if an individual denies intent/wish to die, it may be inferred clinically from the behavior or 
circumstances. For example, a highly lethal act that is clearly not an accident so no other intent but suicide can be 
inferred (e.g. gunshot to head, jumping from window of a high floor/story). Also, if someone denies intent to die, 
but they thought that what they did could be lethal, intent may be inferred.  
Have you made a suicide attempt? 
Have you done anything to harm yourself? 
Have you done anything dangerous where you could have died? 
What did you do? 
Did you______ as a way to end your life?  
Did you want to die (even a little) when you_____?  
Were you trying to end your life when you _____? 
Or did you think it was possible you could have died from_____? 
Or did you do it purely for other reasons / without ANY intention of killing yourself                                      
(like to relieve stress, feel better, get sympathy, or get something else to happen)?  (Self-Injurious Behavior 
without suicidal intent) 




Has subject engaged in Non-Suicidal Self-Injurious Behavior? 
Yes     No 




















  Yes      No 
□   □ 
Interrupted Attempt:   
When the person is interrupted (by an outside circumstance) from starting the potentially self-injurious act (if not 
for that, actual attempt would have occurred). 
Overdose: Person has pills in hand but is stopped from ingesting.  Once they ingest any pills, this becomes an 
attempt rather than an interrupted attempt. Shooting: Person has gun pointed toward self, gun is taken away by 
someone else, or is somehow prevented from pulling trigger. Once they pull the trigger, even if the gun fails to fire, 
it is an attempt. Jumping: Person is poised to jump, is grabbed and taken down from ledge. Hanging: Person has 
noose around neck but has not yet started to hang - is stopped from doing so. 
Has there been a time when you started to do something to end your life but someone or something 
stopped you before you actually did anything? 
If yes, describe: 
 
Yes     No 




Total  # of 
interrupted 
____ 
Aborted Attempt:   
When person begins to take steps toward making a suicide attempt, but stops themselves before they actually have 
engaged in any self-destructive behavior. Examples are similar to interrupted attempts, except that the individual 
stops him/herself, instead of being stopped by something else. 
Has there been a time when you started to do something to try to end your life but you stopped yourself 
before you actually did anything? 
If yes, describe:  
 
Yes     No 
□   □ 
 
Total # of 
aborted 
____ 
Preparatory Acts or Behavior: 
Acts or preparation towards imminently making a suicide attempt. This can include anything beyond a verbalization 
or thought, such as assembling a specific method (e.g. buying pills, purchasing a gun) or preparing for one’s death by 
suicide (e.g. giving things away, writing a suicide note).  
Have you taken any steps towards making a suicide attempt or preparing to kill yourself (such as 
collecting pills, getting a gun, giving valuables away or writing a suicide note)? 




Yes     No 
□   □ 
Suicidal Behavior: 
Suicidal behavior was present during the assessment period? 
Yes     No 
□   □ 
Completed Suicide: Yes     No 
□   □ 




















Actual Lethality/Medical Damage:   
0.  No physical damage or very minor physical damage (e.g. surface 
scratches). 
1.  Minor physical damage (e.g. lethargic speech; first-degree burns; 
mild bleeding; sprains). 
2.  Moderate physical damage; medical attention needed (e.g. 
conscious but sleepy, somewhat responsive; second-degree 
burns; bleeding of major vessel). 
3.  Moderately severe physical damage; medical hospitalization and 
likely intensive care required (e.g. comatose with reflexes 
intact; third-degree burns less than 20% of body; extensive 
blood loss but can recover; major fractures). 
4.  Severe physical damage; medical hospitalization with intensive 
care required (e.g. comatose without reflexes; third-degree 
burns over 20% of body; extensive blood loss with unstable 
vital signs; major damage to a vital area). 
















Potential Lethality: Only Answer if Actual 
Lethality=0 
Likely lethality of actual attempt if no medical damage (the 
following examples, while having no actual medical damage, had 
potential for very serious lethality: put gun in mouth and pulled the 
trigger but gun fails to fire so no medical damage; laying on train 
tracks with oncoming train but pulled away before run over). 
 
0 = Behavior not likely to result in injury 
1 = Behavior likely to result in injury but not likely to cause death 
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